Conditions: Obesity and Diabetes Mellitus, Type 2
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 196
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess the effects of JNJ-64565111 compared with placebo in severely obese Type 2 Diabetes Mellitus (T2DM) participants after 12 weeks of treatment on: the percentage change in body weight from baseline and safety and tolerability.

Detailed description:

Arms:
arm 1: Participants will receive JNJ-64565111 Dose Level 1 subcutaneously (SC) once-weekly for 12-week treatment phase. arm 2: Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly for 12-week treatment phase. arm 3: Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly for 12-week treatment phase. arm 4: Participants will receive placebo matching to JNJ-64565111 SC once-weekly for 12-week treatment phase.

Interventions: intervention 1: JNJ-64565111 Dose Level 1 intervention 2: JNJ-64565111 Dose Level 2 intervention 3: JNJ-64565111 Dose Level 3 intervention 4: Placebo
Intervention descriptions: intervention 1: Participants will receive JNJ-64565111 Dose Level 1 SC once-weekly until Week 12. intervention 2: Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly until Week 12. intervention 3: Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly until Week 12. intervention 4: Participants will receive matching placebo to JNJ-64565111 SC once-weekly until Week 12.

Protocol document:
Prot_000.pdf: 
1
Status: Approved,  Date: 23 August 2018
Janssen Research & Development *
Clinical Protocol
Protocol Title
A Randomized, Double-blind Placebo-controlled, Parallel-group, Multicenter, Dose-
ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese 
Subjects with Type 2 Diabetes Mellitus
Short Title
Evaluation of JNJ-64565111 in Severely Obese Subjects with Type 2 Diabetes Mellitus
Protocol 64565111OBE2002; Phase 2b
AMENDMENT 1
JNJ-64565111  
*Janssen Research & Development is a global organization that operates through different legal entities in 
various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development 
studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen 
Biologics, BV; Janssen-Cilag International NV; Janssen, Inc; Janssen Pharmaceutica NV; Janssen 
Sciences Ireland UC; or Janssen Research & Development, LLC. The term “sponsor” is used throughout 
the protocol to represent these various legal entities; the sponsor is identified on the Contact Information 
page that accompanies the protocol.  
US sites of this study will be conducted under US Food & Drug Administration IND regulations 
(21 CFR Part 312).]
Status:
Approved
Date:
23 August 2018
Prepared by:
Janssen Research & Development, LLC  
EDMS number:
EDMS-ERI-156156741, 2.0
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements. 
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidential and 
may not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the 
information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed
by them. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as 
privileged or confidential.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
2
Approved, Date: 23 August 2018
TABLE OF CONTENTS
TABLE OF CONTENTS ............................................................................................................................... 2
LIST OF IN-TEXT TABLES AND FIGURES................................................................................................ 4
PROTOCOL AMENDMENTS....................................................................................................................... 5
1.
PROTOCOL SUMMARY ..................................................................................................................... 6
1.1.
Synopsis........................................................................................................................................... 6
1.2.
Schema .......................................................................................................................................... 11
1.3.
Schedule of Activities (SoA)........................................................................................................... 13
2.
INTRODUCTION................................................................................................................................ 17
2.1.
Study Rationale.............................................................................................................................. 19
2.2.
Background .................................................................................................................................... 20
2.3.
Benefit/Risk Assessment ............................................................................................................... 27
3.
OBJECTIVES AND ENDPOINTS ..................................................................................................... 30
4.
STUDY DESIGN ................................................................................................................................ 32
4.1.
Overall Design................................................................................................................................ 32
4.2.
Scientific Rationale for Study Design............................................................................................. 34
4.2.1.
Study-Specific Ethical Design Considerations ........................................................................... 37
4.3.
Justification for Dose...................................................................................................................... 38
4.4.
End of Study Definition................................................................................................................... 38
5.
STUDY POPULATION ...................................................................................................................... 39
5.1.
Inclusion Criteria ............................................................................................................................ 39
5.2.
Exclusion Criteria ........................................................................................................................... 41
5.3.
Lifestyle Considerations................................................................................................................. 46
5.4.
Screen Failures .............................................................................................................................. 46
6.
STUDY TREATMENT........................................................................................................................ 46
6.1.
Study Drugs Administered ............................................................................................................. 46
6.2.
Preparation/Handling/Storage/Accountability ................................................................................ 49
6.3.
Measures to Minimize Bias: Randomization and Blinding............................................................. 50
6.4.
Study Drug Compliance ................................................................................................................. 51
6.5.
Prestudy and Concomitant Therapy .............................................................................................. 51
6.6.
Glycemic Rescue Medication......................................................................................................... 52
6.7.
Dose Modification........................................................................................................................... 52
6.8.
Study Drug After the End of the Study........................................................................................... 52
7.
DISCONTINUATION FROM STUDY DRUG AND DISCONTINUATION FROM STUDY ................ 53
7.1.
Discontinuation from Study Drug ................................................................................................... 53
7.2.
Discontinuation from the Study...................................................................................................... 54
7.2.1.
Withdrawal of Consent................................................................................................................ 55
7.2.2.
Withdrawal from the Use of Research Samples......................................................................... 55
7.3.
Lost to Follow-up............................................................................................................................ 55
8.
STUDY ASSESSMENTS AND PROCEDURES ............................................................................... 55
8.1.
Efficacy Assessments .................................................................................................................... 57
8.2.
Safety Assessments....................................................................................................................... 59
8.2.1.
Physical Examination.................................................................................................................. 61
8.2.2.
Vital Signs................................................................................................................................... 61
8.2.3.
Electrocardiogram (ECG) ........................................................................................................... 61
8.2.4.
Clinical Safety Laboratory Assessments .................................................................................... 62
8.3.
Adverse Events and Serious Adverse Events ............................................................................... 62
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
3
Approved, Date: 23 August 2018
8.3.1.
Time Period and Frequency for Collecting Adverse Event and Serious Adverse Event 
Information.................................................................................................................................. 64
8.3.2.
Follow-up of Adverse Events and Serious Adverse Events ....................................................... 64
8.3.3.
Regulatory Reporting Requirements for Serious Adverse Events ............................................. 64
8.3.4.
Pregnancy................................................................................................................................... 64
8.4.
Treatment of Overdose .................................................................................................................. 65
8.5.
Pharmacokinetics........................................................................................................................... 65
8.6.
Pharmacodynamics........................................................................................................................ 66
8.7.
Genetics ......................................................................................................................................... 66
8.8.
Archive Samples for Exploratory Biomarker Research.................................................................. 66
8.9.
Health Economics/Medical Resource Utilization and Health Economics ...................................... 66
8.10.
Further Assessments ..................................................................................................................... 66
8.10.1.
Immunogenicity Assessments .................................................................................................... 66
8.10.2.
Survey on Experience with Self-injection of Study Drug ............................................................ 67
9.
STATISTICAL CONSIDERATIONS.................................................................................................. 67
9.1.
Statistical Hypotheses.................................................................................................................... 67
9.2.
Sample Size Determination ........................................................................................................... 67
9.3.
Populations for Analyses................................................................................................................ 67
9.4.
Statistical Analyses ........................................................................................................................ 68
9.4.1.
Efficacy Analyses........................................................................................................................ 68
9.4.2.
Safety Analyses .......................................................................................................................... 69
9.4.3.
Other Analyses ........................................................................................................................... 71
9.5.
Interim Analysis.............................................................................................................................. 72
9.5.1.
Internal Data Monitoring Committee (DMC) ............................................................................... 72
10.
SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS ............................ 73
10.1.
Appendix 1: Adverse Events: Definitions and Procedures for Recording, Evaluating, 
Follow-up, and Reporting............................................................................................................... 73
10.2.
Appendix 2: Regulatory, Ethical, and Study Oversight Considerations......................................... 78
10.3.
Appendix 3: Abbreviations and Trademarks.................................................................................. 88
10.4.
Appendix 4: New York Heart Association Classification of Cardiac Disease ................................ 90
10.5.
Appendix 5: Anthropometric Measurements.................................................................................. 91
10.6.
Appendix 6: Method of Blood Pressure and Pulse Rate Measurement ........................................ 92
10.7.
Appendix 7: Standardized Nonpharmacologic Weight Reduction Therapy................................... 94
10.8.
Appendix 8: Hypoglycemia: Definitions, Symptoms, and Treatment............................................. 95
10.9.
Appendix 9: Clinical Laboratory Tests ........................................................................................... 96
10.10.
Appendix 10: Algorithm for Monitoring Abnormal Liver Function Tests......................................... 98
10.11.
Appendix 11: Pancreatitis Monitoring and Withdrawal Criteria...................................................... 99
10.12.
Appendix 12: Guidelines for Calcitonin Monitoring ...................................................................... 100
10.13.
Appendix 13: Instructions for the Completion of PRO Assessments........................................... 102
10.14.
Appendix 14: Protocol Amendment History ................................................................................. 105
11.
REFERENCES................................................................................................................................. 106
INVESTIGATOR AGREEMENT ............................................................................................................... 108
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
4
Approved, Date: 23 August 2018
LIST OF IN-TEXT TABLES AND FIGURES 
TABLES
Table 1: 
Comparison of JNJ-64565111 Doses Used in Phase 1 Studies .............................................. 22
Table 2: 
Mean (Range) Cmax and AUC of JNJ-64565111 on Weeks 1 and 4 (Study 
645651111EDI1002)................................................................................................................. 25
Table 3:
Glycemic Rescue Criteria ......................................................................................................... 52
Table 4:
Maximum Volume of Blood to be Collected from Each Subject ............................................... 56
Table 5: 
Subject Population Definitions .................................................................................................. 67
FIGURES
Figure 1:
Schematic Overview of the Study............................................................................................. 12
Figure 2:
Mean (SD) Serum Concentration-time Profiles Following Multiple Subcutaneous 
Administration of JNJ-64565111 Weekly for 4 Doses in T2DM Subjects................................. 24
Figure 3:
Schematic Diagram of Drug Injection Schedule ....................................................................... 48
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
5
Approved, Date: 23 August 2018
PROTOCOL AMENDMENTS
Protocol Version
Date
Original Protocol
05 April 2018
Amendment 1
23 August 2018
Amendments below are listed beginning with the most recent amendment.
Amendment 1 (23 August 2018)
The overall reason for the amendment: The overall reasons for the amendment are to provide further instructions 
on the safety monitoring of subjects with adverse events of moderate and severe vomiting that may lead to 
dehydration, to add a discontinuation criterion for subjects who experience severe vomiting, and to correct minor 
errors.
Applicable Section(s)
Description of Change(s)
Rationale: To add a discontinuation criterion about vomiting.
Section 7.1, 
Discontinuation from 
Study Drug
Added discontinuation criterion “Subject experiences an episode of vomiting assessed as 
“severe” lasting more than 24 hours and considered to be at least possibly related to study 
drug without any other potential cause (eg, viral gastroenteritis, food-borne illness).”
Rationale: To provide further instructions on the management of subjects with adverse events of moderate and 
severe vomiting that may lead to dehydration.
Section 8.2, Safety 
Assessments
Added: 

Instructions on the monitoring, evaluation, and follow-up of subjects with moderate 
and severe vomiting 

Instruction on how to manage study drug in subjects with moderate or severe 
vomiting

Clarification on the use of anti-emetics to treat subjects with moderate and severe 
vomiting
Rationale: To fix minor errors.
Section 5.2, Exclusion 
Criteria
Fixed exclusion criterion No, 10 from “the screening visit” to “Week -2 visit.”
Section 7.1, 
Discontinuation from 
Study Drug
Fixed sub-bullet that should be stand-alone bullet (ie, “Subject has persistent episodes of 
tachyarrhythmia (eg, atrial flutter, atrial fibrillation, ventricular tachycardia) or develops 
persistent resting pulse rate >100 bpm for which in the opinion of the investigator it is in 
the best interest of the subject to discontinue study treatment” is now separate from the 
eGFR criterion).
Section 8.1, Efficacy 
Assessments
Corrected when IWQOL-Lite will be administered (ie, from “Weeks -1” to “Weeks -2.”
Appendix 6, Method 
of Blood Pressure and 
Pulse Rate 
Measurement
Updated text about blood pressure measurements.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
6
Approved, Date: 23 August 2018
1.
PROTOCOL SUMMARY
1.1.
Synopsis
A Randomized, Double-blind Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study to 
Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Subjects with Type 2 Diabetes 
Mellitus (T2DM)
JNJ-64565111 (formerly designated as HM12525A, developed by Hanmi Pharmaceuticals) is a synthetic, 
modified oxyntomodulin (OXM) peptide; it is the site-specific form of HMGLP/GCG25 (a glucagon-like 
peptide-1 [GLP-1]/glucagon dual agonist peptide), that is conjugated to the constant region of a human 
immunoglobulin G4 fragment (HMC001) via a 10 kDa polyethylene glycol linker. 
In vitro, JNJ-64565111 stimulates both GLP-1 and glucagon receptor (GCGR) with comparable potency. 
Moreover, JNJ-64565111 lowers body weight and plasma glucose in animal models of obesity and 
T2DM. The mechanisms mediating body weight loss by JNJ-64565111 are thought to be via synergistic 
effects on caloric (food) intake and energy expenditure. In addition, the theoretical potential for blood 
glucose elevation with JNJ-64565111 due to GCGR agonism, appears to be efficiently offset by its 
GLP-1 receptor activity, as demonstrated by reduced blood glucose levels in mice and in humans with 
T2DM. JNJ-64565111 lowers cholesterol, low-density lipoprotein (LDL), and triglycerides in animal 
models of dyslipidemia.
OBJECTIVES AND ENDPOINTS
Primary Objectives
The primary objectives are to assess the effects of JNJ-64565111 compared with placebo in severely 
obese T2DM subjects after 12 weeks of treatment on:

the percentage change in body weight from baseline

safety and tolerability
Secondary Objectives
The secondary objectives are to assess the effects of JNJ-64565111 compared with placebo in severely 
obese T2DM subjects after 12 weeks of treatment on:

the absolute change in body weight from baseline

the proportion of subjects with 5% weight loss from baseline
Exploratory Objectives
The exploratory objectives are to assess the effects of JNJ-64565111 compared with placebo in severely 
obese T2DM subjects after 12 weeks of treatment on:

the proportion of subjects with 10% weight loss from baseline

the change in body mass index (BMI) from baseline

the change in waist circumference from baseline

the change in glycated hemoglobin (HbA1c) from baseline

the change in fasting plasma glucose (FPG) from baseline

the change in fasting insulin from baseline
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
7
Approved, Date: 23 August 2018

the change in fasting C-peptide from baseline

the changes in Homeostasis Model Assessment for B cell function (HOMA-B) and HOMA-insulin 
resistance (IR) from baseline

the change in systolic blood pressure (SBP) from baseline

the change in diastolic blood pressure (DBP) from baseline

the change in pulse rate from baseline

the change in pulse-pressure product from baseline

the change in fasting lipids (total cholesterol, low-density lipoprotein cholesterol [LDL-C], 
high-density lipoprotein cholesterol [HDL-C], and triglycerides) from baseline

pharmacokinetic (PK) exposure

the change in scores on the Impact of Weight on Quality of Life – Lite (IWQOL-Lite) from baseline

the change in scores on the Patient-Reported Outcomes Measurement Information System 
(PROMIS®) Physical Function Short Form 10a (PROMIS SF 10a) from baseline

the change in scores on the Eating-related Concept Questionnaire (ERCQ) from baseline 
Hypotheses
In severely obese subjects with T2DM, treatment for 12 weeks with JNJ-64565111 compared with 
placebo leads to:
Primary:

Greater percentage reduction in body weight from baseline
Secondary:

Greater absolute reduction in body weight from baseline

Greater proportion of subjects with ≥5% weight loss from baseline
OVERALL DESIGN
This is a randomized, double-blind, placebo-controlled, parallel-group, 4-arm, multicenter study in 
severely obese subjects with T2DM. Subjects who are 18 and 70 years of age and have a BMI 
≥35 kg/m2 to ≤50 kg/m2 are eligible to participate if they have a HbA1c of 6.5% to ≤9.5% at the 
screening visit on diet and exercise alone or on a stable dose of a single oral antihyperglycemic agent 
(AHA) or dual-combination oral AHAs for 12 weeks prior to screening.
NUMBER OF SUBJECTS
A target of 188 subjects will be randomly assigned in this study.
TREATMENT GROUPS AND DURATION
On Day 1, subjects who continue to meet eligibility criteria, will be randomly assigned in a 1:1:1:1 ratio 
to blinded treatment with placebo or JNJ-64565111 5.0 mg, 7.4 mg, or 10 mg and enter a 12-week
treatment phase. Post-randomization visits will be conducted at Week 2, 6, 12/end-of-treatment [EOT] 
visit, and the follow-up visit 5 weeks after the last dose of study drug. At Weeks 4 and 10, all subjects 
will be contacted preferably by telephone to reinforce the adherence to diet and exercise, study drug 
dosing reminder, assessment of subjects’ status, and compliance with the protocol procedures (eg, diary 
completion reminder).
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
8
Approved, Date: 23 August 2018
Counseling should be done by dietitians/nutritionists on Day 1 to provide assessment and 
recommendation on a reduced-calorie diet and exercise regimen. In addition, subjects will be counseled 
on maintaining proper hydration throughout the study especially in circumstances of potential dehydration 
(eg, nausea and vomiting). At subsequent visits (Week 2 and Week 6), counseling and reinforcement of 
the recommended diet/exercise and hydration regimens will be conducted by a trained counselor. In 
addition, beginning at Week -2 visit, subjects will be counseled to comply and perform fasting self-
monitored blood glucose (SMBG) testing at least 2 times per week. At each treatment visit, the 
investigator or qualified, assigned designee will review the subject’s diaries, concomitant medications and 
the adverse events (AEs) that started or changed since the last visit.
Study Drugs Administered
Open-label AHA Background Therapy
Subjects on oral AHA will be required to have been on a stable treatment regimen (ie. same agent and 
same dose) for at least 12 weeks prior to screening and to remain on such regimen throughout the 
remainder of the study. 
Antihyperglycemic agents allowed at screening and as glycemic rescue medication during study are: 
metformin, sulphonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter 2 
(SGLT-2) inhibitors, and thiazolidinediones (TZDs).
Basal insulin is not allowed at screening but can be used as a glycemic rescue medication.
On days of protocol-specified study visits, subjects are to withhold their morning dose of subjects’ oral 
AHA until after the completion of all study visit procedures.
JNJ-64565111/Placebo During Run-in Period
At the Week -2 visit, subjects will be instructed on the use of prefilled safety injectors to perform 
subcutaneous (SC) self-injections, and will be asked to perform a self-injection in the presence of the 
study-site staff. Only subjects who express willingness and demonstrate the ability to administer once 
weekly SC injections are eligible to participate in the study. To assess compliance with the dosing 
regimen, eligible subjects will be dispensed prefilled safety injectors containing 0.5 mL open-label 
placebo and instructed to perform self-injections once weekly at home during the run-in phase, as well as 
keep a study drug diary of their injection schedule.
Double-blind JNJ-64565111 or Matching Placebo During Double-Blind Treatment Period
JNJ-64565111 will be supplied as a solution for injection at a concentration of 20 mg/mL. Blinded study 
drug will be provided in prefilled safety injectors with attached SC needle, prefilled with nominal 
volumes of 0.25, 0.37, or 0.50 mL of JNJ-64565111 (5.0, 7.4, and 10.0 mg, respectively) or 1 of 
3 matching volumes of placebo. The prefilled safety injector is intended for SC administration and 
consists of a syringe, a needle safety device, and grip accessory. Study drug will be manufactured and 
provided under the responsibility of the sponsor. Refer to the Investigator’s Brochure for a list of 
excipients.
On Day 1, subjects randomly assigned to the double-blind treatment arms will receive a supply of their 
randomly-assigned study drug and will be reminded of the once weekly dosing regimen and to record the 
date and time of each administered dose in the study drug diary. Subjects will self-administer the first 
dose of JNJ-64565111 or matching placebo at the site under the supervision of study staff.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
9
Approved, Date: 23 August 2018
Drug Administration
Subjects will be instructed to administer study drug SC once weekly for the entire duration of the 
12-week treatment phase or until early discontinuation.
Subjects will be instructed to inject to the 4 quadrants of the anterior abdominal wall. For consistency, 
and to avoid dosing in the same abdominal area, subjects should be instructed to begin in one quadrant 
and on subsequent dosing days proceed in the next quadrant in a counterclockwise manner.
Injections can be done at any time of day irrespective of meals. However, it is preferable that study drug 
be injected during the same overall time period of the day on a week-to-week basis.
Study drug should be taken on the same day of the week throughout the study (ie, the regularly scheduled 
study drug day).
If the day of the once weekly injection coincides with the day of a clinic visit, subjects are NOT to 
inject JNJ-64565111 or matching placebo before arriving at the clinic. Instead, AFTER all study visit 
procedures have been completed, subjects may self-administer blinded study drug either at the study site 
or once they have returned home.
Subjects are to record the date and time of study drug administration on the study drug diary, and should 
mark a calendar to remind them of when to take the next weekly dose. Subjects will be instructed to 
record the date and time of each self-injection throughout the run-in and treatment phase which allows an 
assessment of treatment compliance and the relationship of PK measurements and safety assessments to 
the time of study-drug dosing. The information will be entered into electronic case report forms (eCRFs)
by the site personnel.
Subjects should be instructed not to take 2 doses within 3 days (72 hours) of each other. If a subject 
misses taking the next dose of study drug on their regularly scheduled study drug day, the missed dose 
should be taken as soon as possible, if there are at least 3 days (72 hours) until their next regularly 
scheduled study drug day. If there are less than 3 days remaining, the subject should skip the missed dose 
and take the next dose on their regularly scheduled study drug day.
Glycemic Rescue Medication
During the 12-week treatment phase, glycemic rescue therapy will be implemented in subjects with FPG 
values (repeated and confirmed within 7 days) meeting the prespecified criteria. Subjects should be 
counseled to contact the site if their fasting SMBG consistently (ie, ≥3 days within a week) exceeds 
200 mg/dL, and an FPG measurement to determine eligibility for glycemic rescue therapy should be 
obtained. Subjects should have reinforcement of diet and exercise recommendations before obtaining the 
repeat FPG value. At the investigator’s discretion, based upon recent fasting SMBG values that are 
consistent with the initial FPG result meeting glycemic rescue criteria, this single FPG (ie, without a 
repeat FPG value) may be used to demonstrate eligibility for glycemic rescue therapy.
Rescue therapy may include increasing the dose of a current AHA or the initiation of a new AHA. 
Investigators will manage rescue therapy, including the selection of the specific AHA, its clinically 
appropriate initial dose and titration regimen (if applicable), the need to switch from one AHA rescue 
medication to another (eg, poor glycemic response to prior rescue medication), and be consistent with the 
labeled use within the country of the study site. Metformin, sulphonylureas, TZDs, SGLT-2 inhibitors, 
DPP-4 inhibitors, and insulin (basal only) are allowed as rescue medication. GLP-1 agonists and short-
acting or intermediate insulins are not allowed as rescue medications.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
10
Approved, Date: 23 August 2018
EFFICACY EVALUATIONS
The primary efficacy endpoint will be the percentage change in body weight from baseline to Week 12 
between JNJ-64565111 compared with placebo.
The secondary measures of efficacy at Week 12 include proportion of subjects with 5% weight loss from 
baseline, and the absolute change in body weight from baseline.
Exploratory efficacy endpoints at Week 12 include proportion of subjects with 10% weight loss from 
baseline, change from baseline in BMI, waist circumference, HbA1c, FPG, fasting insulin, fasting C-
peptide, HOMA-B, HOMA-IR, fasting lipids (ie, total cholesterol, LDL-C, HDL-C, triglycerides), SBP, 
DBP, pulse rate, pulse-pressure product, PK exposure, and patient-reported outcomes (PROs) (ie, changes 
in IWQOL-Lite, PROMIS SF 10a, and ERCQ).
PHARMACOKINETIC EVALUATIONS
Venous blood samples will be collected from all subjects according to the Schedule of Activities for 
determination of serum trough concentrations of JNJ-64565111 to assess attainment of steady-state 
concentrations. In addition, a non-trough (peak) sample on Day 4 will be collected from all subjects, as 
well as a post-treatment sample at 16 weeks from all subjects. 
IMMUNOGENICITY EVALUATIONS
Anti-JNJ-64565111 antibodies will be evaluated in serum samples collected from all subjects according 
to the Schedule of Activities. 
SAFETY EVALUATIONS
Safety evaluations will include the monitoring of AEs (including protocol-specified AEs of interest), vital 
sign measurements, clinical laboratory tests (including serum chemistry, calcitonin, lipase, amylase, 
hematology, and urinalysis), physical examination including complete skin examination, serum/urine 
pregnancy testing, electrocardiogram (ECG), SMBG, assessment of hypoglycemia episodes, and review 
of concomitant medications.
STATISTICAL METHODS
A total of 188 subjects will be randomly assigned in this study with 47 subjects per group allocated to 
each of the 4 treatment groups. Sample size was determined based on assessing the primary hypothesis 
that treatment with JNJ-64565111 at 1 or more dose levels for 12 weeks leads to greater percentage 
reduction in body weight compared with placebo. 
Assuming a common standard deviation (SD) of 4% with respect to percent change in body weight at 
Week 12 and a 2-sided type I error rate of 0.05, it is estimated that a sample size of 47 randomly assigned 
subjects per group will have approximately 90% power to detect a treatment difference of 2.7%.
Primary Efficacy Endpoint
The primary efficacy endpoint will be the percentage change in body weight between JNJ-64565111 and 
placebo from baseline to Week 12.
The primary efficacy endpoint will be analyzed based on the modified intent-to-treat (mITT) analysis set 
using a mixed model for repeated measures (MMRM). The analysis will use the observed data through 
Week 12 while on treatment (up to the last dose of study drug plus 7 days) and prior to rescue medication. 
The analysis model will include the fixed, categorical effects of treatment, visit, and treatment-by-visit 
interaction, as well as the continuous covariates of baseline body weight and baseline-by-visit interaction. 
An unstructured covariance will be used to model the within-patient errors. The treatment comparisons 
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
11
Approved, Date: 23 August 2018
will be made between each of the JNJ-64565111 treatment groups and placebo at Week 12 based on this 
model.
A secondary analysis of the primary endpoint will be based on the intent-to-treat (ITT) analysis set and 
will employ pattern mixture models using multiple imputation methods. This analysis will use all 
observed data, including the measurements off treatment. Responses for subjects who discontinued from 
the study earlier than Week 12 will be imputed based on subjects who discontinued treatment prematurely 
but subsequently provided off-treatment measurements. The imputation will be done within randomized 
treatment groups. Data will be analyzed using the same model as in the primary analysis. The treatment 
comparisons between each of the JNJ-64565111 treatment groups and placebo will be made at Week 12. 
Details of this approach will be provided in the SAP.
Finally, the primary efficacy endpoint will be analyzed based on the completers analysis set. Additional 
analysis using a Multiple Comparison Procedure – Modeling approach will be performed to explore the 
dose-response relationship.
Secondary Efficacy Endpoints
Secondary efficacy analyses at Week 12 will include the absolute change in body weight from baseline 
and the proportion of subjects with 5% weight loss.
The absolute change in body weight from baseline at Week 12 will be analyzed with an MMRM model 
similar to the primary efficacy endpoint based on the mITT analysis set.
The proportion of subjects with 5% weight loss will be analyzed longitudinally using a generalized 
linear mixed model (Multiple Comparison Procedure – Modeling) based on the mITT analysis set. The 
analysis will use the observed data through Week 12 while on treatment (up to the last dose of study drug 
plus 7 days) and prior to rescue medication. The model will include the fixed, categorical effects of 
treatment, visit, and treatment-by-visit interaction, as well as the continuous covariates of baseline weight, 
and baseline-by-visit interactions. An unstructured covariance will be used to model the within-patient 
errors. The odds ratio and associated p-value for the treatment comparison between each of the 
JNJ-64565111 treatment groups versus placebo at Week 12 based on this model will be provided.
A secondary analysis of the secondary endpoints will be based on the ITT analysis set and will employ 
pattern mixture models using multiple imputation methods based on information from retrieved dropouts 
as described above. For the proportion of subjects with 5% weight loss, response status will be 
determined from the imputed continuous response based on subjects who discontinued treatment 
prematurely but subsequently provided off-treatment measurements.
Safety Analyses
The evaluation of safety will be based on the incidence of AEs and hypoglycemia episodes, and changes 
in clinical laboratory test results and vital sign results (blood pressure, pulse rate). The safety analyses 
will be based on the safety analysis set including all data, regardless of the initiation of glycemic rescue 
therapy (ie, including data after initiation of rescue therapy). Additional analysis of hypoglycemia will be 
performed based on the data prior the initiation of glycemic rescue therapy only. Summaries of AEs, 
clinical laboratory test results, and vital sign results will be provided by treatment group. There will be no 
imputation of missing values for clinical safety laboratory test results, and vital sign measurements.
1.2.
Schema
A diagram of the study design is provided in Figure 1.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
12
Approved, Date: 23 August 2018
Figure 1:
Schematic Overview of the Study
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
13
Approved, Date: 23 August 2018
1.3.
Schedule of Activities (SoA)
Protocol Activity
Pre-treatment
Treatment Phase
Post-treatment
Screening
Run-In
Wk -3
Wk -2
Wk-1
Day 1
(Randomization) Day 4
Wk 2 
Wk 4 
(RC)a
Wk 6
Wk 10 
(RC)a
Wk 11
Wk 12/
EOTb
SAE Follow-
Upc
Screening/Administrative
Informed consent d
X
Inclusion/exclusion criteria
X
X
X
Medical history & demographics
X
Prior therapy reporting and review e
X
X
X
IWRS log-in
X
X
X
X
X
X
Randomization
X
Study Drug Administration
Show and/or describe injection device
X
Dispense run-in medication 
X
Dispense double-blind medication 
X
X
X
Injection at study site f
X
X
Dispense study drug diary 
X
X
X
X
Review study drug diary
X
X
X
X
Run-in compliance assessment
X
Drug return and accountability
X
X
X
X
Survey on self-administration of study drug g
X
Clinical Procedures
Physical examination h
X
X
Vital signs (PR and BP, in triplicate) i
X
X
X
X
X
Weight j
X
X
X
X
X
Height
X
Waist circumference j
X
X
12-lead ECG (local)
X
Laboratory Assessments k
Fasting fingerstick glucose l,m
X
Glycated hemoglobin (HbA1c)
X
X
X
X
X
Fasting plasma glucose (FPG)l
X
X
X
X
X
Fasting C-peptide l
X
X
X
Fasting insulin l
X
X
Fasting lipid profile l
X
X
X
Serum chemistry
X
X
X
X
X
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
14
Approved, Date: 23 August 2018
Protocol Activity
Pre-treatment
Treatment Phase
Post-treatment
Screening
Run-In
Wk -3
Wk -2
Wk-1
Day 1
(Randomization) Day 4
Wk 2 
Wk 4 
(RC)a
Wk 6
Wk 10 
(RC)a
Wk 11
Wk 12/
EOTb
SAE Follow-
Upc
Hematology
X
X
X
Calcitonin
X
X
X
Serum β-hydroxybutyrate
X
X
X
X
Urine dipstick/urinalysis
X
X
Serum pregnancy test n
X
X
Urine pregnancy test
Xo
Follicle-stimulating hormone p
X
Trough Pharmacokinetic and Immunogenicity 
Anti-Drug Antibodies samples q
X
X
X
X
X
Non-trough Pharmacokinetic sample
X
Fasting plasma, serum, and urine archive 
samples for exploratory research l
X
X
Patient-Reported Outcomes r
IWQOL-Lite
X
X
Dispense diary containing Eating-related 
Concepts Questionnaire (ERCQ) 
X
X
Contact subjects to remind completion of the 
7-day ERCQ diary 
X
Completion of 7-day ERCQ diary 
X----------------Xs
X-----------Xs
PROMIS Physical Function Short Form 
(PROMIS SF 10a) 
X
X
X
Patient Global Impression Status (PGIS) 
Xt
Xt
Patient Global Impression of Change (PGIC) 
Xt
Subject Counseling and Ongoing 
Review/Assessments
Diet/exercise and hydration counseling and 
reinforcement u
X
X
X
SMBG and hypoglycemia counseling v,w
X
Dispense glucose meter, test strips, and blood 
sugar diary w
X
X
X
X
Record SMBG level, hypoglycemic episodes, 
and concomitant medications x, e
X
X
X
X
X
X
X
X
X
X
Review/discuss blood sugar diary (which 
includes SMBG results, hypoglycemia 
events, and concomitant medications)
X
X
X
X
X
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
15
Approved, Date: 23 August 2018
Protocol Activity
Pre-treatment
Treatment Phase
Post-treatment
Screening
Run-In
Wk -3
Wk -2
Wk-1
Day 1
(Randomization) Day 4
Wk 2 
Wk 4 
(RC)a
Wk 6
Wk 10 
(RC)a
Wk 11
Wk 12/
EOTb
SAE Follow-
Upc
Adverse Event reporting and review y
X
X
X
X
X
X
X
X
X
X
AE=adverse event; AHA=antihyperglycemic agent; BP=blood pressure; ECG=Electrocardiogram; eCRF=electronic case report form; EOT=end-of-treatment; ERCQ=Eating-related 
Concepts Questionnaire; FPG=Fasting plasma glucose; FSH=Follicle-stimulating hormone; HbA1c= Hemoglobin A1c; HR=heart rate; IWQOL-Lite=Impact Of Weight On Quality Of Life-
Lite; IWRS=interactive web response system; PK=Pharmacokinetics; PROMIS SF 10a=Patient-Reported Outcomes Measurement Information System Physical Function Short Form 10a; 
RC=remote contact; SAE=serious adverse event; SMBG=Self-monitored blood glucose; Wk=Week. 
a)
Study-site staff will contact subjects preferably by telephone to reinforce the adherence to diet and exercise, proper hydration, study drug dosing reminder, assessment of 
subjects' status, and compliance with the protocol procedures (eg, diary completion reminder). 
b)
Subjects who prematurely discontinue study drug will require an immediate EOT assessment (either on the day of study drug discontinuation or as soon as possible following 
study drug discontinuation). Subjects that discontinue study drug early will continue in the study and be assessed with the off-treatment procedures at the subsequent visit(s) per 
the Schedule of Activities, starting at the next scheduled visit from when study drug was permanently discontinued up to the final Week 12 visit. These off-treatment procedures 
will include assessment and collection of SAEs, specific AEs of interest (ie, major adverse cardiac events, acute pancreatitis, and possible cases of thyroid neoplasm), vital signs 
(including body weight), and concomitant medications.
c)
The SAE follow-up visit will be conducted for all subjects approximately 5 weeks after the last dose of study drug to collect serious adverse events since the last visit unless the 
subject has died, has been lost to follow-up, or has withdrawn consent. Blood samples will also be collected for PK and immunogenicity (ie, anti-drug antibody) measurement. 
Subjects who prematurely discontinue study drug for any reason prior to Week 12 and have not withdrawn consent, will continue (off-treatment) in the study following the EOT 
visit and undergo the off-treatment procedures based on the predefined study visit schedule.
d)
Informed Consent must be signed at the screening visit before any study procedures are performed.
e)
Record any medications taken from up to 30 days before screening (and up to 6 months before screening for AHA) until the first dose of treatment phase study drug on Day 1 
(baseline) as prestudy therapy in the corresponding eCRF. Concomitant therapy includes all medications taken since the first dose of treatment phase study drug on Day 1.
f)
Subjects will be asked to perform a self-injection of open-label JNJ-64565111-matching placebo (Week -2) or their randomly-assigned study drug (Day 1) at the study site in the 
presence of the study-site staff. After Day 1, injections may be performed by the subject at home.
g)
A survey will be given to English-speaking subjects to assess subject satisfaction with the experience of self-administering JNJ-64565111 or matching placebo.
h)
Physical examinations will include a full review of body systems including a complete skin examination. Physical examination abnormalities noted after the baseline assessment 
will be collected if considered an adverse event by the investigator (recorded on adverse event eCRF). In addition to the physical examination required at the screening visit and 
EOT visit, investigators should use their clinical judgment whether additional physical examinations (either full of focused) are needed (eg, subject reporting injection site 
reaction, flank pain, pedal edema, etc.).
i)
Blood pressure and pulse rate: 3 seated readings will be recorded in the source and eCRF. See Appendix 6, Method of Blood Pressure and Heart Rate Measurement.
j)
Body weight will be measured using a calibrated scale; subjects should be weighed wearing underwear and a gown. Note: if disrobing for weighing is logistically impossible, the 
subject must be dressed as lightly as possible, with consistency from visit to visit; subjects will be instructed to take off their shoes and to empty their bladders before being 
weighed. Anthropometric measurements, for height, body weight, and waist circumference measurement procedures, are described in Appendix 5, Anthropometric 
Measurements.
k)
Specific details about specimen collection, storage, packaging, and shipping will be provided in an operations manual from the central laboratory.
l)
Subjects must fast for at least 8 hours before blood sample collection. For fasting samples to be collected at the screening visit, if subject is not fasting, the subject should return 
to the site soon after the screening visit (and before the start of the run-in phase) to have a fasting sample collected.
m)
Fasting fingerstick glucose values may be obtained by study-site staff at the study site or by the subject at home on the morning of Day 1. 
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
16
Approved, Date: 23 August 2018
n)
Serum (β-human chorionic gonadotropin [β-hCG]) pregnancy testing will be performed for all women of childbearing potential (ie, unless they are permanently sterilized or 
unless there is a documented history of their postmenopausal status, as defined in Section 5.1, Inclusion Criteria) at the screening and Week 12/EOT visits. Additional serum or 
urine pregnancy tests may be conducted throughout the study in sufficient number, as determined by the investigator or required by local regulations, to establish the absence of 
pregnancy during the study.
o)
Urine pregnancy test must be negative before dosing can proceed. In the case of an ambiguous test result, a serum pregnancy test will be performed and randomization will be 
delayed by a few days in order to obtain the test result. Randomization may only proceed if the result of the serum pregnancy test is negative.
p)
FSH will be measured in women >45 years of age with amenorrhea for at least 6 months and <18 months prior to screening.
q)
For PK sampling, subjects will be instructed to refrain from taking the study drug in the morning before the clinic visit. The subject must report the time that the study drug was 
taken on the day preceding the clinic visit. 
r)
All patient-reported outcome assessments should be completed at the beginning of the clinic visit (whenever possible) for site visit-based assessments and completed at the same 
time each day in the same setting each day for home-based assessments as specified in the Schedule of Activities, or at the time the subject discontinues the study drug, before all 
other evaluations, as specified in the Schedule of Activities. Assessments (whenever possible) should be completed before any tests, procedures, or discussion of AEs or the 
subject’s medical condition. Refer to Appendix 13 for more details. 
s)
ERCQ diary should be completed at home for 7 consecutive days at these time points: (1) between day after Week -2 and day before Day 1 for 7 consecutive days and 
(2) between the day after Week 10 contact reminder and day before Week 12.
t)
Patient Global Impression Status (PGIS) and Patient Global Impression of Change (PGIC) are needed to calculate responder definitions for new patient-reported outcome 
instruments ERCQ and PROMIS SF 10a. These are not exploratory efficacy endpoints.
u)
Subjects will be counseled to maintain a diet and exercise regimen consistent with those outlined in treatment guidelines for T2DM (eg, the American Diabetes Association 
guideline). In addition, subjects will be counseled on maintaining proper hydration throughout the study especially in circumstances of potential dehydration (eg, nausea and 
vomiting).
v)
Subjects will be instructed to return with their completed diaries to the study site for review by study-site personnel at each clinic visit (eg, for review of hypoglycemic events, 
insulin dosage changes [only for subjects who are on insulin], SMBG values, concomitant medications, timing of study drug taken and any missed doses of study drug).
w)
Subjects will be provided with and instructed on the use of a home blood glucose monitoring system. Blood glucose testing supplies will also be provided as necessary.
x)
Hypoglycemic episodes should be recorded on the hypoglycemia eCRF and also on the Adverse Event eCRF if considered an adverse event by the investigator (see 
Appendix 8 – Hypoglycemia: Definitions, Symptoms, and Treatment).
y)
Adverse events will be monitored throughout the study from the time of signing the informed consent form until 5 weeks after the last dose of study drug.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
17
Approved, Date: 23 August 2018
2.
INTRODUCTION
The prevalence of obesity is increasing worldwide. The World Health Organization (WHO) 
estimated that worldwide obesity has nearly tripled since 1975, affecting more than 650 million 
adults (WHO 2017). In the United States (US) in 2015-2016, 39.8% of adults and 18.5% of 
children and adolescents were obese, representing a significantly increasing trend compared to 
the prevalence of 30.5% and 13.9%, respectively, reported in the 1999-2000 period (Hales 2017). 
The US Centers for Disease Control and Prevention predict that obesity-related deaths could 
soon overtake smoking-related illnesses as the leading cause of mortality in the US. Indeed,
obesity represents a major risk factor for cardiovascular (CV) diseases (eg, hypertension, 
atherosclerotic diseases, stroke), metabolic diseases (eg, type 2 diabetes mellitus [T2DM], 
dyslipidemia, non-alcoholic fatty liver disease [NAFLD]/steatohepatitis [NASH]), conditions of 
the genito-urinary system (polycystic ovary syndrome, sexual dysfunction, stress urinary 
incontinence), musculoskeletal apparatus (eg, degenerative arthritis, pain). In addition, obesity is 
associated with impaired health-related quality of life, an increased risk of depression, and 
several types of cancers, predominantly of the digestive tract and female reproductive system 
(Kyrgiou 2017; Wolfe 2017). The increased obesity-related morbidity was recently demonstrated 
in the Patient Outcome Research to Advance Learning study of more than 12 million individuals 
in the US who were overweight or had obesity and assessed for the prevalence of 
cardiometabolic risk factors: elevated blood pressure, elevated triglycerides, low high-density 
lipoprotein–cholesterol (HDL-C), and prediabetes. Compared with being overweight, obesity 
classes I (body mass index [BMI] 30.0-34.9 kg/m2), II (BMI 35.0–39.9 kg/m2), and III (BMI 
40 kg/m2) were associated with a nearly 2-fold, 3-fold, and 4-fold, respectively, greater 
probability of having at least 1 cardiometabolic risk factor (Nichols 2017). Hence, subjects with 
severe obesity (BMI≥35 kg/m2) are consequently more affected by the disease, have a poor 
quality of life, and thus have the greatest need for weight-loss therapy. Indeed, these comorbid 
conditions are expected to improve or go into remission in the presence of effective and 
sustained weight loss. 
Current treatments for severe obesity include dietary and behavioral interventions, 
pharmacologic therapies, and eventually bariatric surgery. While combination strategies using 
diet, exercise, and behavior therapy have been shown to be more effective in the short term than 
diet and exercise alone (NIH 2000), these treatments are usually ineffective in subjects who are 
severely obese. Although weight reduction by as little as 5% of body weight has been shown to 
improve many obesity comorbidities, this modest weight reduction is insufficient to result in 
significant improvement in this population. Additionally, weight regain is common in severely 
obese patients, even when approaches are used that combine dietary therapy with exercise and 
behavior modification.
Pharmacotherapy is the second-line therapy recommended when lifestyle changes are ineffective 
in yielding significant weight loss. Currently available drug therapies include gastrointestinal 
(GI) lipase inhibitors such as orlistat (Xenical® [Xenical USPI], Roche Laboratories, Inc. or 
Alli®, GlaxoSmithKline Inc.), selective 5-HT2C-receptor agonists such as lorcaserin (Belviq® 
[Belviq USPI], Arena Pharmaceuticals Inc.), glucagon-like peptide-1 (GLP-1) receptor agonists 
such as liraglutide (Saxenda® [Saxenda USPI], Novo Nordisk Inc.), the combination of 
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
18
Approved, Date: 23 August 2018
naltrexone, an opioid antagonist, and bupropion, a dopamine and norepinephrine-reuptake-
inhibitor (Contrave®, Mysimba®, Orexigen Therapeutics Ireland Ltd.), and the combination of 
phentermine, a sympathomimetic amine, and topiramate, an anti-epileptic drug (Qsymia® 
[Qsymia USPI] in the US, Vivus Inc.). In addition, phentermine (Adipex-P USPI), as well as 
some other anorectic agents (including diethylpropion, benzphetamine, and phendimetrazine), 
are registered in the US for short-term use (a few weeks, according to the label). 
Pharmacological compounds have variable efficacy and their use can be limited by side effects 
including diarrhea, abdominal cramps, and reduced absorption of fat-soluble vitamins with 
orlistat (Xenical USPI); serotonin-associated adverse reactions; cognitive impairment, 
psychiatric disorders, and possible valvular heart disease with lorcaserin (Belviq USPI); nausea, 
vomiting, elevation in pulse rate, and acute pancreatitis with liraglutide (Saxenda USPI); GI side 
effects, psychiatric, neurocognitive and sleep disorders with the combination of naltrexone and 
bupropion (Contrave USPI); and cognitive impairment, psychiatric disorders, and elevation in 
pulse rate with the combination of phentermine and topiramate (Qsymia USPI); and adverse 
events (AEs) related to the central nervous system or the cardiovascular system with 
phentermine (Adipex-P USPI). 
Although bariatric surgery represents the most effective treatment option for severe obesity as it 
provides significant and sustained weight loss, and is more effective than lifestyle or 
pharmacological management in achieving glycemic control and reductions in morbidity and 
mortality, it can be associated with peri-operative (eg, venous thromboembolism, anastomotic 
leaks, wound infections, bleeding, and hernias) and post-operative (eg, nausea, vomiting, 
dumping syndrome, fat-soluble vitamin malabsorption) complications.
Given the above, there is a need for more effective and well-tolerated weight-management 
therapies that may also positively affect obesity-related comorbidities such as hypertension, 
dyslipidemia and T2DM (Padwal 2003). 
While patients who undergo gastric banding and gastric bypass surgery have a reduction in 
caloric intake, there are also changes in several gut hormones that may play a role in reducing 
appetite and enhancing glucose control (le Roux 2007). Among the changes that have been 
consistently observed following bariatric surgery are increased postprandial levels of glucagon, 
GLP-1, and oxyntomodulin (OXM) (Chandarana 2012; le Roux 2007). Therefore, administration 
of metabolically stable endogenous gut peptides represents a potential therapeutic approach to 
modulating the pathophysiology of obesity and T2DM.
Oxyntomodulin is an endogenous 37-amino acid peptide secreted from enteroendocrine L-cells 
in the gut in response to and in proportion to nutrient ingestion. Oxyntomodulin is a dual agonist, 
acting at both the GLP-1 receptor (GLP-1R) and the glucagon receptor (GCGR). These 
combined actions at the GLP-1R (enhanced glucose-stimulated insulin secretion and suppression 
of food intake) and the GCGR (suppression of food intake, increased energy expenditure, and 
improved lipid metabolism) suggest that OXM-based therapeutics could provide several benefits 
to obese patients and might produce superior weight loss as compared to currently available 
weight-management medications. Rodent and human studies support this hypothesis. 
Oxyntomodulin-based agonists cause marked weight loss in obese mice, and that effect is 
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
19
Approved, Date: 23 August 2018
reduced in mice lacking either GLP-1R or GCGR (Day 2009). Oxyntomodulin treatment in 
humans reduced food intake acutely by 14 to 20% (Cohen 2003; Field 2010) and resulted in a 
2% body weight reduction after 4 weeks relative to subjects who received placebo 
(Wynne 2005).
JNJ-64565111 (formerly designated as HM12525A, developed by Hanmi Pharmaceuticals) is a 
synthetic, modified OXM peptide; it is the site-specific form of HMGLP/GCG25 (a 
GLP-1/glucagon dual agonist peptide), that is conjugated to the constant region of a human 
immunoglobulin G4 fragment (HMC001) via a 10 kDa polyethylene glycol linker. The constant 
region of human immunoglobulin G4 fragment was chosen as the stabilizing agent, because it is 
a highly prevalent blood protein and has an in vivo half-life of several weeks, and lacks immune 
effector functions, such as complement-dependent cytotoxicity or antibody-dependent cell-
mediated cytotoxicity.
In vitro, JNJ-64565111 stimulates both GLP-1 and GCGR with comparable potency. Moreover, 
JNJ-64565111 lowers body weight and plasma glucose in animal models of obesity and T2DM. 
The mechanisms mediating body weight loss by JNJ-64565111 are thought to be via synergistic 
effects on caloric (food) intake and energy expenditure. In addition, the theoretical potential for 
blood glucose elevation with JNJ-64565111 due to GCGR agonism, appears to be efficiently 
offset by its GLP-1 receptor activity, as demonstrated by reduced blood glucose levels in mice 
and in humans with T2DM. JNJ-64565111 lowers cholesterol, low-density lipoprotein (LDL), 
and triglycerides in animal models of dyslipidemia.
For the most comprehensive nonclinical and clinical information regarding JNJ-64565111, refer 
to the latest version of the Investigator's Brochure for JNJ-64565111 (JNJ-64565111 IB). 
The term "sponsor" used throughout this document refers to the entities listed in the Contact 
Information page(s), which will be provided as a separate document.
2.1.
Study Rationale
JNJ-64565111 has been studied in a first in human study consisting of a single- and multiple-
ascending dose study in overweight/obese subjects with and without T2DM for up to a 4-week 
period. In addition, 2 other multiple ascending dose studies were conducted in overweight/obese 
subjects with T2DM for 4 weeks to further assess higher doses and a different dosing regimen.
Across all studies, JNJ-64565111 was generally well-tolerated and no safety signals precluding 
further development were seen. This Phase 2b dose-ranging study is being conducted to assess 
the safety and efficacy of JNJ-64565111 over a 12-week period in severely obese subjects with 
T2DM being treated with diet and exercise alone or on a stable dose of single oral 
antihyperglycemic agent (AHA) or dual-combination oral AHA(s) for ≥12 weeks prior to 
screening. This information can then be used to select JNJ-64565111 dose(s) to be assessed in 
Phase 3 studies.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
20
Approved, Date: 23 August 2018
2.2.
Background
Nonclinical Studies
Pharmacologic Profile
Simultaneous activation of GLP-1R and GCGR were shown to have beneficial effects in body 
weight loss by synergistic regulation mechanisms in energy intake and expenditure. Using a 
high-fat, diet-induced obese animal model (ie, DIO mice), studies showed potent body weight 
loss by food intake inhibition as well as increased energy expenditure following treatment with 
JNJ-64565111. The body weight loss was mainly derived from the fat mass reduction, and 
accompanied with improvements in serum lipid profile. In addition, the simultaneous activity of 
JNJ-64565111 on GLP-1R and GCGR resulted in glucose-lowering in other animal models. 
JNJ-64565111 normalized the glycemic excursion following an intraperitoneal glucose tolerance 
test in DIO mice and improved glycemic control in an animal model of T2DM (ie, db/db mice).
Safety Pharmacology 
In safety pharmacology studies, JNJ-64565111 was evaluated in neurobehavioral, pulmonary, 
and cardiovascular pharmacology studies. In a neurobehavioral safety pharmacology study in 
rats up to 100 nmol/kg, JNJ-64565111 induced some changes (hunched posture, abnormal gait, 
reduced body temperature, tremor, etc.) but the changes were considered to be secondary to the 
large body weight losses recorded, which was an expected pharmacological effect. 
JNJ-64565111 produced no significant effects on any of the respiratory parameters (respiratory 
rate, tidal volume, and minute volume) measured in rats up to a dose of 100 nmol/kg. In 
cardiovascular safety pharmacology studies, JNJ-64565111 did not inhibit human ether-a-go-go-
related gene (hERG) channel current in vitro even at a 100-fold higher concentration (half 
maximal inhibitory concentration, IC50 >9.39 M) than a pharmacological active concentration. 
In conscious telemetered cynomolgus monkeys, the pulse rate, Rautaharju corrected QT interval 
(QTcR) and body temperature generally remained within the vehicle range except for the night 
periods where increases compared with the vehicle control were observed at 15, 40, and 
100 nmol/kg, but these changes remained within the high value limits of historical background 
data. Blood pressure values were generally lower than the vehicle in the whole study period and 
may be consistent with the vasodilatory effects of GLP-agonists. In a subsequent cardiovascular 
safety pharmacology study in conscious telemetered cynomolgus monkeys given lower doses of 
1 and 5 nmol/kg, there was no effect on body temperature, electrocardiogram (ECG) intervals 
(PR, QRS, QT, and QTcR), or blood pressure at either dose, and a slight non-adverse decrease in 
pulse rate during the nocturnal periods for the 1 nmol/kg dose that was not evident at 5 nmol/kg. 
Overall, JNJ-64565111 was well tolerated across the battery of safety pharmacology studies.
Toxicology
The safety of JNJ-64565111 was addressed in several studies, including single- and repeat-dose 
studies of up to 24 weeks in rats and 16 weeks in monkeys. All safety studies, pivotal repeat-
dose toxicity studies in rats and cynomolgus monkeys, genotoxicity studies, and pivotal embryo-
fetal development studies were conducted in compliance with Good Laboratory Practices.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
21
Approved, Date: 23 August 2018
No mutagenic effects were detected with JNJ-64565111 during in vitro and in vivo genotoxicity 
studies. In embryo-fetal development studies, JNJ-64565111 was not teratogenic in rats at up to 
4 nmol/kg, whereas this high dose in rabbits caused major external and underlying skeletal 
abnormalities primarily affecting the skull and limbs.
In general, JNJ-64565111 exposure increased with dose with no substantive sex differences in rat 
and monkey. Anti-drug antibodies (ADA) were produced in monkey, but not in rats. There were 
no toxicological findings that resulted from antigen-antibody complex. No test-item related 
injection site lesion was observed in either the rat or monkey studies.
In all studies, reduced body weight and food consumption were dose-limiting in rats and 
monkeys, with the most common clinical signs in rats being hunched position, abnormal gait, 
and decreased activity. In addition, anemia characterized by decreased red blood cell count, 
hemoglobin, and hematocrit occurred in rats and monkeys, and these changes in red blood cell 
parameters were due to bone marrow damage consistent with malnutrition.
All changes in organs observed in the rat 4-week toxicity study (0, 10, 30, and 60 nmol/kg/week) 
were attributed to effects caused by decreased food consumption, body weight loss, and 
associated metabolic stress, not by a direct effect of JNJ-64565111. These included effects on 
liver, pancreas, intestine, bone and bone marrow, reproductive organs, and immune organs 
(thymus, etc.), and generally consisted of decreases in functional activity and organ size. The No 
Observed Adverse Effect Level (NOAEL) was 30 nmol/kg. Findings in the rat 26-week toxicity 
study (0, 3, and 10 nmol/kg/week for 26 weeks, and at 20 and 30 nmol/kg/week for only 7 weeks 
because of the poor condition of the animals) were consistent with those in the shorter term 
4-week rat study, were attributed to dose-related sequelae of exaggerated pharmacology, and 
showed evidence of reversibility during the 6-week recovery period. The NOAEL was 
considered to be 3 nmol/kg/week. At the NOAEL, Week 26 exposure in male and female rats 
corresponded to a maximum concentration (Cmax) of 9.09 and 10.13 nmol/L, and an area under 
the curve in the interval 0–168 hours (AUC168hr) of 1,271 and 1,261 h.nmol/L, respectively.
JNJ-64565111 was generally well tolerated in a monkey4-week toxicity study (0, 15, 40, and 
100 nmol/kg/week) with the predominant treatment-related effects (reduced food intake, body 
weight loss, and/or poor body weight gain) attributable to the pharmacological action of the test 
substance resulting in a number of secondary findings on the erythrocytic and clinical chemistry 
parameters, liver and pancreas. Increases in pulse rate and QTcR were considered to be within 
the historical background range for monkeys. Based on non-adverse but pharmacology-related 
changes up to high dose, the NOAEL in a 4-week toxicity study in monkeys was 100 nmol/kg. In 
the 16-week study in cynomolgus monkeys (0, 15, 25, and 40 nmol/kg/week), administration of 
JNJ-64565111 resulted in exaggerated pharmacological effects of body weight loss and/or poor 
body weight gain that led to secondary erythrocytic and clinical chemistry changes. Significant 
neutralizing ADA development with clearance of JNJ-64565111 in the majority of animals 
impacted the overall toxicological assessment, as few animals had continuous exposure to study 
drug. Based on minimal to slight pathological changes, mainly of the pancreas and liver tissues, 
and persistent weight loss predominantly at 40 nmol/kg/week, the NOAEL was 
25 nmol/kg/week.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
22
Approved, Date: 23 August 2018
The findings attributed to secondary effects of decreased food consumption and body weight loss 
were more severe in rats than monkeys. The findings generally showed partial or complete 
recovery after a treatment-free period in both rats and monkeys. Monkeys presented only liver 
(increased or decreased glycogen content) and pancreatic changes (degranulation of acinar cells 
related to fasting effects, and increased cellularity). Increased pancreas cellularity has been 
observed for other GLP-1 agonists (eg, exenatide) and is considered a pharmacological effect.
In conclusion, the majority of findings recorded in the toxicity studies in rat and monkey are 
considered to be secondary to decreased food consumption and the large body weight losses 
recorded, an expected pharmacological effect, and JNJ-64565111 was considered well tolerated.
Clinical Studies
Clinical experience with JNJ-64565111 includes a first in human study (ie, HM-OXM-101) and 
two 4-week MAD studies (ie, 64565111EDI1001 and 64565111EDI1002). 
The first in human study had a single ascending dose (SAD) part in healthy subjects (dose levels: 
0.25, 0.5, 1.0, 2.0, and 4.0 nmol/kg) and a MAD part in subjects with T2DM (dose levels: 0.5, 
1.0, 1.5, and 2.0 nmol/kg, administered once weekly for 4 weeks).
The second MAD study, 64565111EDI1001, was conducted in subjects with T2DM and 
explored higher doses of JNJ-64565111 (2.5 and 3.0 nmol/kg). Results from this study showed 
non-dose-proportional pharmacokinetic (PK) data after repeated doses compared with data 
observed in the SAD portion of Study HM-OXM-101. Hence, an additional 4-week MAD study 
(64565111EDI1002) is being conducted to evaluate the full-dose range and PK profile. In this 
study, 4 groups of subjects with T2DM and treated with metformin have been dosed with 5.0, 
10.0, 12.4, and 15.0 mg of JNJ-64565111, (approximately equivalent to the body weight-based 
doses of 1.0, 2.0, 2.5, and 3.0 nmol/kg, respectively, for a 90 kg individual; see Table 1) once 
weekly for 4 weeks. Each group is to be composed of 8 subjects randomly assigned to 
JNJ-64565111 and 2 subjects randomly assigned to placebo. As of 01 February 2018, all subjects 
have completed treatment with study drug, but subjects in the 15 mg group are still in the post-
treatment follow-up period. Since the study is still ongoing, the individual subjects’ level safety 
data remain blinded and the group level efficacy results from this study described below are to be 
considered preliminary.
Table 1: 
Comparison of JNJ-64565111 Doses Used in Phase 1 Studies
Weight-based dose of 64565111 (nmol/kg)
0.5 
1.0
1.5
2.0
2.5
3.0
Fixed dose of 64565111 (mg)
2.5
5.0
7.4
10.0
12.4
15.0
Pharmacokinetics
In the first 2 Phase 1 studies, JNJ-64565111 was administered using weight-adjusted doses. PK 
analyses from these studies showed that following single subcutaneous (SC) administration, 
JNJ-64565111 is slowly absorbed with time to maximum concentration (Tmax) at approximately 
4 to 6 days post-administration. The terminal half-life (t1/2) of JNJ-64565111 is 7 to 8 days with 
an accumulation ratio of approximately 3- to 4-fold after repeated dosing. 
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
23
Approved, Date: 23 August 2018
The PK parameters in the ongoing Study 64565111EDI1002, where the full range of 
JNJ-64565111 was studied using a fixed dose rather than weight-based dose showed that 
following the first dose of JNJ-64565111 of 5 to 15 mg, the mean (standard deviation [SD]) 
JNJ-64565111 Cmax ranged from 0.259 (0.072) to 0.744 (0.22) g/mL and the range for Tmax was 
2 to 7 days post-dose.  
Following the last of the 4 weekly doses of JNJ-64565111 of 5 to 15 mg, the mean (±SD) 
JNJ-64565111 Cmax ranged from 0.565 (0.20) µg/mL to 2.14 (0.66) µg/mL and the range of Tmax 
was 0 to 6 days post-dose. 
The mean accumulation ratio calculated as the ratio of Week 4 AUCτ versus Week 1 AUC168h
was 2.33 to 4.01 for the 5 to 15 mg dose range, indicating moderate accumulation of 
JNJ-64565111 exposure upon multiple dosing that was commensurate with the dosing interval 
and t½ of JNJ-64565111 (t½=6 to 7 days in Study 64565111EDI1002). The mean JNJ-64565111 
trough serum concentrations on Days 8, 15, 22, and 29 (Figure 2) indicate that JNJ-64565111 
had not attained steady-state following 4 weekly doses. This is also commensurate with the 
observed t½ but >90% of steady-state was achieved by Week 4.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
24
Approved, Date: 23 August 2018
Figure 2:
Mean (SD) Serum Concentration-time Profiles Following Multiple Subcutaneous
Administration of JNJ-64565111 Weekly for 4 Doses in T2DM Subjects
a. Linear-Linear
b. Log-Linear
Legend
5.0 mg JNJ-64565111
10.0 mg JNJ-64565111
12.4 mg JNJ-64565111
15.0 mg JNJ-64565111
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
25
Approved, Date: 23 August 2018
Mean Week 1 and Week 4 Cmax and AUC of JNJ-64565111, shown in Table 2, after the first and 
fourth dose increased for 5, 10, and 15 mg doses. However, the exposure from the 12.4 mg dose 
showed deviation from this behavior. The reason for the complex PK characteristics after 
administration of 12.4 mg dose in Study 64565111EDI1002 is currently not understood. 
Table 2: 
Mean (Range) Cmax and AUC of JNJ-64565111 on Weeks 1 and 4 (Study 645651111EDI1002) 
Mean (Range)
Cohort 1 (5 mg)
Cohort 2 (10 mg)
Cohort 3 (12.4 mg)
Cohort 4 (15 mg)
Cmax (µg/mL)
Week 1
0.259
(0.155 – 0.373)
0.613
(0.367 – 0.920)
0.363
(0.233 – 0.579)
0.744
(0.321 – 1.01)
Week 4
0.565
(0.387 – 0.869)
1.23
(0.774 – 2.38)
1.09
(0.794 – 1.39)
2.14
(1.22 – 2.76)
AUC (µg·h/mL)
Week 1
34.4
(19.0 – 48.6)
81.8
(49.2 – 121)
46.7
(25.4 – 77.7)
93.6
(36.4 – 136)
Week 4
79.2
(48.0 – 121)
182
(112 – 352)
160
(128 – 192)
307
(174 – 388)
Key: AUC= area under the curve; Cmax= maximum concentration.
Safety and Tolerability
Based on the completed and ongoing Phase 1 studies, treatment with JNJ-64565111 appears to 
be generally well tolerated. As with other GLP-1R agonists, the majority of the AEs were related 
to the GI system, with nausea, vomiting, abdominal distension, dyspepsia, and diarrhea being 
reported as the most common AEs. Of the non-GI AEs, the most common were decreased 
appetite and fatigue. No documented event of hypoglycemia has been reported. While there 
appeared to be a trend in dose-dependent increase in the incidence of AEs, most were mild in 
intensity. In general, no treatment-related or clinically relevant trends were observed for the 
hematology, coagulation, and biochemistry parameters, as well as for serum calcitonin, amylase 
and lipase values, and for the urinalysis parameters across dose groups. There were no clinically 
relevant changes in ECG parameters. None of the subjects in the completed Phase 1 studies that 
were treated with JNJ-64565111 experienced a serious adverse event (SAE) or discontinued due 
to AEs. 
In the ongoing Study 64565111EDI1002, 2 SAEs occurred in the 10 mg/placebo group. 
Specifically, 1 subject who had low plasma sodium levels at baseline (132 mmol/L 
[132 mEq/L]), had a SAE of hyponatremia, (sodium levels of 114 mmol/L [114 mEq/L]), 
associated with mild hypokalemia and dehydration following protracted nausea, vomiting, and 
diarrhea, and which was treated with saline. The SAE occurred 4 days after the last dose of study 
drug and was considered to be related to study drug by the investigator. Laboratory and imaging 
workup for inappropriate antidiuretic hormone secretion (including brain on magnetic resonance 
imaging [MRI] and chest computed tomography [CT] scan to evaluate for central nervous 
system or pulmonary etiologies, respectively) were negative. The second SAE was influenza 
pneumonia that occurred 49 days after the last dose of study drug and was considered not related 
to study drug by the investigator. In addition, 3 subjects were withdrawn from the study due to 
AEs: 2 from Group 3 (12.4 mg/placebo) and 1 from Group 4 (15 mg/placebo). One subject in the 
12.4 mg/placebo group had an AE of chest pain and ECG changes suggestive of ischemia on 
Day 8, after the first study drug dose. This event was considered not related to study drug by the 
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
26
Approved, Date: 23 August 2018
reporting investigator. Another subject in the 12.4 mg/placebo group withdrew consent on 
Day 22 (after receiving 3 doses of study drug) due to an AE of nausea. This event was 
considered related to study drug by the reporting investigator. There was no clinical, laboratory, 
or imaging evidence for pancreatitis or hepatobiliary pathology. In the 15 mg/placebo group, 
1 subject discontinued on Day 22 (after receiving 3 doses) due to elevation in FPG (up to 
24.42 mmol/L [440 mg/dL]) and hyponatremia and mild hypokalemia. The subject was treated 
with the addition of a sulfonylurea that rapidly improved FPG levels, with subsequent 
improvement in serum sodium. Both AEs were considered to be drug related by the 
investigators. 
Pulse rate and blood pressure were assessed in all studies by use of ambulatory blood pressure 
monitoring. In general, there was a consistent trend of increase in pulse rate and decrease in 
systolic blood pressure (SBP) and diastolic blood pressure (DBP) across studies. In 
Study HM-OXM-101, following repeated doses, there was an increase in pulse rate after the 1.5 
and 2 nmol/kg doses (least square means differences relative to placebo of 5.6 beats per minute 
[bpm] and 7.7 bpm, respectively). At the dose of 2 nmol/kg, SBP decreased by -7.8 mm Hg 
(least square means differences relative to placebo). There was no consistent trend in changes in 
DBP. 
In Study 64565111EDI1001, mean increases in pulse rate of 6.6 and 15.3 bpm were observed in 
the 2.5 and 3 nmol/kg groups, respectively, compared with a 1.3 bpm increase on placebo. Both 
SBP and DBP decreased by a mean of 11.8 and 4.2 mm Hg, respectively, in the 2.5 nmol/kg 
group but remained unchanged in the 3 nmol/kg group and increased by 7.3 and 4.7 mm Hg on 
placebo. A similar trend has been observed in the ongoing Study 64565111EDI1002 but 
individual treatment assignment is still blinded. 
Efficacy
Body weight change
After 4 weeks of treatment in Study HM-OXM-101, a reduction in mean body weight was 
observed in all JNJ-64565111 groups while no changes in body weight were seen in subjects in 
the placebo group. Percentages of body weight loss were -1.3, -3.0, -4.1, and -3.9% in the 0.5, 
1.0, 1.5, and 2.0 nmol/kg, respectively. In Study 64565111EDI1001, the 2.5 nmol/kg and 
3.0 nmol/kg groups showed a mean body weight loss of -6.2% and -5.3%, respectively, relative 
to baseline compared with a mean weight loss of -1.4% in the placebo group. Weight loss was 
also observed in Study 64565111EDI1002, with decrease of approximately -4% in the 5, 10, and 
12.4 mg group and approximately -6% in the 15 mg group compared with a decrease of 
approximately 1% in the placebo group.
Glycemic parameters 
In Study HM-OXM-101, after 4 weeks of treatment, change in mean FPG from baseline 
of -1.62 mmol/L (-29.2 mg/dL), -0.64 mmol/L (-11.5 mg/dL), -2.21 mmol/L (-39.8 mg/dL), 
and -0.29 mmol/L (-5.2 mg/dL) were observed in the 0.5, 1.0, 1.5 nmol/kg, and placebo groups, 
respectively, compared with
virtually no change in the 2.0 nmol/kg group. In 
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
27
Approved, Date: 23 August 2018
Study 64565111EDI1001, the mean changes from baseline in FPG were 0.30 (5.4 mg/dL) 
and 
-0.48 
mmol/L 
(-8.7 mg/dL) 
in 
the 
2.5 and 
3.0 nmol/kg 
group, 
respectively, 
and -0.71 mmol/L (-12.8 mg/dL) in placebo. In the ongoing Study 64565111EDI1002, in which 
the mean baseline HbA1c was higher compared with the previous Phase 1 studies, hence resulting 
in a greater glucose variability, the mean changes in FPG were approximately -0.83 mmol/L 
(-15 mg/dL), 1.05 mmol/L (19 mg/dL), -0.67 mmol/L (-12 mg/dL), and 0.28 mmol/L (5 mg/dL) 
in the 5, 10, 12.4, and 15 mg groups, respectively, and -1.83 mmol/L (-33 mg/dL) in the placebo 
group. The median changes in FPG were approximately -1.22 mmol/L (-22 mg/dL), 
0.56 mmol/L 
(10 mg/dL), 
-0.39 
mmol/L 
(-7 mg/dL), 
-0.78 
mmol/L 
(-14 
mg/dL), 
and -2.0 mmol/L (-36 mg/dL) in the 5, 10, 12.4, 15 mg, and placebo groups, respectively.
After 4 weeks of treatment, mean HbA1c values decreased from baseline in all groups in Study 
HM-OXM-101. Mean HbA1c decreases from baseline were -0.19, -0.28, -0.73, -0.22, 
and -0.06 for the 0.5, 1.0, 1.5, and 2.0 nmol/kg groups and placebo, respectively. In 
Study 64565111EDI1001, mean HbA1c decreases from baseline were -0.1% and -0.23% in the 
2.5 nmol/kg and 3.0 nmol/kg groups, respectively, compared with an increase of 0.01% in the 
placebo group. In the ongoing Study 64565111EDI1002, HbA1c reduction ranging from 
approximately -0.3 to -0.5% were observed in the 5 mg, 10 mg, 12.4 mg, and placebo group 
compared with an increase of approximately 0.3% in the 15 mg group.
Changes in fasting lipids
Across studies, 4 weeks of treatment with JNJ-64565111 was associated with decreases in mean 
values for total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides. The 
decreasing trend in these parameters was generally not observed in the placebo subjects. 
Compared to Study HM-OXM-101 where small decreases in high-density lipoprotein cholesterol 
(HDL-C) were observed in subject treated with JNJ-64565111, in Study 64565111EDI1001 and 
Study 64565111EDI1002, small decreases were observed with no apparent dose-dependency, 
ranging from -0.03 to -0.35 mmol/L (-1.2 to -13.7 mg/dL).
2.3.
Benefit/Risk Assessment
Potential Benefits
The currently available pharmacologic treatments for obesity provide modest weight loss and are 
limited in use by tolerability. Although bariatric surgery represents the most effective treatment 
option currently available, it is typically reserved for only patients who have a BMI ≥40 kg/m2 or 
≥35 kg/m2 with at least 1 serious obesity-related comorbidity. Bariatric surgery has been shown 
to provide significant short-term weight loss; however, uncertainty remains about long-term 
complication rates and the sustainability of weight loss and comorbidity control. Thus, there is a 
need for more effective and well tolerated weight-management therapies that may also positively 
affect obesity-related comorbidities such as hypertension, dyslipidemia, and T2DM (Ettaro 2004;
Jonsson 2002; Padwal 2003). 
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
28
Approved, Date: 23 August 2018
JNJ-64565111 stimulated both GLP-1R and GCGR with generally similar in vitro potencies. As 
a dual agonist, it can be an attractive treatment option for obese and obese diabetic patients based 
on its pharmacological effects such as body weight loss and blood glucose-lowering. The 
underlying synergistic mechanisms that mediated the effects of JNJ-64565111 on body weight 
loss observed in rodents were probably combined effects on energy intake and energy 
expenditure. In addition, the potential blood glucose-raising effects of JNJ-64565111 mediated 
by its glucagon-stimulating activity were likely efficiently counter-regulated by its GLP-1 
activity, as JNJ-64565111 lowered blood glucose levels in db/db mice and during an 
intraperitoneal glucose tolerance test in diet-induced obese mice. 
Clinical evidence of weight loss with JNJ-64565111 treatment has been shown in initial Phase 1 
studies, with an observed 2% to 6% body weight reduction after 4 weeks across the dose range 
compared with a decrease of approximately 1% in subjects who received placebo. In addition, 
treatment with JNJ-64565111 was associated with decreases in mean values for total cholesterol, 
LDL-C, and triglycerides. There was also a consistent mean reduction in HbA1c values from 
baseline after 4 weeks in the treatment groups compared with no change or a slight increase in 
the placebo group. Overall, these data suggest that treatment with JNJ-64565111 could lead to 
meaningful weight reduction along with an improvement in other metabolic parameters.
Potential Risks
Based on available data from nonclinical and clinical JNJ-64565111 findings and known data 
from other GLP-1 agonists, potential adverse human effects may occur. These include increase 
in HR, GI intolerability, pancreatitis, and elevation in calcitonin. In addition to the routine 
assessment of AEs, the following safety measures are included to monitor and address these 
potential effects: Subjects with personal or family histories of medullary thyroid carcinoma or 
multiple endocrine neoplasia type 2 (MEN2), active or chronic pancreatitis, and hepatic disease 
will be excluded from participating in the study, and those enrolled will undergo periodic 
monitoring of pancreatic and liver parameters (through laboratory tests), thyroid changes 
(through monitoring of calcitonin levels and physical examination of the thyroid), vital signs 
(through periodic measurements of blood pressure and HR), and assessment of selected 
cardiovascular events (ie, cardiovascular death, nonfatal myocardial infarction, nonfatal stroke). 
Specific monitoring algorithms are provided in case of elevations that warrant further follow-up 
and investigations in subjects experiencing prespecified elevation of these parameters.
Hypoglycemia is a common AE in patients with T2DM and may occur more frequently 
following weight loss. Treatment with JNJ-64565111 in the Phase 1 studies did not appear to 
lead to an increase in hypoglycemia. As part of study-specific glycemic monitoring, subjects will 
be provided with a glucose meter and will be instructed to collect fasting self-monitored blood 
glucose (SMBG) values. Subjects will be counseled on the signs and symptoms of hypoglycemia 
and instructed to measure their blood glucose and seek appropriate treatment for any potential 
episode of hypoglycemia. Reports of potential events of hypoglycemia will be carefully collected 
and evaluated.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
29
Approved, Date: 23 August 2018
In subjects with T2DM treated with metformin in the Phase 1 studies, the addition of 
JNJ-64565111 led to inconsistent changes in glycemic endpoints after 4 weeks of treatment, with 
some subjects experiencing an increase in FPG and 24-hour mean glucose. While glucagon and 
GLP-1 agonism have counteracting effects on glucose control, dual agonism of GLP-1 and 
GCGR generally leads to improved glucose control in subjects with T2DM as the effects of 
GLP-1 to increase insulin secretion appear to overcome the effects of glucagon agonism to 
increase endogenous glucose production. However, it is possible that some subjects may be more 
sensitive to the glucagon agonism induced by JNJ-64565111 than to the GLP-1 agonism, and 
these subjects may have plasma glucose concentrations increased by treatment with 
JNJ-64565111. Subjects will be instructed to contact the site if their fasting SMBG values are
consistently elevated. Additionally, FPG from the clinic visits that meet prespecified and 
progressively more stringent glycemic rescue cut-offs will be defined for the investigators. 
During the study, if a subject's FPG values meet these thresholds and no readily identifiable 
cause of worsened glycemic control is evident, then the subject will receive glycemic rescue 
medication.
An increase in ketones is a normal physiologic response to fasting, prolonged exercise, and 
certain dietary weight-loss regimens (eg, low-carbohydrate, high-fat diets) in which fatty acids 
are transformed in the liver into the ketones, aceto-acetate, and β-hydroxybutyrate. 
Physiologically, these ketones are used by the brain and muscles, including the heart, as an 
alternative fuel source when glucose is not readily available (Laffel 1999). The production of 
free fatty acids and their conversion to ketone bodies is stimulated by glucagon and inhibited by 
insulin. In the presence of near-normal or normal insulin function, the rate of hepatic ketone 
formation is balanced by the rate of the body’s ketones utilization and, to a certain degree, 
ketones loss into the urine. Although ketones can increase in the blood and urine under 
physiological conditions in subjects with and without diabetes and is termed “ketosis,” under 
certain circumstances, ketones can accumulate to high levels and lead to an acidic state, termed 
“ketoacidosis,” which is associated with significant illness and metabolic decompensation, 
requiring emergent medical attention. While ketoacidosis is known to occur in patients with type 
1 diabetes (ie, diabetic ketoacidosis [DKA]), patients with T2DM can on very rare occasion 
develop ketoacidosis, especially in the absence of inadequate carbohydrate intake and insulin 
deficiency (either absolute or relative due to increased insulin resistance observed in acute 
illness). A 2- to 3-fold increase in the serum levels of the ketone, β-hydroxybutyrate (generally 
<1.0 mmol/L), relative to placebo was seen in the Phase 1 Studies 64565111EDI1001 and 
64565111EDI1002 in which 50 subjects with T2DM (on either diet/exercise alone or on 
metformin monotherapy) were treated for 4 weeks with JNJ-64565111 which would be expected 
given the weight loss observed and the dual agonism of JNJ-64565111 at the GLP-1 and 
glucagon receptors. Importantly, in these 2 studies conducted in subjects with T2DM, no AEs of 
ketoacidosis or metabolic acidosis were reported. Therefore, subjects receiving JNJ-64565111 
may develop ketosis due to reduced food intake/weight loss, but it is unlikely, although 
theoretically possible, that they could develop DKA under certain conditions. Subjects with signs 
and symptoms of DKA should have appropriate laboratory evaluations (eg, blood pH, serum 
ß-hydroxybutyrate, anion gap) performed. Subjects who develop biochemically confirmed DKA 
will be permanently discontinued from study drug.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
30
Approved, Date: 23 August 2018
In Study 64565111EDI1002, two subjects were reported to have AEs of hyponatremia in the 
context of dehydration or following episodes of vomiting. A few other subjects had mild 
reduction in plasma sodium levels not considered to be clinical meaningful by the reporting 
investigators. It is not known whether changes in plasma sodium are related to concomitant GI 
AEs (such as vomiting) or to other mechanisms. In the present study, electrolytes will be 
monitored frequently, and subjects with low sodium levels will not be allowed to participate in 
the study. In addition, those who develop persistent reductions in sodium levels will be 
permanently discontinued from study drug.
Risk-Benefit Ratio and Risk Mitigation
Overweight and obesity are a worldwide epidemic and a significant health issue. As noted 
previously, it is estimated that worldwide obesity has nearly tripled since 1975, affecting more 
than 650 million adults (WHO 2017). Pharmacological treatment options are limited, have 
variable degrees of efficacy, which is not necessarily sustained, and are associated with a range 
of potential safety or tolerability issues. Additional clinical data are needed to assess whether 
JNJ-64565111 could be a well-tolerated treatment for severe obesity.
Although definitive information from studies in humans is not yet available, safety information 
from the Phase 1 studies indicates that JNJ-64565111 is generally well tolerated and no safety 
concerns precluding further clinical development have been identified. Clinical and laboratory 
evaluations will be performed throughout the study (according to the Schedule of Activities) to 
monitor the safety of subjects. Potential risks will be managed and minimized by appropriate 
protocol eligibility criteria, subject management procedures, specific discontinuation criteria, and 
careful internal safety monitoring.
More detailed information about the known and expected benefits and risks of JNJ-64565111
may be found in the Investigator’s Brochure.
3.
OBJECTIVES AND ENDPOINTS
OBJECTIVES
Primary Objectives
The primary objectives are to assess the effects of JNJ-64565111 compared with placebo in 
severely obese T2DM subjects after 12 weeks of treatment on:

the percentage change in body weight from baseline

safety and tolerability
Secondary Objectives
The secondary objectives are to assess the effects of JNJ-64565111 compared with placebo in 
severely obese T2DM subjects after 12 weeks of treatment on:

the absolute change in body weight from baseline
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
31
Approved, Date: 23 August 2018

the proportion of subjects with 5% weight loss from baseline
Exploratory Objectives
The exploratory objectives are to assess the effects of JNJ-64565111 compared with placebo in 
severely obese T2DM subjects after 12 weeks of treatment on:

the proportion of subjects with 10% weight loss from baseline

the change in BMI from baseline

the change in waist circumference from baseline

the change in glycated hemoglobin (HbA1c) from baseline

the change in fasting plasma glucose (FPG) from baseline

the change in fasting insulin from baseline

the change in fasting C-peptide from baseline

the changes in Homeostasis Model Assessment for B cell function (HOMA-B) and HOMA-
insulin resistance (IR) from baseline

the change in SBP from baseline

the change in DBP from baseline

the change in pulse rate from baseline

the change in pulse-pressure product from baseline

the change in fasting lipids (total cholesterol, LDL-C, high-density lipoprotein cholesterol 
[HDL-C], and triglycerides) from baseline

pharmacokinetic (PK) exposure

the change in scores on the Impact of Weight on Quality of Life – Lite (IWQOL-Lite) from 
baseline

the change in scores on the Patient-Reported Outcomes Measurement Information System 
(PROMIS®) Physical Function Short Form 10a (PROMIS SF 10a) from baseline

the change in scores on the Eating-related Concept Questionnaire (ERCQ) from baseline
ENDPOINTS
Primary Endpoint(s)
The primary efficacy endpoint will be the percentage change in body weight from baseline to 
Week 12 between JNJ-64565111 compared with placebo.
Secondary Endpoint(s)
The secondary measures of efficacy at Week 12 include the absolute change in body weight from 
baseline and the proportion of subjects with 5% weight loss from baseline.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
32
Approved, Date: 23 August 2018
Exploratory Endpoint(s)
Exploratory efficacy endpoints at Week 12 include proportion of subjects with 10% weight loss 
from baseline, change from baseline in BMI, waist circumference, HbA1c, FPG, fasting insulin, 
fasting C-peptide, HOMA-B, HOMA-IR, fasting lipids (total cholesterol, LDL-C, HDL-C, 
triglycerides), SBP, DBP, pulse rate, pulse-pressure product, PK exposure, and patient-reported 
outcomes (PROs) (ie, changes in IWQOL-Lite, PROMIS SF 10a, ERCQ). 
Refer to Section 8, Study Assessments and Procedures, for evaluations related to endpoints.
HYPOTHESIS
In severely obese subjects with T2DM, treatment for 12 weeks with JNJ-64565111 compared 
with placebo leads to:
Primary:

Greater percentage reduction in body weight from baseline
Secondary:

Greater absolute reduction in body weight from baseline

Greater proportion of subjects with ≥5% weight loss from baseline
4.
STUDY DESIGN
4.1.
Overall Design
This is a randomized, double-blind, placebo-controlled, parallel-group, 4-arm, multicenter study
in severely obese subjects with T2DM. Subjects who are 18 and 70 years of age and have a 
BMI ≥35 kg/m2 to ≤50 kg/m2 are eligible to participate if they have a HbA1c of 6.5% to ≤9.5% 
at the screening visit on diet and exercise alone or on a stable dose of single oral AHA or dual-
combination oral AHAs for 12 weeks prior to screening. A target of 188 subjects will be 
randomly assigned in this study.
Subjects meeting all enrollment criteria will enter a 2-week run-in phase, which is to occur 
approximately 1 week after the screening visit and is designed to train the subject on SC self-
injection and to establish the subject’s ability to comply with the protocol-specified 
requirements. On Day 1, subjects who continue to meet eligibility criteria, will be randomly 
assigned in a 1:1:1:1 ratio to blinded treatment with placebo or JNJ-64565111 5.0 mg, 7.4 mg, or 
10 mg and enter a 12-week treatment phase. Post-randomization visits will be conducted at 
Week 2, 6, 12/end-of-treatment [EOT] visit, and the SAE follow-up visit 5 weeks after the last 
dose of study drug. At Weeks 4 and 10, all subjects will be contacted preferably by telephone to 
reinforce the adherence to diet and exercise, study drug dosing reminder, assessment of subjects’ 
status, and compliance with the protocol procedures (eg, diary completion reminder). 
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
33
Approved, Date: 23 August 2018
During the pretreatment/run-in and treatment phases, subjects will undergo efficacy and safety 
assessments including physical examination, ECG, laboratory testing and vital signs 
measurement. A serum pregnancy test will be performed at screening and Week 12/EOT along 
with a urine pregnancy test at Day 1 in women of childbearing potential. 
Counseling should be done by dietitians/nutritionists on Day 1 to provide assessment and 
recommendation on a reduced-calorie diet and exercise regimen (Appendix 7, Standardized 
Nonpharmacologic Weight Reduction Therapy). In addition, subjects will be counseled on 
maintaining proper hydration throughout the study especially in circumstances of potential 
dehydration (eg, nausea and vomiting). At subsequent visits (Week 2 and Week 6), counseling 
and reinforcement of the recommended diet/exercise and hydration regimens will be conducted 
by a trained counselor. In addition, beginning at Week -2 visit, subjects will be counseled to 
comply and perform fasting SMBG testing at least 2 times per week. At each treatment visit, the 
investigator or qualified, assigned designee will review the subject’s diaries, concomitant 
medications and the AEs that started or changed since the last visit. 
The efficacy evaluation will include the percentage change in body weight from baseline as the 
primary efficacy endpoint.
Safety evaluations will include the monitoring of AEs (including protocol-specified AEs of 
interest), vital sign measurements, clinical laboratory tests (including serum chemistry,
calcitonin, lipase, amylase, hematology, and urinalysis), physical examination including 
complete skin examination, serum/urine pregnancy testing, ECG, SMBG, assessment of 
hypoglycemia episodes, and review of concomitant medications. Refer to Section 8.2, Safety 
Assessments, for further details.
Subjects who prematurely discontinue study drug will require an immediate EOT assessment 
(either on the day of study drug discontinuation or as soon as possible following study drug 
discontinuation) and the SAE follow-up visit. Subjects that discontinue study drug early will 
continue in the study and be assessed with the off-treatment procedures at the subsequent visit(s) 
per the Schedule of Activities table, starting at the next scheduled visit from when study drug 
was permanently discontinued up to the final Week 12 visit. These off-treatment visits will 
include collection of SAEs, specific AEs of interest (ie, major adverse cardiac events [MACEs], 
acute pancreatitis, and possible cases of thyroid neoplasm), vital signs (including body weight), 
and concomitant medications. All subjects, except those who died, were lost to follow-up, or 
have a withdrawn consent, will have a follow-up visit at least 5 weeks after the last dose of study 
drug was taken to collect any SAEs and blood samples for PK and immunogenicity ADA
assessments will be obtained.
The ERCQ is a home-based assessment in contrast to the IWQOL-Lite, PROMIS SF 10a, Patient 
Global Impression Status (PGIS), and Patient Global Impression of Change (PGIC), which are 
site-based assessments.
Subjects who withdraw from the study will not be replaced.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
34
Approved, Date: 23 August 2018
During the 12-week treatment phase (Day 1 to Week 12), subjects meeting protocol-specified 
glycemic rescue criteria will have rescue therapy initiated, and will remain in the study, 
continuing double-blind study drug. Rescue therapy may include increasing the dose of a current 
AHA or the initiation of a new AHA. Investigators will manage rescue therapy, including the 
selection of the specific AHA, its clinically appropriate initial dose and titration regimen (if 
applicable), the need to switch from one AHA rescue medication to another (ie, poor glycemic 
response to prior rescue medication), and be consistent with the labeled use within the country of 
the study site. Metformin, sulphonylureas, thiazolidinediones (TZDs), sodium-glucose 
cotransporter 2 (SGLT-2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, and insulin (basal
only) are allowed as rescue medication; GLP-1 agonists and short-acting or intermediate insulins 
are not allowed as rescue medication.
The overall study duration is approximately 19 weeks and comprises of 3 phases:

Pretreatment phase: 3 weeks comprised of:

Screening phase: 1 week

Run-in (injection-training) phase: 2 weeks

Treatment phase (double-blind)

Placebo-controlled treatment phase: 12 weeks

Post-treatment phase (SAE follow-up visit): 4 weeks
Approximately 188 subjects will be randomly assigned in a 1:1:1:1 ratio to one of the following 
once weekly SC treatments:

47 subjects to double-blind placebo matching JNJ-64565111,

47 subjects to double-blind JNJ-64565111 5.0 mg,

47 subjects to double-blind JNJ-64565111 7.4 mg,

47 subjects to double-blind JNJ-64565111 10 mg.
A diagram of the study design is provided in Section 1.2, Schema.
4.2.
Scientific Rationale for Study Design
The study was designed in general accordance with the US Food and Drug Administration 
(FDA) and European Medicines Agency (EMA) guidance on the development of medications 
and clinical investigations for the treatment of obesity (FDA 2009; Guidance for Industry 
Developing Products for Weight Management 2007; Guideline on Clinical Investigation of 
Medicinal Products Used in Weight Management 2016).
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
35
Approved, Date: 23 August 2018
Blinding, Control, Study Phase/Periods, Treatment Groups
Randomization will be used to minimize bias in the assignment of subjects to treatment groups, 
to increase the likelihood that known and unknown subject attributes (eg, demographic and 
baseline characteristics) are evenly balanced across treatment groups, and to enhance the validity 
of statistical comparisons across treatment groups. Blinded treatment will be used in the 
JNJ-64565111 and placebo treatment arms to reduce potential bias during data collection and 
evaluation of clinical endpoints.
The 1-week screening phase will allow time prior to the beginning of the injection-training phase 
to obtain laboratory results that are needed to determine the subject’s eligibility for the study. 
Subjects enrolled in this study will likely have no prior experience with self-injection of 
medication. Therefore, a 2-week SC injection-training phase will include training of subjects by 
the study staff on the use of the prefilled safety injectors for self-injection. Study staff will also 
evaluate the subject’s ability and willingness to self-inject prior to being randomized.
The duration of the treatment phase in this study is 12 weeks, which should be sufficient to 
capture statistically significant weight-loss effects of the active doses relative to placebo and 
provide information on the trajectory of the weight loss for each treatment group. The follow-up 
phase is designed to assess safety by collecting data on SAEs or resolution of ongoing SAEs that 
occurred since the last study visit, as well as collection of PK and ADA samples approximately 
5 weeks after the last dose of study drug.
Study Population
The randomized study population consists of men and women, ages 18 to 70 years at screening, 
inclusive, with severe obesity (BMI 35 to 50 kg/m2) and T2DM (ie, HbA1c of 6.5% to 9.5% 
at screening) treated with either diet/exercise alone or with single or dual oral AHA regimen. In 
this study, the definition of “severe” obesity, which is commonly used within the surgical 
community to refer to subjects who are eligible for bariatric surgery, is inclusive of the WHO 
definition of Obese Class II (35-39 kg/m2) and III (40 kg/m2) (WHO 2017). Consistent with 
Health Authority guidance, this study is being conducted in obese subjects with T2DM to 
understand the
magnitude of weight loss and to assess any unique safety issues 
(eg, hypoglycemia) in this population. Given the potential contribution of weight loss on HbA1c-
lowering, the study will provide experience in severely obese subjects across a broad spectrum of 
different diabetes treatment regimens.
Choice of Efficacy Measures
The primary efficacy endpoint will be a comparison of percentage change in body weight 
between the JNJ-64565111-treated and placebo-treated groups. This is an accepted endpoint for 
clinical trials of weight management products (FDA 2009). Secondary and exploratory endpoints 
are also consistent with the current FDA and EMA guidelines for the development of weight-
management drugs and will provide further information on the magnitude and proportion of 
subjects experiencing weight loss along with any potential impact on other weight related 
comorbidities (ie, glycemic control, vital signs, lipids), and PROs.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
36
Approved, Date: 23 August 2018
Rationale for Use of Placebo Control
A placebo control will be used to establish the frequency and magnitude of changes in clinical 
endpoints that may occur in the absence of active treatment, improving the precision of the 
assessments of both efficacy and safety. A study without a placebo arm cannot properly 
determine the weight-reducing efficacy of a weight management product, given the impact of co-
interventions (eg, diet and exercise counseling). Similarly, given background occurrence of AEs
in this population in which comorbidities are common, without a placebo treatment group, it is 
not possible to precisely define the safety and tolerability profile of a new weight management 
product.
Choice of Patient-Reported Outcome Measures 
Evaluation of health status and treatment experience from the subject’s perspective is 
increasingly important in the evaluation of new treatments. Several PRO instruments have been 
selected to measure health-related quality of life and physical functioning in this study 
(ie, IWQOL-Lite, PROMIS SF 10a, PGIS, and PGIC). The ERCQ will also be administered to 
measure eating-related concepts such as hunger, appetite, cravings, and satiety. These 
exploratory PRO endpoints will be used to describe outcomes/benefits associated with weight 
loss and treatment from a subject’s perspective.
Collection of Additional Information for Selected Adverse Events
For selected adverse events of interest as per Health Authority guidance and based on class of 
effects of GLP-1 agonists and potential mechanistic physiological effects of glucagon receptor 
agonism, investigators will be asked to provide additional information which may include the use 
of subjects’ source documentation or supplementary electronic case report forms (eCRFs) to 
support more detailed analyses. These include selected hypotension-related adverse events, 
adverse events of pancreatitis, calcitonin elevation, thyroid neoplasm, and episodes of 
hypoglycemia.
Pharmacokinetic Samples
Pharmacokinetics will be evaluated to explore exposure-response relationships, and to develop a 
population PK model. All PK data from subjects in this study will be combined with data from 
other clinical studies of JNJ-64565111 for a pooled population PK analysis to develop a 
structural PK model of JNJ-64565111 and to evaluate the dependence of the PK of 
JNJ-64565111 on population covariates.
Archive Samples for Exploratory Research
Numerous biomarkers have been studied as potentially important surrogate measures of 
cardiovascular and overall health of subjects (Ridker 2004). Plasma, serum, and urine archive 
samples will be collected (where local regulations permit) to allow for the analysis of important 
biomarkers (not prespecified) that could help to further explain and examine the efficacy and 
safety findings in this study.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
37
Approved, Date: 23 August 2018
4.2.1.
Study-Specific Ethical Design Considerations
This Phase 2b dose-ranging study is being conducted to assess the safety and efficacy of 
JNJ-64565111 over a 12-week period in severely obese subjects with T2DM and to provide 
information to select JNJ-64565111 dose(s) to be assessed in Phase 3 studies.
The primary ethical concern of this study is that the safety profile of JNJ-64565111 is not fully 
established and therefore subjects may be placing themselves at an increased risk of unexpected 
events by participating in this study. Although definitive information from studies in humans is 
not yet available, safety information from the Phase 1 studies indicates that JNJ-64565111 is 
generally well tolerated and no safety concerns precluding further clinical development have 
been identified. As discussed in Section 2.3, Benefit/Risk Assessment, clinical and laboratory 
evaluations will be performed throughout the study (according to the Schedule of Activities) to 
monitor the safety of subjects. Potential risks will be managed and minimized by appropriate 
protocol eligibility criteria, subject management procedures, specific discontinuation criteria, and 
careful internal safety monitoring.
Subjects who discontinue early from the study will have a post-study visit, so as to collect 
information on SAEs, and support a complete assessment of key safety events in the intact 
randomized study population. Specific monitoring algorithms are provided in case of elevations 
that warrant further follow-up and investigations in subjects experiencing prespecified elevation 
of these parameters.
The general scientific aspects of this study are in accordance with established FDA and EMA 
guidelines for the development of weight-control drugs. This study design includes the use of a 
placebo group, which is of key importance in helping to characterize both the safety and efficacy 
of JNJ-64565111. A study without a placebo arm cannot properly determine the weight-lowering 
efficacy of an agent, given the dynamic nature of the disease. Similarly, given background 
occurrence of adverse events in this population in which comorbidities are common, without a 
placebo, it is not possible to precisely define the safety and tolerability profile of a new drug. 
However, the importance of the placebo group must be balanced with the increased risk that 
subjects allocated to placebo may not achieve weight loss and the concomitant benefit of 
glycemic control. In that regard, some subjects may have glycemic levels that are not consistent 
with current diabetes guidances during their participation in this study. Therefore, all subjects 
will receive diet and exercise counseling, undergo regular fingerstick glucose monitoring, and 
have glycemic rescue therapy implemented with progressively lower glucose cutpoints.
Potential subjects will be fully informed of the risks and requirements of the study and, during the 
study, subjects will be given any new information that may affect their decision to continue 
participation. They will be told that their consent to participate in the study is voluntary and may be 
withdrawn at any time with no reason given and without penalty or loss of benefits to which they 
would otherwise be entitled. Only subjects who are fully able to understand the risks, benefits, and 
potential adverse events of the study, and provide their consent voluntarily will be enrolled.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
38
Approved, Date: 23 August 2018
Women of childbearing potential enrolled in the study and who are sexually active must agree to 
use a highly effective birth control method (failure rate of <1% per year when used consistently 
and correctly) throughout the study. Serum pregnancy testing will be performed on all women of 
childbearing potential at screening along with a urine pregnancy test at Day 1, in addition to 
selected time points during the study at the discretion of the investigator. Women must also agree 
not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study or for 
a period of at least 4 weeks after the last dose of study drug.
The total blood volume to be collected is 147.0 mL, which is considered to be an acceptable 
amount of blood to be collected over this time period from the population in this study based upon 
the standard of the American Red Cross (American Red Cross).
4.3.
Justification for Dose
Dose Selection and Dose Interval of JNJ-64565111
The t½ of 6 to 8 days allows for a weekly dosing frequency for JNJ-64565111. While in earlier 
Phase 1 studies, JNJ-64565111 was administered using weight-based doses, fixed doses of 
JNJ-64565111 were tested in Study 64565111EDI1002. As such, the dosing regimen is more 
practical and is likely to be associated with greater adherence. Fixed weekly doses of 5 and 
10 mg of JNJ-64565111 in the Phase 1 Study 64565111EDI1002 showed similar exposures 
compared with doses of 1.0 and 2.0 nmol/kg/week observed in the previous Phase 1 MAD study
(HM-OXM-101; see Section 2.2, Background). Moreover, fixed dosing resulted in overall 
similar variability in exposure compared with body weight-based dosing for equivalent doses of 
5 and 10 mg of JNJ-64565111. In 4-week studies in overweight and obese subjects with T2DM, 
doses of JNJ-64565111 in this dose range resulted in approximately 2% to 4% reduction in body 
weight. As this duration of treatment is too short to observe the full weight-loss potential of any 
pharmacological intervention, this study is being conducted with the doses specified for 
12 weeks of treatment. Twelve weeks is generally sufficient to assess weight loss and any 
significant safety issues in a Phase 2 study. The upper end of the dose range was selected 
because 
drug 
exposures 
are 
highly 
variable 
beyond 
doses 
of 
10 
mg 
weekly 
(Study 64565111EDI1002). Moreover, doses above 10 mg, while leading to greater weight loss, 
also appeared to be less tolerated as indicated by a dose-dependent increase in the incidence in 
GI AEs as well as increase in mean pulse rate. The 7.4 and 10 mg doses are expected to produce 
clinically meaningful weight reduction and are therefore included in the study. The 5-mg dose 
was included to add a third anchor point, which is needed to evaluate a dose-response 
relationship as suggested by the dose-response guidance International Conference on 
Harmonisation (ICH) E4 (which states: Several dose levels are needed, at least 2 in addition to 
placebo, but in general, study of more than the minimum number of doses is desirable).
4.4.
End of Study Definition
A subject will be considered to have completed the study if he or she has completed assessments 
through Week 12 of the treatment phase.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
39
Approved, Date: 23 August 2018
Subjects who prematurely discontinue study drug for any reason before completion of the 
double-blind treatment phase will continue in the study and will be followed with selected study 
procedures at the subsequent visit(s) schedule as post-treatment follow-up (starting at the next 
scheduled visit when study drug was permanently discontinued up to the final Week 12 visit).
The end of study is considered as the last visit/contact for the last subject in the study. The final 
data from the study site will be sent to the sponsor (or designee) after completion of the final 
subject visit/contact at that study site, in the time frame specified in the Clinical Trial 
Agreement.
5.
STUDY POPULATION
The inclusion and exclusion criteria for enrolling subjects in this study are described below. If 
there is a question about these criteria, the investigator must consult with the appropriate sponsor 
representative and resolve any issues before enrolling a subject in the study. Waivers are not 
allowed. 
For a discussion of the statistical considerations of subject selection, refer to Section 9.2, Sample 
Size Determination.
5.1.
Inclusion Criteria
Each potential subject must satisfy all of the following criteria to be enrolled in the study: 
1.
Male or female (according to their reproductive organs and functions assigned by
chromosomal complement)
2.
18 (or the legal age of consent in the jurisdiction in which the study is taking place) to 
70 years of age, inclusive
3.
BMI 35 to 50 kg/m2 at screening
4.
Stable weight (ie, change of ≤5% within 12 weeks before screening based on medical or 
subject reported history)
5.
HbA1c of 6.5% and 9.5% at screening as determined by the central laboratory and 
meets one of the inclusion criteria below:

On diet and exercise alone ≥12 weeks prior to screening

On stable dose of single oral AHA or dual-combination oral AHAs for 
≥12 weeks prior to screening (AHAs allowed at screening include: 
metformin, sulphonylureas, DPP-4 inhibitors, SGLT-2 inhibitors, and 
TZDs)
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
40
Approved, Date: 23 August 2018
6.
Subjects are, in the investigator’s opinion, well-motivated, capable, and willing to:

perform fasting SMBG testing at least 2 times per week

learn how to self-inject treatment, as required for this study
7.
On Day 1, subjects must have 100% compliance with the open-label placebo run-in 
medication based on unused prefilled safety injector(s), used empty study drug 
carton(s), and/or injections recorded in study drug diary during the pretreatment phase.
8.
Willing and able to adhere to the prohibitions and restrictions specified in this protocol
9.
Must sign an informed consent form (ICF) indicating that he or she understands the 
purpose of, and procedures required for, the study and is willing to participate in the 
study. 
10.
Women must be either:

postmenopausal, defined as:

>45 years of age with amenorrhea for at least 18 months, or

>45 years of age with amenorrhea for at least 6 months and <18 months 
and a serum follicle-stimulating hormone (FSH) level >40 mIU/mL 
(>40 IU/L), or

permanently sterilized (eg, bilateral tubal occlusion [which includes tubal 
ligation procedures as consistent with local regulations], hysterectomy, bilateral 
salpingectomy, bilateral oophorectomy); or otherwise be incapable of 
pregnancy, or

heterosexually active and practicing a highly effective method of birth control 
(failure rate of <1% per year when used consistently and correctly), including 
combined (estrogen- and progestogen-containing) hormonal contraception 
associated with inhibition of ovulation: oral, intravaginal, and transdermal; 
progestogen-only hormone contraception associated with inhibition of 
ovulation: oral, injectable, or implantable; intrauterine device (IUD); 
intrauterine hormone-releasing system (IUS); vasectomized partner (provided 
that the partner is the sole sexual partner of the woman of childbearing 
potential and the absence of sperm has been confirmed; if not, additional highly 
effective method of contraception should be used), and agrees to remain on a 
highly effective method of contraception throughout the study and for at least 
4 weeks after the last dose of study drug
Note: Typical use failure rates may differ from those when used consistently 
and correctly. Use should be consistent with local regulations regarding the use 
of contraceptive methods for subjects participating in clinical studies.

not heterosexually active
Note: Women who are not heterosexually active at screening must agree to 
utilize a highly effective method of birth control if they become heterosexually 
active during their participation in the study and for at least 4 weeks after the 
last dose of study drug
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
41
Approved, Date: 23 August 2018
11.
Women of childbearing potential (ie, those subjects who do not meet the 
postmenopausal definition in the Inclusion Criterion above, regardless of age) must have 
a negative highly sensitive serum -human chorionic gonadotropin (-hCG) pregnancy 
test at screening and a negative urine pregnancy test on Day 1.
Note: In the case of an ambiguous urine pregnancy test result, a serum pregnancy test 
will be performed and randomization will be delayed by a few days in order to obtain 
the test result. Subject may only be randomized and receive first dose of blinded study 
medication if the result of the serum pregnancy test is negative.
5.2.
Exclusion Criteria
Any potential subject who meets any of the following criteria will be excluded from participating 
in the study: 
Diabetes-related/Metabolic/Endocrine 
1.
History of obesity with a known secondary cause (eg, Cushing’s disease/syndrome)
2.
History of Type 1 diabetes mellitus, DKA, pancreas or β-cell transplantation, or 
diabetes secondary to pancreatitis or pancreatectomy
3.
Fasting C-peptide <0.7 ng/mL at screening as determined by the central laboratory.
4.
Fasting fingerstick glucose of 270 mg/dL (15 mmol/L) on Day 1
Note: Fasting fingerstick glucose values may be obtained by study-site staff at the 
study site or by the subject at home on the morning of Day 1. At the 
investigator’s discretion, based upon review of recent SMBG values, subjects not 
meeting the Day 1 criterion may return to the study site within 7 days for a one-
time repeat fingerstick glucose and continue in the study if the subject’s repeat 
fingerstick glucose meets the criterion.
5.
Ongoing, inadequately controlled thyroid disorder as assessed by the investigator’s 
review of the subject’s medical history. Subjects taking thyroid hormone replacement 
therapy must be on stable doses for at least 6 weeks before the screening visit
6.
History of glucagonoma
7.
Screening calcitonin of 50 pg/mL (50 ng/L), personal history or family history of 
medullary thyroid cancer, or of MEN2, regardless of time prior to screening
Note: Investigators are recommended to refer subjects with screening calcitonin value 
of 50 pg/mL (50 ng/L) to an endocrinologist for follow-up
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
42
Approved, Date: 23 August 2018
Cardiovascular
8.
Myocardial infarction, unstable angina, revascularization procedure (eg, stent or 
bypass graft surgery), or cerebrovascular accident within 12 weeks before screening, 
or a revascularization procedure is planned during the trial
9.
Heart failure of New York Heart Association Class II-IV cardiac disease according to 
the Criteria Committee of the New York Heart Association Classification of Cardiac 
Disease (Appendix 4)
10.
Findings on 12-lead electrocardiogram (ECG) at Week -2 visit that would require 
urgent diagnostic evaluation or intervention (eg, clinically important arrhythmia or 
conduction disturbance)
11.
History of tachyarrhythmia (eg, atrial flutter, atrial fibrillation, ventricular 
tachycardia) within 6 months before screening
12.
An average of 3 seated blood pressure readings of SBP 160 mm Hg and/or DBP 
100 mm Hg at the screening visit (refer to Appendix 6, Method of Blood Pressure 
and Pulse Rate Measurement)
13.
An average of 3 seated pulse rate readings of <50 or >100 bpm
Gastrointestinal
14.
Known significant liver disease (eg, acute hepatitis, chronic active hepatitis, cirrhosis)
15.
History of acute or chronic pancreatitis
16.
History of bariatric surgical procedure or a known clinically significant gastric 
emptying abnormality (eg, severe gastroparesis or gastric outlet obstruction)
Psychiatric-Related
17.
History of a clinically significant eating disorder (eg, anorexia nervosa, bulimia, or 
binge-eating)
18.
Any history of major depressive disorder within the last 2 years
19.
Any history of other severe psychiatric disorders (eg, schizophrenia, bipolar disorder, 
etc.)
20.
Any lifetime history of suicide attempt
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
43
Approved, Date: 23 August 2018
Laboratory
21.
Estimated glomerular filtration rate (eGFR) <55 mL/min/1.73 m2 using the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-Epi) formula (Levey 2009) at 
screening (refer to Appendix 9, Clinical Laboratory Tests)
Note: A one-time repeat measurement is allowed at the discretion of the investigator, 
if the value for eGFR is not consistent with recent values
22.
Alanine aminotransferase (ALT) level is >2.0 times the upper limit of normal (ULN)
or total bilirubin is >1.5 times the ULN (unless consistent with history of Gilbert's 
disease) at screening
Note: A one-time repeat of ALT is allowed at the discretion of the investigator, if the 
screening value is not consistent with recent values
23.
Fasting triglycerides 600 mg/dL (6.77 mmol/L) at screening (or subsequent visit 
prior to randomization, if not fasting at screening)
Note: A one-time repeat of the serum triglycerides is allowed, at the discretion of the 
investigator, if the screening value is not consistent with recent values
24.
Serum sodium <130 mEq/L (<130 mmol/L) at screening 
Other Conditions
25.
History of malignancy within 5 years before screening (eg, any evidence of active 
disease within 5 years, or diagnosis of malignancy within this period)
Note: Subjects with squamous or basal cell carcinomas of the skin, carcinomas in situ 
of the cervix, or a malignancy that in the opinion of the investigator, with concurrence 
with the sponsor’s medical monitor, are considered cured with minimal risk of 
recurrence, may participate
26.
Previous (ie, within 12 weeks from screening visit) or current use of a highly active 
anti-retroviral therapy 
27.
Major surgery (eg, requiring general anesthesia) within 12 weeks before screening, or 
has not fully recovered from surgery, or planned major surgery during the 
participation of the current study
Note: Subjects with planned surgical procedures to be conducted under local 
anesthesia may participate
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
44
Approved, Date: 23 August 2018
28.
Clinically important hematologic disorder (eg, symptomatic anemia, proliferative 
bone marrow disorder, thrombocytopenia) or a disorder of hemoglobin (ie, a 
hemoglobinopathy)
Medications/Therapies
29.
Previous or current participation in a JNJ-64565111 study
30.
Known allergies, hypersensitivity, contraindication, or intolerance to the excipients of 
JNJ-64565111 (ie, citric acid, mannitol, methionine, and polysorbate 20)
31.
Known or potential history of intolerance to any GLP-1 receptor agonist (eg, adverse 
events, lack of efficacy) which, in the opinion of the investigator, makes participation 
not in the best interest of the subject
32.
Currently treated with antihypertensive or antihyperlipidemic therapy that is not on 
stable dose for at least 4 weeks prior to screening
Note: If during the screening phase adjustments to the antihypertensive or 
antihyperlipidemic medication regimen are considered to be clinically necessary, the 
subject should be excluded from continuing in the study. The subject may be 
rescreened after adjustments in the antihypertensive or antihyperlipidemic medication 
regimen have been made and the dose has been stable for at least 4 weeks
33.
Use of prescription weight-management medication (including but not limited to 
orlistat, topiramate and/or phentermine, lorcaserin, naltrexone and/or bupropion), or 
over-the-counter weight-loss medications or therapies within 12 weeks before the 
screening or plans to initiate non-study-related weight-loss treatment during the study
34.
Use of medications that may cause weight change (ie, gain or loss), within the 
12 weeks before screening or likely to require treatment with such medications during 
study treatment phase, including but not limited to the following:

Injectable AHAs including exenatide, GLP-1 or GLP-1 analogues, and any 
type of insulin. (Note: if a subject temporarily requires insulin treatment due 
to a transient condition (eg, due to hospitalization, surgery, or other acute 
illness) for 7 days, they are eligible to participate in the study)

Antipsychotic drugs

Anticonvulsants

Tricyclic antidepressants, lithium, levodopa, and dopamine receptor agonists
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
45
Approved, Date: 23 August 2018
35.
Use of selective serotonin reuptake inhibitors (including but not limited to fluoxetine, 
sertraline, paroxetine, escitalopram, citalopram, dapoxetine, seproxetine, zimelidine, 
mesembrine, reboxetine) and serotonin-norepinephrine reuptake inhibitors (including 
but not limited to venlafaxine, duloxetine, desvenlafaxine, milnacipran, fluvoxamine) 
that have not been stable for at least 12 weeks prior to the screening visit because of 
their potential to cause weight change.
36.
Use of systemic corticosteroid medication within 12 weeks before the screening visit 
or likely to require treatment with systemic corticosteroid medication during study 
treatment phase (for longer than 2 consecutive weeks in duration)
Note: Subjects using inhaled, intranasal, intra-articular, or topical corticosteroids or 
corticosteroids in therapeutic replacement doses may participate
37.
Received an investigational drug (including investigational vaccines) other than a 
placebo agent, or used an investigational medical device within 12 weeks prior to 
screening
General
38.
Significant change in smoking habits within 12 weeks before screening
39.
Female subject is pregnant or breastfeeding, planning to become pregnant during the 
study or follow-up period, or planning to donate eggs (ova, oocytes) for the purposes 
of assisted reproduction during the study or for a period of 4 weeks after the last dose 
of study drug
40.
An employee of the investigator or study site, with direct involvement in the proposed 
study or other studies under the direction of that investigator or study site, or is a 
family member of an employee or the investigator
41.
Any condition for which, in the opinion of the investigator, participation would not be 
in the best interest of the subject (eg, compromise the well-being) or that could 
prevent, limit, or confound the protocol-specified assessments
NOTE: Investigators should ensure that all study enrollment criteria have been met at screening. 
If a subject's clinical status changes (including any available laboratory results or receipt of 
additional medical records) after screening but before the first dose of study drug is given such 
that he or she no longer meets all eligibility criteria, then the subject should be excluded from 
participation in the study. The required source documentation to support meeting the enrollment 
criteria are noted in Appendix 2, Regulatory, Ethical, and Study Oversight Considerations.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
46
Approved, Date: 23 August 2018
5.3.
Lifestyle Considerations
Potential subjects must be willing and able to adhere to the following lifestyle restrictions during 
the course of the study to be eligible for participation:
1.
Refer to Section 6.5, Prestudy and Concomitant Therapy, for details regarding 
prohibited and restricted therapy during the study.
2.
Agree to follow all requirements that must be met during the study as noted in the 
Inclusion and Exclusion Criteria (eg, contraceptive requirements).
5.4.
Screen Failures
Subject Identification, Enrollment, and Screening Logs
The investigator agrees to complete a subject identification and enrollment log to permit easy 
identification of each subject during and after the study. This document will be reviewed by the 
sponsor study-site contact for completeness.
The subject identification and enrollment log will be treated as confidential and will be filed by 
the investigator in the study file. To ensure subject confidentiality, no copy will be made. All 
reports and communications relating to the study will identify subjects by subject
Rescreening
Individuals who do not meet the criteria for participation in this study (screen failure) may, at the 
discretion of the investigator, be rescreened 1 time if the reason for non-eligibility relates to 
duration of stable thyroid hormone replacement, antihypertensive, or antihyperlipidemic therapy, 
or time from a MI, unstable angina, revascularization procedure or cerebrovascular accident. 
Subjects who are to be rescreened must sign a new informed consent before rescreening.
6.
STUDY TREATMENT
6.1.
Study Drugs Administered
Open-label AHA Background Therapy
Subjects on oral AHA will be required to have been on a stable treatment regimen (ie. same 
agent and same dose) for at least 12 weeks prior to screening and to remain on such regimen 
throughout the remainder of the study. 
Antihyperglycemic agents allowed at screening and as glycemic rescue medication during study 
are: metformin, sulphonylureas, DPP-4 inhibitors, SGLT-2 inhibitors, and TZDs.
Basal insulin is not allowed at screening but can be used as a glycemic rescue medication.
On days of protocol-specified study visits, subjects are to withhold their morning dose of 
subjects’ oral AHA until after the completion of all study visit procedures.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
47
Approved, Date: 23 August 2018
JNJ-64565111/Placebo During Run-in Period
At the Week -2 visit, subjects will be instructed on the use of prefilled safety injectors to perform 
SC self-injections, and will be asked to perform a self-injection in the presence of the study-site 
staff. Only subjects who express willingness and demonstrate the ability to administer once 
weekly SC injections are eligible to participate in the study (see Section 5.1, Inclusion Criteria). 
To assess compliance with the dosing regimen, eligible subjects will be dispensed prefilled 
safety injectors containing 0.5 mL open-label placebo and instructed to perform self-injections 
once weekly at home during the run-in phase, as well as keep a study drug diary of their injection 
schedule.
Double-blind JNJ-64565111 or Matching Placebo During Double-Blind Treatment Period
JNJ-64565111 will be supplied as a solution for injection at a concentration of 20 mg/mL. 
Blinded study drug will be provided in prefilled safety injectors with attached SC needle, 
prefilled with nominal volumes of 0.25, 0.37, or 0.50 mL of JNJ-64565111 (5.0, 7.4, and 
10.0 mg, respectively) or 1 of 3 matching volumes of placebo. The prefilled safety injector is 
intended for SC administration and consists of a syringe, a needle safety device, and grip 
accessory. Study drug will be manufactured and provided under the responsibility of the sponsor. 
Refer to the Investigator’s Brochure for a list of excipients.
On Day 1, subjects randomly assigned to the double-blind treatment arms will receive a supply 
of their randomly-assigned study drug and will be reminded of the once weekly dosing regimen 
and to record the date and time of each administered dose in the study drug diary. Subjects will 
self-administer the first dose of JNJ-64565111 or matching placebo at the site under the 
supervision of study staff. 
Drug Administration
Subjects will be instructed to administer study drug SC once weekly for the entire duration of the 
12-week treatment phase or until early discontinuation.
Subjects will be instructed to inject to the 4 quadrants of the anterior abdominal wall. For 
consistency, and to avoid dosing in the same abdominal area, subjects should be instructed to 
begin in one quadrant and on subsequent dosing days proceed in the next quadrant in a 
counterclockwise manner.
Injections can be done at any time of day irrespective of meals. However, it is preferable that 
study drug be injected during the same overall time period of the day on a week-to-week basis.
Study drug should be taken on the same day of the week throughout the study (ie, the regularly 
scheduled study drug day).
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
48
Approved, Date: 23 August 2018
If the day of the once weekly injection coincides with the day of a clinic visit, subjects are 
NOT to inject JNJ-64565111 or matching placebo before arriving at the clinic. Instead, 
AFTER all study visit procedures have been completed, subjects may self-administer blinded 
study drug either at the study site or once they have returned home.
Subjects are to record the date and time of study drug administration on the study drug diary, and 
should mark a calendar to remind them of when to take the next weekly dose. Subjects will be 
instructed to record the date and time of each self-injection throughout the run-in and treatment 
phase which allows an assessment of treatment compliance and the relationship of PK 
measurements and safety assessments to the time of study-drug dosing. The information will be 
entered into eCRFs by the site personnel.
Subjects should be instructed not to take 2 doses within 3 days (72 hours) of each other. If a 
subject misses taking the next dose of study drug on their regularly scheduled study drug day, the 
missed dose should be taken as soon as possible, if there are at least 3 days (72 hours) until their 
next regularly scheduled study drug day. If there are less than 3 days remaining, the subject 
should skip the missed dose and take the next dose on their regularly scheduled study drug day.
Study-site personnel will instruct subjects on how to store study drug for at-home use as 
indicated for this protocol. Figure 3 is a schematic diagram of the study drug injection schedule.
Figure 3:
Schematic Diagram of Drug Injection Schedule
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
49
Approved, Date: 23 August 2018
6.2.
Preparation/Handling/Storage/Accountability
All study drug should be stored in the refrigerator at controlled temperatures ranging from 36°F 
to 46°F (2°C to 8°C). Site should keep the study drug cartons until ready to be used, protect them 
from direct heat and light, and avoid shaking the safety injectors. Study drug can be left out at 
room temperature up to 8 hours. 
Study drug administration should be captured in the source documents and eCRF. JNJ-64565111
will be manufactured and provided under the responsibility of the sponsor.
The investigator is responsible for ensuring that all study drug received at the site is inventoried 
and accounted for throughout the study. The dispensing of study drug to the subject, and the 
return of study drug from the subject (if applicable), must be documented on the drug 
accountability form and/or interactive web response system (IWRS) drug accountability web 
portal. Details on drug accountability will be outlined in the IWRS site user manual. All study 
drug will be stored and disposed of according to the sponsor's instructions. 
Subjects should be instructed to return the following at the drug return visits:

unused safety injectors

empty study drug cartons 

study drug diary 
Study drug must be handled in strict accordance with the protocol and the study drug label, and 
must be stored at the study site in a limited-access area or in a locked cabinet under appropriate 
environmental conditions. Unused study drug, and study drug returned by the subject, must be 
available for verification by the sponsor's study-site monitor during on-site monitoring visits.
The return to the sponsor of unused study drug for destruction, will be documented on the drug
return form and/or IWRS drug accountability web portal. When the study site is an authorized 
destruction unit and study drug supplies are destroyed on-site, this must also be documented on 
the drug return form and/or IWRS drug accountability web portal.
Potentially hazardous materials such as used safety injectors containing residual liquids should 
be disposed of immediately in a safe manner and therefore will not be retained for drug 
accountability purposes. 
Study drug should be dispensed under the supervision of the investigator or a qualified member 
of the study-site personnel, or by a hospital/clinic pharmacist. Study drug will be supplied only 
to subjects participating in the study. Returned of unused study drug must not be dispensed 
again, even to the same subject. Study drug may not be relabeled or reassigned for use by other 
subjects. The investigator agrees neither to dispense the study drug from, nor store it at, any site 
other than the study sites agreed upon with the sponsor.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
50
Approved, Date: 23 August 2018
6.3.
Measures to Minimize Bias: Randomization and Blinding
Randomization and Blinding Procedures
On Day 1, subjects will be randomly assigned to 1 of 4 treatment groups based on a computer-
generated randomization schedule prepared before the study by or under the supervision of the 
sponsor. The randomization will use randomly permuted blocks.
At baseline (Day 1), the treatment code, which is linked to the randomization schedule, will be 
assigned after logging on to the IWRS designated by the sponsor. The requestor must use his or 
her own user identification and personal identification number when contacting the IWRS, and 
will then give the relevant subject details to uniquely identify the subject. Based on this 
information, the IWRS will assign a unique treatment code, which will dictate the treatment 
assignment and matching study drug kit for the subject. As subjects are randomly assigned to 
treatment, the IWRS will assign a study drug kit to be dispensed at that visit. New study drug kits 
will be assigned each time the IWRS is accessed for dispensing additional study drug.
Blinding
The investigator will not be provided with randomization codes. The codes will be maintained 
within the IWRS, which has the functionality to allow the investigator to break the blind for an 
individual subject.
Data that may potentially unblind the study drug assignment (ie, study drug serum 
concentrations, anti-JNJ-64565111 antibodies, study drug preparation/accountability data, study 
drug allocation, FPG, HbA1c, serum β-hydroxybutyrate, and urine ketones) will be handled with 
special care to ensure that the integrity of the blind is maintained and the potential for bias is 
minimized. This can include making special provisions, such as segregating the data in question 
from view by the investigators, clinical team, or others as appropriate until the time of database 
lock and unblinding.
Under normal circumstances, the blind should not be broken until all subjects have completed 
the study and the database is finalized. The investigator may in an emergency determine the 
identity of the study drug by contacting the IWRS. While the responsibility to break the study 
drug code in emergency situations resides solely with the investigator, it is recommended that the 
investigator contact the sponsor or its designee if possible to discuss the particular situation, 
before breaking the blind. In the event the blind is broken, the sponsor must be informed as soon 
as possible. The date and reason for the unblinding must be documented in the appropriate 
section of the eCRF and in the source document. The documentation received from the IWRS 
indicating the code break must be retained with the subject's source documents in a secure 
manner so as not to unblind the treatment assignment to the study site or sponsor personnel. The 
investigator is also advised not to reveal the study treatment assignment to the study site (except 
as necessary for the clinical management of the subject) or sponsor personnel.
In general, treatment codes will be disclosed fully only after the study is completed and the 
clinical database is closed.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
51
Approved, Date: 23 August 2018
6.4.
Study Drug Compliance
The investigator or designated study-site personnel will maintain a log of all study drug 
dispensed and returned. Drug supplies for each subject will be inventoried and accounted for 
throughout the study. Subjects who are poorly compliant with blinded study drug (based on 
unused safety injector(s), used empty study drug cartons, and/or study drug diary) should receive 
counseling on the importance of dosing compliance.
During the course of the study, the investigator or designated study-site personnel will be 
responsible for providing additional instructions to re-educate any subject who is not compliant 
with taking the study drug.
6.5.
Prestudy and Concomitant Therapy
Prestudy therapy includes any therapy used before the first dose of treatment phase study drug. 
Concomitant therapy is any therapy used after the first dose of treatment phase study drug that is 
administered on Day 1.
Prestudy therapies administered up to 30 days before first dose of double-blind treatment phase 
study drug must be recorded.
All therapies (prescription or over-the-counter medications, including vaccines, vitamins, herbal 
supplements; non-pharmacologic therapies such as electrical stimulation, acupuncture, special 
diets, exercise regimens) different from the study drug must be recorded in the eCRF. 
Prohibited Therapies
1.
Prescription weight-management drugs (including but not limited to orlistat, topiramate 
and/or phentermine, lorcaserin, naltrexone and/or bupropion), or over-the-counter weight-
loss medications or therapies
2.
Oral, intravenous, or intramuscular corticosteroids for longer than 2 consecutive weeks in 
duration
Note: Inhaled, intranasal, intra-articular, or topical corticosteroids, or corticosteroids in 
therapeutic replacement doses are allowed
3.
Previous (ie, within 12 weeks from screening visit) or current use of a highly active anti-
retroviral therapy
4.
GLP-1 agonists and any insulin except basal insulin that serve as rescue AHA use 
Note: if a subject temporarily requires insulin treatment due to a transient condition (eg, due 
to hospitalization, surgery, or other acute illness) for 7 days, they may remain in the study
5.
Antipsychotic drugs
6.
Anticonvulsants
7.
Tricyclic antidepressants, lithium, levodopa, and dopamine receptor agonists
8.
Any other investigational agents during the study
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
52
Approved, Date: 23 August 2018
The sponsor must be notified in advance (or as soon as possible thereafter) of any instances in 
which prohibited therapies are administered.
6.6.
Glycemic Rescue Medication
During the 12-week treatment phase, glycemic rescue therapy will be implemented in subjects 
with FPG values (repeated and confirmed within 7 days) meeting the prespecified criteria
provided in Table 3 below. Subjects should be counseled to contact the site if their fasting 
SMBG consistently (ie, ≥3 days within a week) exceeds 200 mg/dL, and an FPG measurement to 
determine eligibility for glycemic rescue therapy should be obtained. Subjects should have 
reinforcement of diet and exercise recommendations before obtaining the repeat FPG value. At 
the investigator’s discretion, based upon recent fasting SMBG values that are consistent with the 
initial FPG result meeting glycemic rescue criteria, this single FPG (ie, without a repeat FPG 
value) may be used to demonstrate eligibility for glycemic rescue therapy.
Table 3:
Glycemic Rescue Criteria
Time point
Value
After Day 1 through Week 6
FPG >270 mg/dL (>15 mmol/L)
After Week 6 through Week 12
FPG >240 mg/dL (>13.3 mmol/L)
Rescue therapy may include increasing the dose of a current AHA or the initiation of a new 
AHA. Investigators will manage rescue therapy, including the selection of the specific AHA, its 
clinically appropriate initial dose and titration regimen (if applicable), the need to switch from 
one AHA rescue medication to another (eg, poor glycemic response to prior rescue medication), 
and be consistent with the labeled use within the country of the study site. Metformin, 
sulphonylureas, TZDs, SGLT-2 inhibitors, DPP-4 inhibitors, and insulin (basal only) are allowed 
as rescue medication. Both GLP-1 agonists and short-acting or intermediate insulins are not 
allowed as rescue medications.
Subjects on glycemic rescue therapy for at least 2 weeks at the maximum dose considered 
appropriate by the investigator, with FPG >180 mg/dL (10.0 mmol/L), must be discontinued 
from the study drug treatment (see Section 7, Discontinuation from Study Drug and 
Discontinuation from Study).
6.7.
Dose Modification
JNJ-64565111 or matching placebo will not be titrated. Subjects will self-administer the full dose 
of JNJ-64565111 or matching placebo on Day 1 and will remain on their assigned dosages 
throughout the treatment phase (ie, until Week 12 or early discontinuation of study drug).
6.8.
Study Drug After the End of the Study
Subjects will be instructed that study drug will not be made available to them after they have 
completed/discontinued study drug and that they should return to their primary physician to 
determine standard of care.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
53
Approved, Date: 23 August 2018
7.
DISCONTINUATION FROM STUDY DRUG AND DISCONTINUATION FROM
STUDY
7.1.
Discontinuation from Study Drug
A subject's study drug must be discontinued if:

The investigator believes that for safety reasons or tolerability reasons (eg, adverse event) it 
is in the best interest of the subject to discontinue study treatment

The investigator formally unblinds the subject’s treatment allocation

Subject is persistently in poor compliance with study treatment or procedures

Subject's eGFR is <45 mL/min/1.73 m2 (provided by the central laboratory)

For subjects meeting the eGFR discontinuation criterion, a repeat determination should 
be performed within 1 week and study treatment discontinued if the repeat 
determination confirms that the value still meets the criterion

Subject has persistent episodes of tachyarrhythmia (eg, atrial flutter, atrial fibrillation, 
ventricular tachycardia) or develops persistent resting pulse rate >100 bpm for which in the 
opinion of the investigator it is in the best interest of the subject to discontinue study 
treatment

Subject has a serum sodium of <125 mEq/L (<125 mmol/L), confirmed by repeat central 
laboratory measurement.
Note: For subjects meeting the sodium discontinuation criterion, a repeat determination of 
the full chemistry panel should be performed within 1 week and study treatment 
discontinued if the repeat determination confirms that the sodium value still meets the 
criterion (unless a reversible acute cause is identified [eg, severe vomiting, dehydration] in 
which case an additional repeat determination can be performed after resolution of the 
illness). If the sodium value is improving on repeat determination, but value is still 
<130 mEq/L (<130 mmol/L), an additional repeat measurement should be performed within 
1 to 2 weeks to monitor subject’s electrolytes. 

Liver function test abnormalities occur that meet the criteria for permanent discontinuation 
of study drug as outlined in Appendix 10, Algorithm for Monitoring Abnormal Liver 
Function Tests

Acute pancreatitis, defined by the presence of at least 2 of the following 3 circumstances: 
characteristic abdominal pain, amylase and/or lipase >3 x ULN or characteristic findings on 
CT/MRI (see Appendix 11, Pancreatitis Monitoring and Withdrawal Criteria)

The subject becomes pregnant (study drug should be immediately interrupted based upon a 
positive urinary hCG, and permanently discontinued if confirmed by a serum -hCG)

Initiation and planned continued use of disallowed therapy (see Section 6.5, Prestudy and 
Concomitant Therapy)

Subject is on glycemic rescue therapy, and after at least 2 weeks on the maximum dose 
considered appropriate by the investigator, FPG is >180 mg/dL (10.0 mmol/L)
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
54
Approved, Date: 23 August 2018

Subject experiences a SAE
of biochemically-confirmed (eg, blood pH, serum 
ß-hydroxybutyrate, anion gap) DKA

Subject experiences an episode of vomiting assessed as “severe” lasting more than 24 hours 
and considered to be at least possibly related to study drug without any other potential cause 
(eg, viral gastroenteritis, food-borne illness).
Subjects who prematurely discontinue study drug prior to Week 12 will require an immediate 
EOT assessment (either on the day of study drug discontinuation or as soon as possible following 
study drug discontinuation) and the SAE assessment/follow-up and PK and immunogenicity 
(ie, ADA) collection at least 5 weeks since the last dose of study drug. 
Subjects that discontinue study drug early will continue in the study (off treatment) and will be 
assessed at the subsequent visit(s) as described in the Schedule of Activities schedule, starting at 
the next scheduled visit from when study drug was permanently discontinued up to the final 
Week 12 visit. These off-treatment visits will include assessment and collection of:

SAEs

Specific AEs of interest (ie, MACE events, acute pancreatitis, and possible cases of thyroid 
neoplasm)

Vital signs (including body weight)

Concomitant medications
If subjects that discontinued study drug early are unable to return to their site for the scheduled 
on-site study visit, an alternate contact visit should be conducted with the goal of collecting any 
SAEs, MACEs (ie, CV death, nonfatal MI and nonfatal stroke), acute pancreatitis, and AEs of 
thyroid neoplasm. Details regarding discussions via telephone, email, or other methods of 
contact should be properly documented on subject’s source record and/or eCRF, including date 
of contact, outcome and responses provided by the subjects. The site may consult subjects’ 
delegated contact(s) for the off-treatment follow-up if the site is unable to reach the subjects after 
multiple attempts.
7.2.
Discontinuation from the Study
A subject will be discontinued from the study for any of the following reasons:

Lost to follow-up

Withdrawal of consent

Death
When a subject is discontinued from the study, the reason for early study discontinuation is to be 
documented in the eCRF and in the source document. Study drug assigned to a subject who 
discontinued from the study may not be assigned to another subject. Subjects who discontinued 
from the study will not be replaced.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
55
Approved, Date: 23 August 2018
7.2.1.
Withdrawal of Consent
Withdrawal of consent from the study by a subject should be a very unusual occurrence in a 
clinical trial. The investigator should make every effort to maintain a good relationship with 
subjects to avoid this occurrence.
Withdrawal of consent in this study should only be documented in the eCRF after a discussion 
between the investigator and the appropriate sponsor representative (eg, study responsible 
physician).
7.2.2.
Withdrawal from the Use of Research Samples 
Withdrawal from the Use of Archive Samples in Future Research
The subject may withdraw consent for use of archive samples for research (refer to Long-Term 
Retention of Samples for Additional Future Research in Appendix 2, Regulatory, Ethical, and 
Study Oversight Considerations). In such a case, samples will be destroyed after they are no 
longer needed for the clinical study. Details of the sample retention for research are presented in 
the main ICF.
7.3.
Lost to Follow-up
If a subject is lost to follow-up, every reasonable effort must be made by the study-site personnel 
to contact the subject and determine the reason for discontinuation/withdrawal. This should 
include repeated telephone calls, certified letters, email requests, etc. To ensure access to 
follow-up subjects, the sites should obtain both primary and secondary telephone contact 
numbers (eg, home, work, and mobile phone numbers), as well as other contact information 
(eg, email addresses) before randomization. In addition, the site should emphasize the 
importance of follow-up information to the subject before randomization. The measures taken to 
follow-up should be documented.
8.
STUDY ASSESSMENTS AND PROCEDURES
Overview
The Schedule of Activities summarizes the frequency and timing of scheduled visits, and the 
timing of efficacy, safety, PK, immunogenicity, and PRO measurements applicable to this study.
Scheduled study visits should generally occur within a 3-day window (ie, 4 days) around the 
protocol-specified visit schedule (as provided in the Schedule of Activities). For study visits that 
cannot be held within the recommended visit window, the visit should be conducted as closely as 
possible to the study visit schedule. All subsequent visits should be scheduled relative to the date 
of randomization (Day 1), and not the date of the rescheduled visit.
The maximum blood volume (for blood collections shown in the Schedule of Activities) that 
would be collected if a subject were to complete the SAE follow-up visit after the Week 12/EOT 
visit would be approximately 147.0 mL. See Table 4 for details. Repeat or unscheduled samples 
may be taken for safety reasons or for technical issues with the samples.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
56
Approved, Date: 23 August 2018
Blood collections for PK assessments should be kept as close to the specified time as possible. 
Other measurements may be done earlier than specified timepoints if needed. Actual dates and 
times of lab assessments will be recorded in the source documentation (eg, lab requisition form).
Table 4:
Maximum Volume of Blood to be Collected from Each Subject
Type of Sample
Volume per Sample (mL)
No. of Samples per subject 
Total Volume of Blood 
(mL)a
Hematology
1.0
3
3.0
HbA1c
2.0
5
10.0
Serum chemistry
2.5
5
12.5
Calcitonin
1.0
3
3.0
Serum β-hydroxybutyrate
1.0
4
4.0
Fasting insulin
2.0
2
4.0
Fasting C-peptide
1.0
3
3.0
FPG
2.0
5
10.0
Fasting lipid panel
3.5
3
10.5
Serum -hCG pregnancy tests
1.5
2
3.0
FSH
1.5
1
1.5
Pharmacokinetic (PK) trough 
and immunogenicity samples
5.0
5
25.0
PK non-trough
3.5
1
3.5
Plasma, serum archive samples
27
2
54
Approximate Total
147.0
a
Calculated as number of samples multiplied by amount of blood per sample.
Sample Collection and Handling
The actual dates and times of sample collection must be recorded in the laboratory requisition 
form. 
Refer to the Schedule of Activities for the timing and frequency of all sample collections.
Instructions for the collection, handling, storage, and shipment of samples are found in the 
laboratory manual that will be provided. Collection, handling, storage, and shipment of samples 
must be under the specified, and where applicable, controlled temperature conditions as indicated 
in the laboratory manual.
Study-Specific Materials
The investigator will be provided with the following supplies: 

Glucose meter and glucose testing strips

Recruitment and retention tools

IWRS Manual and worksheets

Template ICFs

eCRF completion guidelines

Materials to promote healthy dietary and exercise habits

Study drug diary (ie, JNJ64565111/Placebo diary)
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
57
Approved, Date: 23 August 2018

Blood sugar diary (including SMBG results, hypoglycemia events, and concomitant 
medications)

IWQOL-Lite questionnaire

7-day ERCQ diary 

PROMIS SF 10a questionnaire 

PGIS questionnaire 

PGIC questionnaire 

Survey on Subject Satisfaction with Self-injection (English-speaking subjects)

Laboratory operations manual, requisition forms, sampling supplies, and equipment, if 
necessary

Computer, if the study site is assessed to require a laptop computer to enter eCRF data for 
the study

PRO Completion Guide
8.1.
Efficacy Assessments
Primary Efficacy Endpoint
The primary efficacy endpoint will be the percentage change in body weight from baseline to 
Week 12 between JNJ-64565111 compared with placebo.
Secondary and Exploratory Efficacy Endpoints
The secondary measures of efficacy at Week 12 include proportion of subjects with 5% weight 
loss from baseline, and the absolute change in body weight from baseline.
Exploratory efficacy endpoints at Week 12 include proportion of subjects with 10% weight loss 
from baseline, change from baseline in BMI, waist circumference, HbA1c, FPG, fasting insulin, 
fasting C-peptide, HOMA-B, HOMA-IR, fasting lipids (ie, total cholesterol, LDL-C, HDL-C,
triglycerides), SBP, DBP, pulse rate, pulse-pressure product, PK exposure, and PROs 
(ie, changes in IWQOL-Lite, PROMIS SF 10a, ERCQ). 
Patient-reported Outcomes
Janssen is developing a novel PRO instrument to assess eating-related concepts such as hunger,
appetite, cravings and/or satiety, and to support the use of an existing PRO instrument assessing 
physical functioning. These novel measures along with a previously developed questionnaire will 
be included in this study. Some questionnaires will be completed during scheduled site visits 
(IWQOL-Lite, PROMIS SF 10a, PGIS, PGIC) while another will be completed at home by the 
subject (ERCQ). It is therefore important for sites to be familiar with the Schedule of Activities
to ensure subjects complete the PROs at the correct setting and visit (see Appendix 13). PROs 
will enable the evaluation of subject's experience of treatment and although the PRO endpoints 
are exploratory, the expected treatment-group differences may provide data supporting the value 
of the product from a patient's perspective.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
58
Approved, Date: 23 August 2018
Whenever possible, all site-visit-based PRO assessments (IWQOL-Lite, PROMIS SF 10a, PGIS, 
PGIC) should be completed before any tests, procedures, or discussion of AEs or the subject’s 
medical condition. The home-based PRO assessment (ERCQ) should be completed daily, 
preferably in the evening, and, whenever possible, in the same setting for 7 consecutive days.
All PRO assessments will be done in English-speaking and Spanish-speaking subjects provided 
that a suitable Spanish translation of the materials are available, otherwise, the PRO assessments 
will only be administered to English-speaking subjects.
The Impact of Weight on Quality of Life-Lite (IWQOL-Lite)
The IWQOL-Lite (Kolotkin 2001; Kolotkin 2002) is a 31-item, self-report obesity-specific 
measure that contains 5 domains: Physical Function (11 items), Self-esteem (7 items), Sexual 
Life (4 items), Public Distress (5 items), and Work (4 items). It has been used to quantitatively 
assess an individual’s perception of how their weight affects their day-to-day life. The IWQOL-
Lite has been widely used in clinical trials and is a reliable and valid measure that has 
demonstrated good psychometric properties.
Confirmatory factor analyses provide strong support for the adequacy of the scale structure. The 
5 identified scales and the total score demonstrated excellent psychometric properties in obese 
patients (Coon 2016; Hauber 2010), and the reliability of the scales ranges from 0.90 to 0.94 and 
is 0.96 for the total score (Kolotkin 2001). A published algorithm is used to calculate domain and 
total scores, which range from 0 to 100 with higher scores indicating better well-being. IWQOL-
Lite will be administered at Weeks -2 and 12/EOT visit. A sample of the IWQOL-Lite and 
instructions for completion are provided in the PRO Completion Guide.
Eating-related Concepts Questionnaire (ERCQ)
An instrument developed by the sponsor describes the subject’s rating of eating-related concepts 
such as hunger, appetite, cravings, and satiety. The ERCQ follows the FDA’s Guidance for 
Industry for developing new PRO measures (FDA 2009).
At the Week -2 visit, subjects will be provided the ERCQ diary to complete at home. The ERCQ 
should be completed by the subject at the same time and in the same setting each day for 
7 consecutive days, starting at Week -1 up to the day prior to Day 1 visit.
At the Week 6 visit, another ERCQ diary will be provided to the subjects to start completing at 
around Week 11. The site should contact subjects at Week 10, preferably by telephone, to remind 
the completion of this ERCQ diary 7 consecutive days starting at Week 11 up to the day prior to 
their scheduled Week 12 visit. The completed final ERCQ diary should be returned by the 
subjects and collected by the site at the Week 12 visit. For subjects who discontinue early from 
study drug, no ERCQ diary completion is required at the EOT visit. A sample of the ERCQ and 
instructions for completion are provided in the PRO Completion Guide.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
59
Approved, Date: 23 August 2018
PROMIS Physical Function Short Form 10a (PROMIS SF 10a)
The Patient-Reported Outcomes Measurement Information System (PROMIS®) is a set of 
person-centered measures that evaluate physical, mental, and social health in adults and children 
(HealthMeasures website). These measures can be used with the general population and with 
individuals living with chronic conditions. PROMIS Profile instruments are a collection of short 
forms containing a fixed number of items from different domains (Depression, Anxiety, Physical 
Function, Pain Interference, Fatigue, Sleep Disturbance, and Ability to Participate in Social 
Roles and Activities). The PROMIS Profile instruments are administered as short forms and are 
ideal when researchers prefer to ask the same question of all respondents or of the same 
respondent over time. These measures were developed and validated with state-of-the-science 
methods to be psychometrically sound (HealthMeasures website). 
The PROMIS SF 10a will be administered at Week -2, baseline Day 1, and Week 12/EOT visit. 
A sample of the PROMIS SF 10a and instructions for completion are provided in the PRO 
Completion Guide.
Patient Global Impression Status (PGIS) and Patient Global Impression of Change (PGIC)
Interpreting meaningful change in scores on PRO instruments is an important step in instrument 
development. The methods for interpreting meaningful change to derive responder definitions 
have evolved over time and various approaches exist. Yet, in many cases, anchor-based methods 
are preferred over distribution-based methods. Anchor-based methods link scores on the PRO to 
an external criterion that identifies subjects who have experienced an important change in their 
condition. Distribution-based approaches use the variability of PRO scores to quantify the 
magnitude of change (Coon 2016). The PGIS and the PGIC will be used as anchors, external 
criterion, to determine meaningful change in scores for the ERCQ and the PROMIS SF 10a in 
this population of severely obese subjects with T2DM. The PGIS contains questions on how the 
subject would currently rate their ability on the concept(s) of interest. The PGIC contains 
questions on how the subject would rate their ability on the concept(s) of interest compared with
before starting the study.
The PGIS will be administered at Week -2 and Week 12/EOT visit and PGIC at Week 12/EOT 
visit only. Samples of the PGIS and PGIC and instructions for completion are provided in the 
PRO Completion Guide.
8.2.
Safety Assessments 
Safety evaluations will include the monitoring of AEs (including protocol-specified AEs of 
interest), vital sign measurements, clinical laboratory tests (including serum chemistry, 
calcitonin, lipase, amylase, hematology, and urinalysis), physical examination including 
complete skin examination, serum/urine pregnancy testing, ECG, SMBG, assessment of 
hypoglycemia episodes, and review of concomitant medications.
At Week -2, subjects will be provided with and instructed on the use of a home blood glucose 
meter that will measure their fasting SMBG (to be done at least twice weekly). Subjects will be 
counseled on the signs/symptoms and how to manage an episode of hypoglycemia (see 
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
60
Approved, Date: 23 August 2018
Appendix 8, Hypoglycemia: Definitions, Symptoms, and Treatment). In addition, subjects 
should be counseled to contact the site if their fasting SMBG consistently (ie, ≥3 days within a 
week) exceeds 200 mg/dL, and an FPG measurement to determine eligibility for glycemic rescue 
therapy should be obtained (see Section 6.6, Glycemic Rescue Medication). 
Investigators will remind subjects to contact the investigational sites in the presence of 
signs/symptoms that may be consistent with acute pancreatitis (see Appendix 11, Pancreatitis 
Monitoring and Withdrawal Criteria), or in the presence of severe nausea/vomiting that limits the 
ability of the subject to keep adequate fluid intake even for a few hours, hence increasing the risk 
of dehydration and electrolyte imbalances, as well as DKA. Based on the assessment, the 
investigators should use their clinical judgment to determine whether the subject may require 
immediate medical attention (eg, emergency room visit) or whether the subjects should be 
scheduled as soon as possible for an unscheduled visit to undergo clinical and pertinent 
laboratory assessments, and if deemed appropriate by the investigator, study drug should be 
interrupted until results have been reviewed. 
If a subject experiences an adverse event of vomiting assessed by the investigator as “severe” in 
intensity (see Appendix 1, Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting) lasting more than 24 hours and considered to be at least 
possibly related to study drug, the subject must be discontinued from study treatment (see 
Section 7.1, Discontinuation from Study Drug). 
If a subject experiences an adverse event of vomiting assessed as “moderate” in intensity lasting 
more than 48 hours, considered to be at least possibly related to study drug, and occurring within 
3 days of the next scheduled dose, further administration of study drug will be interrupted. Based 
upon the investigator’s assessment of the subject’s clinical status (which may be done via a 
telephone contact or in-clinic visit) and/or, if necessary, a review of the laboratory results (either 
obtained by central or local laboratory) and any other clinical data, the investigator will 
determine whether the subject can resume study drug (eg, no signs/symptoms of dehydration, 
reduction in intensity or resolution of adverse event, no clinically significant laboratory 
abnormalities), should continue to interrupt study drug, or  be permanently discontinued from 
study drug (see Section 7.1, Discontinuation from Study Drug).
At the investigator’s discretion, an anti-emetic may be administered or prescribed if needed to 
reduce vomiting so as to avoid subsequent dehydration.
Routine safety monitoring will be conducted by the internal Sponsor clinical study team and will 
be based on the review of blinded data on a regular basis.
Adverse events will be reported and followed by the investigator as specified in Section 8.3, 
Adverse Events and Serious Adverse Events, and Appendix 1, Adverse Events: Definitions and 
Procedures for Recording, Evaluating, Follow-Up, and Reporting.
Any clinically relevant changes occurring during the study must be recorded on the Adverse 
Event section of the eCRF.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
61
Approved, Date: 23 August 2018
Any clinically significant abnormalities persisting at the end of the study/early withdrawal will 
be followed by the investigator until resolution or until a clinically stable endpoint is reached. 
The study will include the following evaluations of safety and tolerability according to the time 
points provided in the Schedule of Activities:
8.2.1.
Physical Examination
Physical examinations will include a full review of body systems including a complete skin 
examination. Physical examination abnormalities noted after the baseline assessment will be 
collected if considered an adverse event by the investigator (recorded on adverse event eCRF). In 
addition to the physical examination required at the screening visit and EOT visit, investigators 
should use their clinical judgment whether additional physical examinations (either full of 
focused) are needed (eg, subject reporting injection site reaction, flank pain, pedal edema, etc.).
8.2.2.
Vital Signs
Vital signs will consist of pulse and blood pressure measurements and will be obtained after the 
subject has been in the sitting position for 5 minutes and before blood sample collection for 
laboratory tests. Blood pressure will be assessed manually with a mercury sphygmomanometer 
or an automated blood pressure monitor. Three consecutive blood pressure and pulse rate 
readings will be taken and recorded, at intervals of at least 1 minute apart, as specified in the 
Schedule of Activities and in Appendix 6, Method of Blood Pressure and Heart Rate 
Measurement.
At the screening visit, blood pressure will be measured in both arms. If there is a difference 
between arms of >10 mm Hg in either systolic or diastolic pressure, the arm with the higher 
pressure should be used to measure blood pressure and should be used for all subsequent blood 
pressure measurements during the study. If possible, if blood pressure is measured manually, it 
should be measured by the same individual, using the same equipment, at each clinic visit to 
reduce variability.
8.2.3.
Electrocardiogram (ECG)
A standard 12-lead ECG will be conducted at the Week -2 visit. Electrocardiograms will be 
conducted and read at the investigator site or affiliated facility. Significant findings that are 
present must be documented in the source and eCRF.
During the collection of ECGs, subjects should be in a quiet setting without distractions 
(eg, television, cell phones). Subjects should rest in a supine position for at least 5 minutes 
before ECG collection and should refrain from talking or moving arms or legs. If blood sampling 
or vital sign measurement is scheduled for the same time point as ECG recording, the procedures 
should be performed in the following order: ECG(s), vital signs, blood draw.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
62
Approved, Date: 23 August 2018
8.2.4.
Clinical Safety Laboratory Assessments
Blood samples for serum chemistry and hematology, and urine samples for urinalysis will be 
collected. The investigator must review the laboratory results, document this review, and record 
any clinically relevant changes occurring during the study in the adverse event eCRF if 
applicable. 
Subjects will be monitored for safety laboratory analytes as described in Appendix 9, Clinical 
Laboratory Tests.
Subjects with elevations in ALT (3 × ULN), in lipase/amylase (2 × ULN) or in calcitonin 
(10 pg/mL [10 ng/L]) will be monitored and managed using the algorithms provided in 
Appendix 10, Algorithm for Monitoring Abnormal Liver Function Tests, Appendix 11, 
Pancreatitis Monitoring and Withdrawal Criteria, and Appendix 12, Guidelines for Calcitonin 
Monitoring.
In the current study, serum -hydroxybutyrate will be assessed by the central lab as a marker of 
target engagement as mild elevations of serum -hydroxybutyrate were generally observed in the 
Phase 1 studies (see Section 2.3, Benefit/Risk Assessment). To avoid the potential unblinding of 
subject to treatment assignment, both serum β-hydroxybutyrate and urinary ketones will remain 
masked to investigators and sponsor.  
Alerts will be provided to investigators by the central laboratory identifying important laboratory 
changes or key out-of-range values, so the investigator can follow-up as necessary. For 
creatinine phosphokinase (CPK) elevations, the investigator should determine if follow-up 
evaluation is clinically appropriate to exclude a potential cardiac event.
8.3.
Adverse Events and Serious Adverse Events
Timely, accurate, and complete reporting and analysis of safety information from clinical studies 
are crucial for the protection of subjects, investigators, and the sponsor, and are mandated by 
regulatory agencies worldwide. The sponsor has established Standard Operating Procedures in 
conformity with regulatory requirements worldwide to ensure appropriate reporting of safety 
information; all clinical studies conducted by the sponsor or its affiliates will be conducted in 
accordance with those procedures.
Anticipated events will not be recorded and reported in this study as to allow full reporting of 
AEs from these studies without any special reporting exceptions for individual case safety 
reports of AEs. 
For further details on AEs and SAEs (Definitions and Classifications; Attribution Definitions; 
Severity Criteria; Special Reporting Situations; Procedures) as well as product quality 
complaints, refer to Appendix 1, Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-Up, and Reporting.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
63
Approved, Date: 23 August 2018
Collection of Protocol-Specified Adverse Events of Interest
For any adverse event considered to be one of the following protocol-specified adverse events of 
interest, and for all deaths, investigators may be asked to provide more detailed information with 
the source documents or completing the applicable supplemental forms or eCRF.
Cardiovascular Events
Investigators will be instructed to identify the following cardiovascular events of interest:

MACE (ie, CV death, nonfatal MI, and nonfatal stroke)

hypotension-related AEs
Pancreatic Events
Investigators will be instructed to identify the following pancreatic events of interest:

adverse event of pancreatitis

adverse events of serious or severe abdominal pain leading to suspicion of pancreatitis

confirmed lipase or amylase elevations 3 × ULN.
See Appendix 11, Pancreatitis Monitoring and Withdrawal Criteria, for details of how to monitor 
and document pancreatic adverse events.
Calcitonin Elevation and Thyroid Neoplasm
Investigators will be instructed to identify elevations in calcitonin and possible cases of thyroid 
hyperplasia, including but not limited to:

C-cell thyroid hyperplasia

Medullary thyroid cancer

Thyroid cancer (papillary, follicular)

Thyroid nodule

See Appendix 12, Guidelines for Calcitonin Monitoring, for details of how to 
monitor and document thyroid neoplasm.
Collection of Information on Possible Hypoglycemic Episodes
Subjects will be asked to collect fingerstick glucose determinations at the time of possible 
hypoglycemic episodes, and to document information on these events, including the fingerstick 
glucose results, in the blood sugar diary. This diary will be reviewed by study-site personnel at 
each scheduled visit (see Appendix 8, Hypoglycemia: Definitions, Symptoms and Treatment). 
Information on possible hypoglycemic episodes will be collected on a separate hypoglycemia 
eCRF, and hypoglycemic episodes that are considered by the investigator to be adverse events of 
hypoglycemia should also be recorded on the adverse event eCRF.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
64
Approved, Date: 23 August 2018
8.3.1.
Time Period and Frequency for Collecting Adverse Event and Serious 
Adverse Event Information
All Adverse Events
All adverse events and special reporting situations, whether serious or non-serious, will be 
reported from the time a signed and dated ICF is obtained until completion of the subject's last 
study-related procedure, which may include contact for follow-up of safety. Serious adverse 
events, including those spontaneously reported to the investigator within 5 weeks after the last 
dose of JNJ64565111/placebo after the last dose of study drug, must be reported using the 
Serious Adverse Event Form. The sponsor will evaluate any safety information that is 
spontaneously reported by an investigator beyond the time frame specified in the protocol.
Serious Adverse Events
All SAEs occurring during the study must be reported to the appropriate sponsor contact person 
by study-site personnel within 24 hours of their knowledge of the event.
Information regarding SAEs will be transmitted to the sponsor using the Serious Adverse Event 
Form and Safety Report Form of the eCRF, which must be completed and reviewed by a 
physician from the study site, and transmitted to the sponsor within 24 hours. The initial and 
follow-up reports of an SAE should be transmitted electronically or by facsimile (fax).
8.3.2.
Follow-up of Adverse Events and Serious Adverse Events
Adverse events, including pregnancy, will be followed by the investigator as specified in 
Appendix 1, Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, 
and Reporting.
8.3.3.
Regulatory Reporting Requirements for Serious Adverse Events
The sponsor assumes responsibility for appropriate reporting of adverse events to the regulatory 
authorities. The sponsor will also report to the investigator (and the head of the investigational 
institute where required) all suspected unexpected serious adverse reactions (SUSARs). The 
investigator (or sponsor, where required) must report SUSARs to the appropriate Independent 
Ethics Committee/Institutional Review Board (IEC/IRB) that approved the protocol unless 
otherwise required and documented by the IEC/IRB. A SUSAR will be reported to regulatory 
authorities unblinded. Participating investigators and IEC/IRB will receive a blinded SUSAR 
summary, unless otherwise specified. 
8.3.4.
Pregnancy
All initial reports of pregnancy in female subjects or partners of male subjects must be reported 
to the sponsor by the study-site personnel within 24 hours of their knowledge of the event using 
the appropriate pregnancy notification form. Abnormal pregnancy outcomes (eg, spontaneous 
abortion, fetal death, stillbirth, congenital anomalies, or ectopic pregnancy) are considered SAEs 
and must be reported using the Serious Adverse Event Form. Any subject who becomes pregnant 
during the study must discontinue further study treatment. 
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
65
Approved, Date: 23 August 2018
Follow-up information regarding the outcome of the pregnancy and any postnatal sequelae in the 
infant will be required.
8.4.
Treatment of Overdose
For this study, more than 3 doses/injections of JNJ-64565111within a 7-day time period will be 
considered an overdose.
In the event of an overdose, the investigator or treating physician should:

Contact the Medical Monitor immediately.

Closely monitor the subject for AE/SAE and laboratory abnormalities.
No antidote to JNJ-64565111 is available. The sponsor does not recommend specific 
intervention for an overdose, but rather appropriate symptomatic medical treatment should be 
given according to the clinical condition.
Decisions regarding dose interruptions or modifications will be made by the investigator in 
consultation with the Medical Monitor based on the clinical evaluation of the subject.
8.5.
Pharmacokinetics
Serum samples will be used to evaluate the PK of JNJ-64565111. Serum collected for PK may 
additionally be used to evaluate safety or efficacy aspects that address concerns arising during or 
after the study period. Genetic analyses will not be performed on these serum samples. Subject
confidentiality will be maintained.
Evaluations
Refer to the Schedule of Activities for the timing and frequency of all sample collections. 
Blood collections for PK assessments should be kept as close to the specified time as possible.
Venous blood samples will be collected from all subjects according to the Schedule of Activities
for determination of serum trough concentrations of JNJ-64565111 to assess attainment of 
steady-state concentrations. In addition, a non-trough (peak) sample on Day 4 will be collected 
from all subjects, as well as a post-treatment sample at 16 weeks from all subjects. On the days 
of the trough clinic visits at which PK samples are to be obtained, subjects are not to inject the 
study drug before arriving at the clinic. 
The non-trough PK sampling time point was prospectively optimized for population-based PK 
analyses. In addition to the trough samples and a post-treatment sample in all subjects, all
subjects will have 1 additional visit (Day 41-day sampling window) to collect a non-trough PK 
sample. 
The exact dates and times of previous study drug injection and blood sampling for PK must be 
recorded in the eCRF or laboratory requisition form for all PK samples. 
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
66
Approved, Date: 23 August 2018
See the laboratory manual for information regarding handling of biologic samples.
Pharmacokinetic Analytical Procedures  
Serum samples will be analyzed to determine concentrations of JNJ-64565111 using a validated, 
specific, and sensitive immunoassay method by or under the supervision of the sponsor.
Parameters
Serum concentrations at each time point of measurement will be evaluated by descriptive 
statistics, including arithmetic mean, geometric mean, standard deviation, coefficient of 
variation, geometric coefficient of variation, minimum, maximum, and median. 
8.6.
Pharmacodynamics
Pharmacodynamics are part of efficacy, see Section 8.1, Efficacy Assessments.
8.7.
Genetics
Pharmacogenomics/Genetics are not evaluated in this study.
8.8.
Archive Samples for Exploratory Biomarker Research
Archived samples may be used for future analysis of biomarkers related to the safety and/or 
efficacy of JNJ-64565111, and/or the study of T2DM, obesity, and its complications.
8.9.
Health Economics/Medical Resource Utilization and Health Economics 
Health Economics/Medical Resource Utilization and Health Economics parameters are not 
evaluated in this study.
8.10.
Further Assessments
8.10.1.
Immunogenicity Assessments 
The detection and characterization of anti-JNJ-64565111 antibodies will be performed using a 
validated assay method by or under the supervision of the sponsor. All samples collected for 
detection of anti-JNJ-64565111 antibodies will also be evaluated for JNJ-64565111 serum 
concentration to enable interpretation of the antibody data.
Anti-JNJ-64565111 antibodies will be evaluated in serum samples collected from all subjects 
according to the Schedule of Activities. Additionally, serum samples should also be collected at 
the final visit from subjects who are discontinued from treatment.
Serum samples will be screened for antibodies binding to JNJ-64565111 and the titer of 
confirmed positive samples will be reported. Other analyses may be performed to verify the 
stability of antibodies to JNJ-64565111 and/or further characterize the immunogenicity of 
JNJ-64565111.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
67
Approved, Date: 23 August 2018
8.10.2.
Survey on Experience with Self-injection of Study Drug
A survey designed to assess subject satisfaction with the experience of self-administering study 
drug will be given to English-speaking subjects at Week 6.
9.
STATISTICAL CONSIDERATIONS
Statistical analysis will be done by the sponsor or under the authority of the sponsor. A general 
description of the statistical methods to be used to analyze the efficacy and safety data is outlined 
below. Specific details will be provided in the Statistical Analysis Plan.
9.1.
Statistical Hypotheses
The goal of the primary efficacy analysis is to determine if there is treatment difference in the 
percentage reduction in body weight from baseline between JNJ-64565111 treatment groups and 
the placebo group at Week 12. The null hypothesis is that there is no difference between the 
treatment groups in the percentage reduction in body weight. The alternative hypothesis is that 
there is a greater percentage reduction in body weight in the JNJ-64565111 treatment groups 
compared with placebo group.
9.2.
Sample Size Determination
A total of 188 subjects will be randomly assigned in this study with 47 subjects per group 
allocated to each of the 4 treatment groups. Sample size was determined based on assessing the 
primary hypothesis that treatment with JNJ-64565111 at 1 or more dose levels for 12 weeks 
leads to greater percentage reduction in body weight compared with placebo. 
Assuming a common SD of 4% with respect to percent change in body weight at Week 12 and a 
2-sided type I error rate of 0.05, it is estimated that a sample size of 47 randomly assigned
subjects per group will have approximately 90% power to detect a treatment difference of 2.7%.
9.3.
Populations for Analyses
For purposes of analysis, the following populations are defined:
Table 5: 
Subject Population Definitions
Population
Description
Enrolled
All subjects who sign the ICF
ITT analysis set
all subjects who are randomly assigned to a treatment group and have a baseline 
measurement of body weight
mITT analysis set
all ITT subjects who have at least 1 post-baseline measurement of body weight within 7 days 
following a dose of study drug and before initiation of any rescue therapy
Completers’ 
analysis set
of all mITT subjects who have completed 12 weeks of double-blind treatment 
(ie, documented in the eCRF by the investigators that the subject has completed participation 
in the study through the Week 12 visit) and without initiation of glycemic rescue therapy
Safety analysis set
all randomized subjects who have received at least one dose of study drug
Key: eCRF=electronic case report form; ICF=informed consent form; ITT=intent-to-treat; mITT=modified intent-to-
treat.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
68
Approved, Date: 23 August 2018
The primary efficacy analysis, to demonstrate the superiority of JNJ-64565111 compared with
placebo on percentage reduction in body weight from baseline to Week 12, as well as all 
secondary efficacy analyses, will be based on the modified intent-to-treat (mITT) analysis set 
and will include only those measurements taken up to and including the last dose of study drug 
plus 7 days and prior to initiation of any glycemic rescue therapy. A secondary analysis of the 
primary and secondary efficacy endpoints will be based on the intent-to-treat (ITT) analysis set. 
This analysis will include all measurements. Sensitivity analyses based on the completers’ 
analysis set will also be performed for the primary endpoint. 
Efficacy data will be analyzed according to the initial randomization assignment, regardless of 
the actual treatment received. Safety data will be analyzed according to the predominant 
treatment received, in the event that a subject receives a treatment other than that to which he/she 
is randomly assigned.
9.4.
Statistical Analyses
9.4.1.
Efficacy Analyses
All hypotheses will be tested 2-sided at a 5% significance level unless otherwise notes.
Primary Efficacy Endpoint
The primary efficacy endpoint will be the percentage change in body weight between 
JNJ-64565111 and placebo from baseline to Week 12.
The primary efficacy endpoint will be analyzed based on the mITT analysis set using a mixed 
model for repeated measures (MMRM). The analysis will use the observed data through 
Week 12 while on treatment (up to the last dose of study drug plus 7 days) and prior to rescue 
medication. The analysis model will include the fixed, categorical effects of treatment, visit, and 
treatment-by-visit interaction, as well as the continuous covariates of baseline body weight and 
baseline-by-visit interaction. An unstructured covariance will be used to model the within-patient 
errors. The treatment comparisons will be made between each of the JNJ-64565111 treatment 
groups and placebo at Week 12 based on this model.
A secondary analysis of the primary endpoint will be based on the ITT analysis set and will 
employ pattern mixture models using multiple imputation methods. This analysis will use all 
observed data, including the measurements off treatment. Responses for subjects who 
discontinued from the study earlier than Week 12 will be imputed based on subjects who 
discontinued treatment prematurely but subsequently provided off-treatment measurements. The 
imputation will be done within randomized treatment groups. Data will be analyzed using the 
same model as in the primary analysis. The treatment comparisons between each of the 
JNJ-64565111 treatment groups and placebo will be made at Week 12. Details of this approach 
will be provided in the statistical analysis plan (SAP).
Finally, the primary efficacy endpoint will be analyzed based on the completers analysis set. 
Additional analysis using a Multiple Comparison Procedure –
Modeling approach 
(Bornkamp 2009; Pinheiro 2014) will be performed to explore the dose-response relationship.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
69
Approved, Date: 23 August 2018
Secondary Efficacy Endpoints
Secondary efficacy analyses at Week 12 will include the absolute change in body weight from 
baseline and the proportion of subjects with 5% weight loss.
The absolute change in body weight from baseline at Week 12 will be analyzed with an MMRM 
model similar to the primary efficacy endpoint based on the mITT analysis set.
The proportion of subjects with 5% weight loss will be analyzed longitudinally using a 
generalized linear mixed model based on the mITT analysis set. The analysis will use the 
observed data through Week 12 while on treatment (up to the last dose of study drug plus 7 days) 
and prior to rescue medication. The model will include the fixed, categorical effects of treatment, 
visit, and treatment-by-visit interaction, as well as the continuous covariates of baseline weight, 
and baseline-by-visit interactions. An unstructured covariance will be used to model the within-
patient errors. The odds ratio and associated p-value for the treatment comparison between each 
of the JNJ-64565111 treatment groups versus placebo at Week 12 based on this model will be 
provided.
A secondary analysis of the secondary endpoints will be based on the ITT analysis set and will 
employ pattern mixture models using multiple imputation methods based on information from 
retrieved dropouts as described above. For the proportion of subjects with 5% weight loss, 
response status will be determined from the imputed continuous response based on subjects who 
discontinued treatment prematurely but subsequently provided off-treatment measurements.
Multiplicity Adjustment
The type I error will be strongly controlled at α=5% for each of the primary endpoint and 
secondary endpoints. The Hochberg approach will be used to adjust the multiplicity of the 
comparisons of each of the JNJ-64565111 doses versus placebo for each endpoint. 
Exploratory Endpoints
The continuous exploratory efficacy endpoints will be analyzed using a MMRM model similar to 
the model used to analyze the primary efficacy endpoint based on the mITT analysis set. The 
categorical exploratory efficacy endpoints will be analyzed using a generalized linear mixed 
model similar to the model used to analyze the proportion of subjects with 5% weight loss. 
9.4.2.
Safety Analyses
The evaluation of safety will be based on the incidence of adverse events and hypoglycemia 
episodes, and changes in clinical laboratory test results and vital sign results (blood pressure, 
pulse rate). The safety analyses will be based on the safety analysis set including all data, 
regardless of the initiation of glycemic rescue therapy (ie, including data after initiation of rescue 
therapy). Additional analysis of hypoglycemia will be performed based on the data prior the 
initiation of glycemic rescue therapy only. Summaries of adverse events, clinical laboratory test 
results, and vital sign results will be provided by treatment group. There will be no imputation of 
missing values for clinical safety laboratory test results, and vital sign measurements.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
70
Approved, Date: 23 August 2018
Adverse Events
The verbatim terms used in the eCRF by investigators to identify adverse events will be coded 
using the Medical Dictionary for Regulatory Activities (MedDRA). Treatment-emergent adverse 
events are adverse events with onset during the treatment phase or that are a consequence of a 
pre-existing condition that has worsened since baseline. All reported adverse events will be 
included in the analysis. For each adverse event, the percentage of subjects who experience at 
least 1 occurrence of the given event will be summarized by treatment group. In addition, 
comparisons between treatment groups will be provided if appropriate.
Summaries, listings, datasets, or subject narratives may be provided, as appropriate, for those 
subjects who die, who discontinue study drug due to an adverse event, or who experience a 
severe or a serious adverse event.
For each adverse event, the percentage of subjects who experience at least 1 occurrence of the 
given event will be summarized by treatment group. The percentage of subjects with specific
treatment-emergent adverse events (TEAEs) will be summarized by severity and relationship to 
study drug, as classified by the investigator, by treatment group. The dose-response relationship 
of dose levels on TEAE will be assessed, assuming that the incidence rates of TEAE will be 
monotonic with respect to dose levels. A listing for non-TEAEs will be provided.
Hypoglycemic events will be classified as severe, documented symptomatic, probable 
symptomatic and asymptomatic. The primary hypoglycemic analysis of interest will be all 
documented hypoglycemic events regardless of the presence of symptoms (ie, documented 
symptomatic and asymptomatic hypoglycemia) plus all severe hypoglycemic events. For each 
type of hypoglycemia, the percentage of subjects with at least one event will be summarized by 
treatment group. The differences in percentage (JNJ-64565111 versus placebo) and their 2-sided 
95% confidence intervals will be estimated.
Hypoglycemic events are collected on a separate eCRF and also collected on the Adverse Event 
eCRF (for all such events considered as adverse events by the investigator). The primary analysis 
of hypoglycemia will be based upon data from the hypoglycemia eCRF (and not from the 
adverse event database). No reconciliation of hypoglycemia data from the Adverse Event eCRF 
and the hypoglycemic eCRF will be performed (except to assure that all adverse events of 
hypoglycemia are also recorded on the hypoglycemia eCRF).
Further analyses, to be described in the SAP for this study which will be finalized before the 
subject is randomized, will be conducted on the prespecified adverse events for which additional 
information is collected from the investigators (refer to Section 8.2, Safety Assessments), and on 
other adverse events.
Clinical Laboratory Tests
Laboratory data will be summarized by type of laboratory test. Normal reference ranges will be 
provided. Criteria for markedly abnormal laboratory values will be prespecified in the SAP. The 
percentage of subjects with markedly abnormal results will be summarized for each laboratory 
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
71
Approved, Date: 23 August 2018
analyte. Descriptive statistics will be reported for each laboratory analyte at baseline and at each 
scheduled time point and for change from baseline.
Resting Vital Signs (Pulse, Blood Pressure)
Descriptive statistics of pulse rate and sitting blood pressure (systolic and diastolic) values and 
changes from baseline will be summarized at each scheduled time point. The percentage of 
subjects with values beyond clinically important limits will be summarized.
Physical Examination
Physical examination findings will not be summarized except when reported as an adverse event.
9.4.3.
Other Analyses
Pharmacokinetic Analyses 
If feasible, population PK analysis of serum concentration-time and exposure-response data of 
JNJ-64565111 may be performed using nonlinear mixed-effects modeling. Data may be 
combined with those of other selected studies to support a relevant structural model. Available 
baseline subject characteristics (demographics, laboratory variables, genotypes, race, etc.) will be 
tested as potential covariates affecting PK parameters. Details will be given in a population PK 
analysis plan, and the results of the population PK analysis will be presented in a separate report. 
A snapshot date for PK samples to be analyzed will be defined, if required. Samples collected 
before this date will be analyzed for JNJ-64565111 and included in the population PK analysis. 
Samples collected after the snapshot date will be analyzed at a later date and may be included in 
a population PK re-analysis when they become available after database lock.
Data will be listed for all subjects with available serum concentrations per treatment group. 
Subjects will be excluded from the PK analysis if their data do not allow for accurate assessment 
of the PK (eg, lack of compliance with administration of the study drug; missing information of 
dosing and sampling times; concentration data not sufficient for PK parameter calculation).
All concentrations below the lowest quantifiable concentration or missing data will be labeled as 
such in the concentration database. All subjects and samples excluded from the analysis will be 
clearly documented in the study report.
For each treatment group, descriptive statistics, including sample size (n), arithmetic mean, 
geometric mean, SD, percent coefficient of variation, percent geometric coefficient of variation,
median, minimum, and maximum will be calculated for serum concentrations for JNJ-64565111
at each time point.
Immunogenicity Analyses 
The incidence of anti-JNJ-64565111 antibodies will be summarized for all subjects who receive 
at least 1 dose of JNJ-64565111 and have appropriate samples for detection of antibodies to 
JNJ-64565111.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
72
Approved, Date: 23 August 2018
A listing of subjects who are positive for antibodies to JNJ-64565111 will be provided. The 
maximum titers of antibodies to JNJ-64565111 will be summarized for subjects who are positive 
for antibodies to JNJ-64565111.
The incidence of neutralizing antibodies (NAbs) to JNJ-64565111 will be summarized for 
subjects who are positive for antibodies to JNJ-64565111 and have samples evaluable for NAbs 
to JNJ-64565111.
Other immunogenicity analyses may be performed to further characterize the immune responses 
that are generated.
9.5.
Interim Analysis
No interim analyses are planned.
9.5.1.
Internal Data Monitoring Committee (DMC)
The study team will perform ongoing blinded monitoring of the study safety data. If during the 
review the study team notes any possible safety signal(s), the study team may request an internal 
DMC to review unblinded study data.
The internal DMC will consist of at least 1 medical expert in the relevant therapeutic area and at 
least 1 statistician. The internal DMC responsibilities, authorities, and procedures will be 
documented in its charter. After the review, the internal DMC will make recommendations 
regarding the continuation of the study or any changes in study conduct. The details will be 
provided in a separate internal DMC charter.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
73
Approved, Date: 23 August 2018
10.
SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS
10.1.
Appendix 1: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting
ADVERSE EVENT DEFINITIONS AND CLASSIFICATIONS
Adverse Event
An adverse event is any untoward medical occurrence in a clinical study subject administered a 
medicinal (investigational or non-investigational) product. An adverse event does not necessarily 
have a causal relationship with the study drug. An adverse event can therefore be any 
unfavorable and unintended sign (including an abnormal finding), symptom, or disease 
temporally associated with the use of a medicinal (investigational or non-investigational) 
product, whether or not related to that medicinal (investigational or non-investigational) product. 
(Definition per International Conference on Harmonisation [ICH])
This includes any occurrence that is new in onset or aggravated in severity or frequency from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory test 
abnormalities.
Note: The sponsor collects adverse events starting with the signing of the ICF (refer to All 
Adverse Events under Section 8.3.1, Time Period and Frequency for Collecting Adverse Events 
and Serious Adverse Events Information, for time of last adverse event recording).
Serious Adverse Event
A serious adverse event based on ICH and EU Guidelines on Pharmacovigilance for Medicinal 
Products for Human Use is any untoward medical occurrence that at any dose:

Results in death

Is life-threatening
(The subject was at risk of death at the time of the event. It does not refer to an event that 
hypothetically might have caused death if it were more severe.)

Requires inpatient hospitalization or prolongation of existing hospitalization

Results in persistent or significant disability/incapacity

Is a congenital anomaly/birth defect

Is a suspected transmission of any infectious agent via a medicinal product

Is Medically Important*
*Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
also appropriate in other situations, such as important medical events that may not be 
immediately life-threatening or result in death or hospitalization but may jeopardize the subject 
or may require intervention to prevent one of the other outcomes listed in the definition above. 
These should usually be considered serious.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
74
Approved, Date: 23 August 2018
Unlisted (Unexpected) Adverse Event/Reference Safety Information
An adverse event is considered unlisted if the nature or severity is not consistent with the 
applicable product reference safety information. For JNJ-64565111, the expectedness of an 
adverse event will be determined by whether or not it is listed in the Investigator's Brochure.
Adverse Event Associated With the Use of the Drug
An adverse event is considered associated with the use of the drug if the attribution is possible, 
probable, or very likely by the definitions listed below (see Attribution Definitions).
ATTRIBUTION DEFINITIONS
Not Related
An adverse event that is not related to the use of the study drug.
Doubtful
An adverse event for which an alternative explanation is more likely, eg, concomitant 
treatment(s), concomitant disease(s), or the relationship in time suggests that a causal 
relationship is unlikely.
Possible
An adverse event that might be due to the use of the study drug. An alternative explanation, 
eg, concomitant treatment(s), concomitant disease(s), is inconclusive. The relationship in time is 
reasonable; therefore, the causal relationship cannot be excluded.
Probable
An adverse event that might be due to the use of the study drug. The relationship in time is 
suggestive (eg, confirmed by dechallenge). An alternative explanation is less likely, 
eg, concomitant treatment(s), concomitant disease(s).
Very Likely
An adverse event that is listed as a possible adverse reaction and cannot be reasonably explained 
by an alternative explanation, eg, concomitant treatment(s), concomitant disease(s). The 
relationship in time is very suggestive (eg, it is confirmed by dechallenge and rechallenge).
SEVERITY CRITERIA
An assessment of severity grade will be made using the following general categorical 
descriptors:
Mild: Awareness of symptoms that are easily tolerated, causing minimal discomfort and not 
interfering with everyday activities.
Moderate: Sufficient discomfort is present to cause interference with normal activity.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
75
Approved, Date: 23 August 2018
Severe: Extreme distress, causing significant impairment of functioning or incapacitation. 
Prevents normal everyday activities.
The investigator should use clinical judgment in assessing the severity of events not directly 
experienced by the subject (eg, laboratory abnormalities).
SPECIAL REPORTING SITUATIONS 
Safety events of interest on a sponsor study drug in an interventional study that may require 
expedited reporting or safety evaluation include, but are not limited to:

Overdose of a sponsor study drug

Suspected abuse/misuse of a sponsor study drug

Accidental or occupational exposure to a sponsor study drug

Medication error involving a sponsor product (with or without subject/patient exposure to 
the sponsor study drug, eg, name confusion)

Exposure to a sponsor study drug from breastfeeding
Special reporting situations should be recorded in the eCRF. Any special reporting situation that 
meets the criteria of a serious adverse event should be recorded on the serious adverse event page 
of the eCRF.
PROCEDURES 
All Adverse Events
All adverse events, regardless of seriousness, severity, or presumed relationship to study drug, 
must be recorded using medical terminology in the source document and the eCRF. Whenever 
possible, diagnoses should be given when signs and symptoms are due to a common etiology 
(eg, cough, runny nose, sneezing, sore throat, and head congestion should be reported as "upper 
respiratory infection"). Investigators must record in the eCRF their opinion concerning the 
relationship of the adverse event to study therapy. All measures required for adverse event 
management must be recorded in the source document and reported, according to sponsor 
instructions.
For all studies with an outpatient phase, including open-label studies, the subject should be 
provided with a "wallet (study) card" and instructed to carry this card with them for the duration 
of the study indicating the following: 

Study number

Statement, in the local language(s), that the subject is participating in a clinical study

Investigator's name and 24-hour contact telephone number

Local sponsor's name and 24-hour contact telephone number (for medical staff only)

Site number
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
76
Approved, Date: 23 August 2018

Subject number

Any other information that is required to do an emergency breaking of the blind
Serious Adverse Events
All serious adverse events that have not resolved by the end of the study, or that have not 
resolved upon discontinuation of the subject's participation in the study, must be followed until 
any of the following occurs:

The event resolves

The event stabilizes

The event returns to baseline, if a baseline value/status is available

The event can be attributed to agents other than the study drug or to factors unrelated to 
study conduct

It becomes unlikely that any additional information can be obtained (subject or health care 
practitioner refusal to provide additional information, lost to follow-up after demonstration 
of due diligence with follow-up efforts)
Suspected transmission of an infectious agent by a medicinal product will be reported as a 
serious adverse event. Any event requiring hospitalization (or prolongation of hospitalization) 
that occurs during the course of a subject's participation in a study must be reported as a serious 
adverse event, except hospitalizations for the following:

Hospitalizations not intended to treat an acute illness or adverse event (eg, social reasons 
such as pending placement in long-term care facility)

Surgery or procedure planned before entry into the study (must be documented in the 
eCRF). 
The cause of death of a subject in a study within 4 weeks of the last dose of study drug, whether 
or not the event is expected or associated with the study drug, is considered a serious adverse 
event.
CONTACTING SPONSOR REGARDING SAFETY
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding safety issues or questions regarding the study are listed in the Contact Information 
page(s), which will be provided as a separate document.
PRODUCT QUALITY COMPLAINT HANDLING 
A product quality complaint (PQC) is defined as any suspicion of a product defect related to 
manufacturing, labeling, or packaging, ie, any dissatisfaction relative to the identity, quality, 
durability, or reliability of a product, including its labeling or package integrity. A PQC may have 
an impact on the safety and efficacy of the product. Timely, accurate, and complete reporting and 
analysis of PQC information from studies are crucial for the protection of subjects, investigators, 
and the sponsor, and are mandated by regulatory agencies worldwide. The sponsor has 
established procedures in conformity with regulatory requirements worldwide to ensure 
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
77
Approved, Date: 23 August 2018
appropriate reporting of PQC information; all studies conducted by the sponsor or its affiliates 
will be conducted in accordance with those procedures.
Procedures
All initial PQCs must be reported to the sponsor by the study-site personnel within 24 hours after 
being made aware of the event.
If the defect is combined with a serious adverse event, the study-site personnel must report the 
PQC to the sponsor according to the serious adverse event reporting timelines (refer to 
Section 8.3.1, Time Period and Frequency for Collecting Adverse Event and Serious Adverse 
Event Information). A sample of the suspected product should be maintained for further 
investigation if requested by the sponsor.
If the product quality issue relates to the device (ie, safety injector), the device should be retained 
in the returns sharp container (also referred to as the evidence tube) provided to the subject. The 
subject is to return the sealed returns sharp container containing the safety injector to the site and 
the site is to ship it as directed by the sponsor for investigation.
If the product quality issue relates to the solution for injection and not to the device, the safety 
injector device should be retained in the returns sharp container (also referred to as the evidence 
tube) provided to the subject. The subject is to return the sealed returns sharp container 
containing the safety injector to the site. The site should maintain the safety injector for further 
investigation if requested by the sponsor and the site is to ship it as directed by the sponsor for 
investigation.
Contacting Sponsor Regarding Product Quality
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding product quality issues are listed in the Contact Information page(s), which will be 
provided as a separate document.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
78
Approved, Date: 23 August 2018
10.2.
Appendix 2: Regulatory, Ethical, and Study Oversight Considerations
REGULATORY AND ETHICAL CONSIDERATIONS 
Investigator Responsibilities
The investigator is responsible for ensuring that the study is performed in accordance with the 
protocol, current ICH guidelines on Good Clinical Practice (GCP), and applicable regulatory and 
country-specific requirements.
Good Clinical Practice is an international ethical and scientific quality standard for designing, 
conducting, recording, and reporting studies that involve the participation of human subjects. 
Compliance with this standard provides public assurance that the rights, safety, and well-being of 
study subjects are protected, consistent with the principles that originated in the Declaration of 
Helsinki, and that the study data are credible.
Protocol Amendments
Neither the investigator nor the sponsor will modify this protocol without a formal amendment 
by the sponsor. All protocol amendments must be issued by the sponsor, and signed and dated by 
the investigator. Protocol amendments must not be implemented without prior IEC/IRB 
approval, or when the relevant competent authority has raised any grounds for non-acceptance, 
except when necessary to eliminate immediate hazards to the subjects, in which case the 
amendment must be promptly submitted to the IEC/IRB and relevant competent authority. 
Documentation of amendment approval by the investigator and IEC/IRB must be provided to the 
sponsor. When the change(s) involve only logistic or administrative aspects of the study, the 
IEC/IRB (where required) only needs to be notified.
During the course of the study, in situations where a departure from the protocol is unavoidable, 
the investigator or other physician in attendance will contact the appropriate sponsor 
representative listed in the Contact Information page(s), which will be provided as a separate 
document. Except in emergency situations, this contact should be made before implementing any 
departure from the protocol. In all cases, contact with the sponsor must be made as soon as 
possible to discuss the situation and agree on an appropriate course of action. The data recorded 
in the eCRF and source documents will reflect any departure from the protocol, and the source 
documents will describe this departure and the circumstances requiring it.
Regulatory Approval/Notification
This protocol and any amendment(s) must be submitted to the appropriate regulatory authorities 
in each respective country, if applicable. A study may not be initiated until all local regulatory 
requirements are met.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
79
Approved, Date: 23 August 2018
Required Prestudy Documentation
The following documents must be provided to the sponsor before shipment of study drug to the 
study site:

Protocol and amendment(s), if any, signed and dated by the principal investigator

A copy of the dated and signed (or sealed, where appropriate per local regulations), written 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if 
applicable, subject compensation programs. This approval must clearly identify the specific 
protocol by title and number and must be signed (or sealed, where appropriate per local 
regulations) by the chairman or authorized designee.

Name and address of the IEC/IRB, including a current list of the IEC/IRB members and 
their function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a letter of explanation, or equivalent, 
from the IEC/IRB, a general statement may be substituted for this list. If an investigator or a 
member of the study-site personnel is a member of the IEC/IRB, documentation must be 
obtained to state that this person did not participate in the deliberations or in the 
vote/opinion of the study.

Regulatory authority approval or notification, if applicable

Signed and dated statement of investigator (eg, Form FDA 1572), if applicable

Documentation of investigator qualifications (eg, curriculum vitae)

Completed investigator financial disclosure form from the principal investigator, where 
required

Signed and dated clinical trial agreement, which includes the financial agreement

Any other documentation required by local regulations
The following documents must be provided to the sponsor before enrollment of the first subject:

Completed investigator financial disclosure forms from all subinvestigators

Documentation of subinvestigator qualifications (eg, curriculum vitae)

Name and address of any local laboratory conducting tests for the study, and a dated copy of 
current laboratory normal ranges for these tests, if applicable

Local 
laboratory 
documentation 
demonstrating 
competence 
and 
test 
reliability 
(eg, accreditation/license), if applicable
Independent Ethics Committee or Institutional Review Board
Before the start of the study, the investigator (or sponsor where required) will provide the 
IEC/IRB with current and complete copies of the following documents (as required by local 
regulations):

Final protocol and, if applicable, amendments

Sponsor-approved ICF (and any other written materials to be provided to the subjects)
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
80
Approved, Date: 23 August 2018

Investigator's Brochure (or equivalent information) and amendments/addenda

Sponsor-approved subject recruiting materials

Information on compensation for study-related injuries or payment to subjects for 
participation in the study, if applicable

Investigator's curriculum vitae or equivalent information (unless not required, as 
documented by the IEC/IRB)

Information regarding funding, name of the sponsor, institutional affiliations, other potential 
conflicts of interest, and incentives for subjects

Any other documents that the IEC/IRB requests to fulfill its obligation
This study will be undertaken only after the IEC/IRB has given full approval of the final 
protocol, amendments (if any, excluding the ones that are purely administrative, with no 
consequences for subjects, data or study conduct, unless required locally), the ICF, applicable 
recruiting materials, and subject compensation programs, and the sponsor has received a copy of 
this approval. This approval letter must be dated and must clearly identify the IEC/IRB and the 
documents being approved.
Approval for the collection of optional samples for research and for the corresponding ICF must 
be obtained from the IEC/IRB. Approval for the protocol can be obtained independent of this 
optional research component.
During the study the investigator (or sponsor where required) will send the following documents 
and updates to the IEC/IRB for their review and approval, where appropriate:

Protocol amendments (excluding the ones that are purely administrative, with no 
consequences for subjects, data or study conduct)

Revision(s) to ICF and any other written materials to be provided to subjects

If applicable, new or revised subject recruiting materials approved by the sponsor

Revisions to compensation for study-related injuries or payment to subjects for participation 
in the study, if applicable

New edition(s) of the Investigator's Brochure and amendments/addenda

Summaries of the status of the study at intervals stipulated in guidelines of the IEC/IRB (at 
least annually)

Reports of adverse events that are serious, unlisted/unexpected, and associated with the 
study drug

New information that may adversely affect the safety of the subjects or the conduct of the 
study

Deviations from or changes to the protocol to eliminate immediate hazards to the subjects

Report of deaths of subjects under the investigator's care

Notification if a new investigator is responsible for the study at the site
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
81
Approved, Date: 23 August 2018

Development Safety Update Report and Line Listings, where applicable

Any other requirements of the IEC/IRB
For all protocol amendments (excluding the ones that are purely administrative, with no 
consequences for subjects, data or study conduct), the amendment and applicable ICF revisions 
must be submitted promptly to the IEC/IRB for review and approval before implementation of 
the change(s).
At least once a year, the IEC/IRB will be asked to review and reapprove this study, where 
required.
At the end of the study, the investigator (or sponsor where required) will notify the IEC/IRB 
about the study completion (if applicable, the notification will be submitted through the head of 
investigational institution).
Country Selection
This study will only be conducted in those countries where the intent is to launch or otherwise 
help ensure access to the developed product if the need for the product persists, unless explicitly 
addressed as a specific ethical consideration in Section 4.2.1, Study-Specific Ethical Design 
Considerations.
Other Ethical Considerations
For study-specific ethical design considerations, refer to Section 4.2.1, Study-Specific Ethical 
Design Considerations.
FINANCIAL DISCLOSURE 
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial 
information in accordance with local regulations to allow the sponsor to submit complete and 
accurate financial certification or disclosure statements to the appropriate regulatory authorities. 
Investigators are responsible for providing information on financial interests during the course of 
the study and for 1 year after completion of the study.
Refer to Required Prestudy Documentation (above) for details on financial disclosure.
INFORMED CONSENT PROCESS 
Each subject must give written consent according to local requirements after the nature of the 
study has been fully explained. The ICF(s) must be signed before performance of any study-
related activity. The ICF(s) that is/are used must be approved by both the sponsor and by the 
reviewing IEC/IRB and be in a language that the subject can read and understand. The informed 
consent should be in accordance with principles that originated in the Declaration of Helsinki, 
current ICH and GCP guidelines, applicable regulatory requirements, and sponsor policy.
Before enrollment in the study, the investigator or an authorized member of the study-site 
personnel must explain to potential subjects the aims, methods, reasonably anticipated benefits, 
and potential hazards of the study, and any discomfort participation in the study may entail. 
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
82
Approved, Date: 23 August 2018
Subjects will be informed that their participation is voluntary and that they may withdraw 
consent to participate at any time. They will be informed that choosing not to participate will not 
affect the care the subject will receive. Finally, they will be told that the investigator will 
maintain a subject identification register for the purposes of long-term follow-up if needed and 
that their records may be accessed by health authorities and authorized sponsor personnel 
without violating the confidentiality of the subject, to the extent permitted by the applicable 
law(s) or regulations. By signing the ICF the subject is authorizing such access. It also denotes 
that the subject agrees to allow his or her study physician to recontact the subject for the purpose 
of obtaining consent for additional safety evaluations, if needed. The physician may also 
recontact the subject for the purpose of obtaining consent to collect information about his or her 
survival status.
The subject will be given sufficient time to read the ICF and the opportunity to ask questions. 
After this explanation and before entry into the study, consent should be appropriately recorded 
by means of the subject's personally dated signature. After having obtained the consent, a copy of 
the ICF must be given to the subject.
DATA PROTECTION 
Privacy of Personal Data
The collection and processing of personal data from subjects enrolled in this study will be 
limited to those data that are necessary to fulfill the objectives of the study.
These data must be collected and processed with adequate precautions to ensure confidentiality 
and compliance with applicable data privacy protection laws and regulations. Appropriate 
technical and organizational measures to protect the personal data against unauthorized 
disclosures or access, accidental or unlawful destruction, or accidental loss or alteration must be 
put in place. Sponsor personnel whose responsibilities require access to personal data agree to 
keep the identity of subjects confidential.
The informed consent obtained from the subject includes explicit consent for the processing of 
personal data and for the investigator/institution to allow direct access to his or her original 
medical records (source data/documents) for study-related monitoring, audit, IEC/IRB review, 
and regulatory inspection. This consent also addresses the transfer of the data to other entities 
and to other countries.
The subject has the right to request through the investigator access to his or her personal data and 
the right to request rectification of any data that are not correct or complete. Reasonable steps 
will be taken to respond to such a request, taking into consideration the nature of the request, the 
conditions of the study, and the applicable laws and regulations.
Biomarker, PK, and immunogenicity research is not conducted under standards appropriate for 
the return of data to subjects. In addition, the sponsor cannot make decisions as to the 
significance of any findings resulting from exploratory research. Therefore, exploratory research 
data will not be returned to subjects or investigators, unless required by law or local regulations. 
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
83
Approved, Date: 23 August 2018
Privacy and confidentiality of data generated in the future on stored samples will be protected by 
the same standards applicable to all other clinical data.
LONG-TERM RETENTION OF SAMPLES FOR ADDITIONAL FUTURE RESEARCH 
Samples collected in this study may be stored for up to 15 years (or according to local 
regulations) for additional research. Samples will only be used to understand JNJ-64565111, to 
understand obesity, to understand differential drug responders, and to develop tests/assays 
related to JNJ-64565111 and obesity. The research may begin at any time during the study or the 
post-study storage period. 
Stored samples will be coded throughout the sample storage and analysis process and will not be 
labeled with personal identifiers. Subjects may withdraw their consent for their samples to be 
stored for research (refer to Section 7.2.2, Withdrawal from the Use of Research Samples).
PUBLICATION POLICY/DISSEMINATION OF CLINICAL STUDY DATA 
All information, including but not limited to information regarding JNJ-64565111 or the 
sponsor’s operations (eg, patent application, formulas, manufacturing processes, basic scientific 
data, prior clinical data, formulation information) supplied by the sponsor to the investigator and 
not previously published, and any data, including exploratory biomarker research data, generated 
as a result of this study, are considered confidential and remain the sole property of the sponsor. 
The investigator agrees to maintain this information in confidence and use this information only 
to accomplish this study, and will not use it for other purposes without the sponsor's prior written 
consent.
The investigator understands that the information developed in the study will be used by the 
sponsor in connection with the continued development of JNJ-64565111, and thus may be 
disclosed as required to other clinical investigators or regulatory agencies. To permit the 
information derived from the clinical studies to be used, the investigator is obligated to provide 
the sponsor with all data obtained in the study.
The results of the study will be reported in a Clinical Study Report generated by the sponsor and 
will contain data from all study sites that participated in the study as per protocol. Recruitment 
performance or specific expertise related to the nature and the key assessment parameters of the 
study will be used to determine a coordinating investigator for the study. Results of exploratory 
biomarker analyses performed after the Clinical Study Report has been issued will be reported in 
a separate report and will not require a revision of the Clinical Study Report. 
Study subject identifiers will not be used in publication of results. Any work created in 
connection with performance of the study and contained in the data that can benefit from 
copyright protection (except any publication by the investigator as provided for below) shall be 
the property of the sponsor as author and owner of copyright in such work.
Consistent with Good Publication Practices and International Committee of Medical Journal 
Editors (ICMJE) guidelines, the sponsor shall have the right to publish such primary 
(multicenter) data and information without approval from the investigator. The investigator has 
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
84
Approved, Date: 23 August 2018
the right to publish study site-specific data after the primary data are published. If an investigator 
wishes to publish information from the study, a copy of the manuscript must be provided to the 
sponsor for review at least 60 days before submission for publication or presentation. Expedited 
reviews will be arranged for abstracts, poster presentations, or other materials. If requested by 
the sponsor in writing, the investigator will withhold such publication for up to an additional 
60 days to allow for filing of a patent application. In the event that issues arise regarding 
scientific integrity or regulatory compliance, the sponsor will review these issues with the 
investigator. The sponsor will not mandate modifications to scientific content and does not have 
the right to suppress information. For multicenter study designs and substudy approaches, 
secondary results generally should not be published before the primary endpoints of a study have 
been published. Similarly, investigators will recognize the integrity of a multicenter study by not 
submitting for publication data derived from the individual study site until the combined results 
from the completed study have been submitted for publication, within 18 months after the study 
end date, or the sponsor confirms there will be no multicenter study publication. Authorship of 
publications resulting from this study will be based on the guidelines on authorship, such as 
those described in the ICMJE Recommendations for the Conduct, Reporting, Editing and 
Publication of Scholarly Work in Medical Journals, which state that the named authors must 
have made a significant contribution to the conception or design of the work; or the acquisition, 
analysis, or interpretation of the data for the work; and drafted the work or revised it critically for 
important intellectual content; and given final approval of the version to be published; and 
agreed to be accountable for all aspects of the work in ensuring that questions related to the 
accuracy or integrity of any part of the work are appropriately investigated and resolved.
Registration of Clinical Studies and Disclosure of Results
The sponsor will register and disclose the existence of and the results of clinical studies as 
required by law.
DATA QUALITY ASSURANCE 
Data Quality Assurance/Quality Control
Steps to be taken to ensure the accuracy and reliability of data include the selection of qualified 
investigators and appropriate study sites, review of protocol procedures with the investigator and 
study-site personnel before the study, and periodic monitoring visits by the sponsor, and direct 
transmission of clinical laboratory data from a central laboratory into the sponsor's data base. 
Written instructions will be provided for collection, handling, storage, and shipment of samples. 
Guidelines for eCRF completion will be provided and reviewed with study-site personnel before 
the start of the study. 
The sponsor will review eCRF for accuracy and completeness during on-site monitoring visits 
and after transmission to the sponsor; any discrepancies will be resolved with the investigator or 
designee, as appropriate. After upload of the data into the study database they will be verified for 
accuracy and consistency with the data sources.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
85
Approved, Date: 23 August 2018
CASE REPORT FORM COMPLETION 
Case report forms are prepared and provided by the sponsor for each subject in electronic format. 
All data relating to the study must be recorded in eCRF. All eCRF entries, corrections, and 
alterations must be made by the investigator or authorized study-site personnel. The investigator 
must verify that all data entries in the eCRF are accurate and correct.
The study data will be transcribed by study-site personnel from the source documents onto an 
eCRF, if applicable. Study-specific data will be transmitted in a secure manner to the sponsor.
Worksheets may be used for the capture of some data to facilitate completion of the eCRF. Any 
such worksheets will become part of the subject's source documents. Data must be entered into 
the eCRF in English. The eCRF must be completed as soon as possible after a subject visit and 
the forms should be available for review at the next scheduled monitoring visit.
All participative measurements (eg, questionnaires) will be completed by the same individual 
who made the initial baseline determinations whenever possible.
If necessary, queries will be generated in the electronic data capture (eDC) tool. If corrections to 
an eCRF are needed after the initial entry into the eCRF, this can be done in either of the 
following ways:

Investigator and study-site personnel can make corrections in the eDC tool at their own 
initiative or as a response to an auto query (generated by the eDC tool).

Sponsor or sponsor delegate can generate a query for resolution by the investigator and 
study-site personnel.
SOURCE DOCUMENTS 
At a minimum, source documents consistent in the type and level of detail with that commonly 
recorded at the study site as a basis for standard medical care must be available for the following: 
subject identification, eligibility, and study identification; study discussion and date of signed 
informed consent; dates of visits; results of safety and efficacy parameters as required by the 
protocol; record of all adverse events and follow-up of adverse events; concomitant medication; 
study drug receipt/dispensing/return records; study drug administration information; and date of 
study completion and reason for early discontinuation of study drug or withdrawal from the 
study, if applicable. 
The author of an entry in the source documents should be identifiable.
Specific details required as source data for the study and source data collection methods will be 
reviewed with the investigator before the study and will be described in the monitoring 
guidelines (or other equivalent document).
An eSource system may be utilized, which contains data traditionally maintained in a hospital or 
clinic record to document medical care (eg, electronic source documents) as well as the clinical 
study-specific data fields as determined by the protocol. This data is electronically extracted for 
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
86
Approved, Date: 23 August 2018
use by the sponsor. If eSource is utilized, references made to the eCRF in the protocol include 
the eSource system but information collected through eSource may not be limited to that found 
in the eCRF.
MONITORING 
The sponsor will use a combination of monitoring techniques (central, remote, or on-site 
monitoring) to monitor this study.
The sponsor will perform on-site monitoring visits as frequently as necessary. The monitor will 
record dates of the visits in a study site visit log that will be kept at the study site. The first post-
initiation visit will be made as soon as possible after enrollment has begun. At these visits, the 
monitor will compare data entered into the eCRF with the source documents 
(eg, hospital/clinic/physician’s office medical records); a sample may be reviewed. The nature 
and location of all source documents will be identified to ensure that all sources of original data 
required to complete the eCRF are known to the sponsor and study-site personnel and are 
accessible for verification by the sponsor study-site contact. If electronic records are maintained 
at the study site, the method of verification must be discussed with the study-site personnel. 
Direct access to source documents (medical records) must be allowed for the purpose of 
verifying that the recorded data are consistent with the original source data. Findings from this 
review will be discussed with the study-site personnel. The sponsor expects that, during 
monitoring visits, the relevant study-site personnel will be available, the source documents will 
be accessible, and a suitable environment will be provided for review of study-related 
documents. The monitor will meet with the investigator on a regular basis during the study to 
provide feedback on the study conduct.
ON-SITE AUDITS 
Representatives of the sponsor's clinical quality assurance department may visit the study site at 
any time during or after completion of the study to conduct an audit of the study in compliance 
with regulatory guidelines and company policy. These audits will require access to all study 
records, including source documents, for inspection. Subject privacy must, however, be 
respected. The investigator and study-site personnel are responsible for being present and 
available for consultation during routinely scheduled study-site audit visits conducted by the 
sponsor or its designees. 
Similar auditing procedures may also be conducted by agents of any regulatory body, either as 
part of a national GCP compliance program or to review the results of this study in support of a 
regulatory submission. The investigator should immediately notify the sponsor if he or she has 
been contacted by a regulatory agency concerning an upcoming inspection.
RECORD RETENTION 
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all eCRF 
and all source documents that support the data collected from each subject, as well as all study 
documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct of a 
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
87
Approved, Date: 23 August 2018
Clinical Trial, and all study documents as specified by the applicable regulatory requirement(s). 
The investigator/institution will take measures to prevent accidental or premature destruction of 
these documents.
Essential documents must be retained until at least 2 years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing 
applications in an ICH region or until at least 2 years have elapsed since the formal 
discontinuation of clinical development of the investigational product. These documents will be 
retained for a longer period if required by the applicable regulatory requirements or by an 
agreement with the sponsor. It is the responsibility of the sponsor to inform the 
investigator/institution as to when these documents no longer need to be retained.
If the responsible investigator retires, relocates, or for other reasons withdraws from the 
responsibility of keeping the study records, custody must be transferred to a person who will 
accept the responsibility. The sponsor must be notified in writing of the name and address of the 
new custodian. Under no circumstance shall the investigator relocate or dispose of any study 
documents before having obtained written approval from the sponsor.
If it becomes necessary for the sponsor or the appropriate regulatory authority to review any 
documentation relating to this study, the investigator/institution must permit access to such 
reports.
STUDY AND SITE CLOSURE 
Study Termination
The sponsor reserves the right to close the study site or terminate the study at any time for any 
reason at the sole discretion of the sponsor. Study sites will be closed upon study completion. A 
study site is considered closed when all required documents and study supplies have been 
collected and a study-site closure visit has been performed.
The investigator may initiate study-site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.
Reasons for the early closure of a study site by the sponsor or investigator may include but are 
not limited to:

Failure of the investigator to comply with the protocol, the requirements of the IEC/IRB or 
local health authorities, the sponsor's procedures, or GCP guidelines

Inadequate recruitment of subjects by the investigator

Discontinuation of further study drug development
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
88
Approved, Date: 23 August 2018
10.3.
Appendix 3: Abbreviations and Trademarks
5-HT2C
5-hydroxytryptamine type 2C receptor
-hCG
serum -human chorionic gonadotropin
ADA
anti-drug antibodies
AE
adverse event
AHA
antihyperglycemic agent
AUC
area under the curve
AUC168hr
area under the curve in the interval 0–168 hours
AUC(0-inf)
area under the curve from time zero (pre-dose) to extrapolated infinite time
AUC(0-last)
area under the curve from time zero (pre-dose) to last measurable concentration
AUC(Tau)
area under the curve from time zero (pre-dose) to the end of dosing period
BMI
body mass index
bpm
beats per minute
Cmax
maximum concentration
CKD-Epi
Chronic Kidney Disease Epidemiology Collaboration
CPK
creatinine phosphokinase
CT
computed tomography
CV
cardiovascular
DBP
diastolic blood pressure
DIO
diet-induced obese
DKA
diabetic ketoacidosis
DMC
data monitoring committee
DPP-4
dipeptidyl peptidase-4
ECG
electrocardiogram
eCRF(s)
electronic case report form(s) 
eDC
electronic data capture
eGFR
estimated glomerular filtration rate
EMA
European Medicines Agency
EOT
end-of-treatment
ERCQ
Eating-related Concept Questionnaire
EU
European Union
FDA
US Food and Drug Administration
FPG
fasting plasma glucose
FSH
follicle-stimulating hormone
GABA
gamma-aminobutyric acid
GCGR
glucagon receptor
GCP
Good Clinical Practice
GI
gastrointestinal
GLP-1
glucagon-like peptide-1
GLP-1R
GLP-1 receptor
HbA1c
Hemoglobin A1c
HCV
hepatitis C virus
HDL-C
high-density lipoprotein cholesterol
hERG
human ether-a-go-go-related gene
HMC001
human immunoglobulin G4 fragment
HMOXM25
GLP-1/Glucagon dual-receptor agonist
HOMA-B
Homeostasis Model Assessment for B cell function
HOMA-IR
Homeostasis Model Assessment of Insulin Resistance
ICF
informed consent form
ICH
International Conference on Harmonisation
IEC
Independent Ethics Committee
IRB
Institutional Review Board
ITT
intent-to-treat
IUD
intrauterine device
IUS
intrauterine hormone-releasing system
IWQOL-Lite
Impact of Weight on Quality of Life-Lite
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
89
Approved, Date: 23 August 2018
IWRS
interactive web response system
LDL-C
low-density lipoprotein cholesterol
MACE
major adverse cardiac event
MAD
multiple ascending dose
MedDRA
Medical Dictionary for Regulatory Activities
MEN2
multiple endocrine neoplasia type 2
mITT
modified intent-to-treat
MMRM
mixed model for repeated measures
MRI
magnetic resonance imaging
NOAEL
No Observed Adverse Effect Level
OXM
oxyntomodulin
PD
pharmacodynamics
PGIC
Patient Global Impression of Change
PGIS
Patient Global Impression Status
PI
Principal Investigator
PK
pharmacokinetics
PQC
product quality complaint
PRO
patient-reported outcome(s) 
PROMIS SF 10a
PROMIS physical function Short Form 10a
QTcR
Rautaharju corrected QT interval
SAD
single ascending dose
SAE
serious adverse event
SAP
statistical analysis plan
SBP
systolic blood pressure
SC
subcutaneous, subcutaneously
SD
standard deviation
SGLT-2
sodium-glucose cotransporter 2
SUSAR
suspected unexpected serious adverse reaction
T2DM
type 2 diabetes mellitus
TEAE(s)
treatment-emergent adverse event(s)
t½
terminal half-life
Tmax
time to maximum concentration
TZD
thiazolidinedione
ULN
upper limit of normal
US
United States
WHO
World Health Organization
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
90
Approved, Date: 23 August 2018
10.4.
Appendix 4: New York Heart Association Classification of Cardiac Disease
The following table represents the New York Heart Association classification of cardiac disease:
Functional Capacity 
Objective Assessment 
Class I. Patients with cardiac disease but without resulting limitation of physical 
activity. Ordinary physical activity does not cause undue fatigue, palpitation, 
dyspnea, or anginal pain.
A. No objective evidence of 
cardiovascular disease.
Class II. Patients with cardiac disease resulting in slight limitation of physical 
activity. They are comfortable at rest. Ordinary physical activity results in fatigue, 
palpitation, dyspnea, or anginal pain.
B. Objective evidence of 
minimal cardiovascular 
disease.
Class III. Patients with cardiac disease resulting in marked limitation of physical 
activity. They are comfortable at rest. Less than ordinary activity causes fatigue, 
palpitation, dyspnea, or anginal pain.
C. Objective evidence of 
moderately severe 
cardiovascular disease.
Class IV. Patients with cardiac disease resulting in inability to carry on any physical 
activity without discomfort. Symptoms of heart failure or the anginal syndrome may 
be present even at rest. If any physical activity is undertaken, discomfort is 
increased.
D. Objective evidence of 
severe cardiovascular disease.
Source: The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of 
Diseases of the Heart and Great Vessels. 9th ed. Boston, Mass: Little, Brown & Co; 1994:253-256.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
91
Approved, Date: 23 August 2018
10.5.
Appendix 5: Anthropometric Measurements
Height will be measured using a wall-mounted stadiometer or one mounted on a balance beam scale, 
whichever is most appropriate for the individual subject. Subjects should be wearing socks or barefoot 
and should not be wearing shoes.
Body weight will be measured using a calibrated scale. Subjects should be weighed wearing underwear 
and a gown; they will be instructed to take off their shoes and to empty their bladders before being 
weighed. The scale should be calibrated according to the manufacturers specifications and at the 
frequency recommended by the manufacturer before the first subject is weighed. Calibration must be 
documented in the calibration log.
Waist circumference will be measured with the subject standing, wearing underwear, with or without a 
gown. The measurement will be performed at a level midway between the superior aspect of the iliac 
crests and the lower lateral margin of the ribs (refer to diagram below). The measurement need not be at 
the level of the umbilicus. The measuring tape will be kept horizontal.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
92
Approved, Date: 23 August 2018
10.6.
Appendix 6: Method of Blood Pressure and Pulse Rate Measurement
Subject Preparation
The subject should remove all clothing that covers the location of cuff placement. (The sleeve should not 
be rolled up so that it has a tourniquet effect.)
The subject should be comfortably seated with legs uncrossed, and back and arm supported, so that the 
upper arm is at the level of the right atrium (midpoint of the sternum).
The subject should be instructed to relax and not talk; approximately 5 minutes should pass before the 
first reading is taken.
Blood Pressure Measurement Device
Blood pressure readings should be taken manually with a mercury sphygmomanometer or an automated 
blood pressure monitor. If an automated blood pressure monitor is used, the pulse rate reading provided 
by the device can be used as the subject’s pulse rate measurement.
Cuff Size
A cuff should be chosen that is appropriate for the individual, based upon the upper arm circumference in 
centimeters. The bladder of the cuff should encircle at least 80% of the arm circumference.
Arm Circumference (cm)
Size
22-26
Small Adult
27-34
Adult
35-44
Large Adult
45-52
Adult Thigh
For the subject with an arm circumference over 50 cm when a thigh cuff cannot be fitted over the arm, an 
appropriately-sized cuff should be placed on the subject’s forearm, the forearm should be supported at 
heart level, and the radial pulse at the wrist should be used.
Cuff Placement
Palpate the brachial artery in the antecubital fossa.
Place the midline of the bladder of the cuff so that it is over the arterial pulse on the subject’s bare upper 
arm. The lower end of the cuff should be 2 to 3 cm above the antecubital fossa to allow space for the 
stethoscope.
Pull the cuff snugly around the bare upper arm. Neither the observer nor the subject should talk.
Inflation/Deflation
Inflate the cuff to at least 30 mm Hg above the point at which the radial pulse disappears. Deflate the 
mercury column at 2 to 3 mm Hg per second.
The first and last audible sounds should be taken as systolic and diastolic pressure.
Number of Measurements
Three readings should be taken at intervals of at least 1 minute apart, and the results recorded.
At screening visit, blood pressure should be measured in both arms (in triplicate as noted above). Record 
the triplicate readings from the arm with the higher blood pressure in the screening vital sign eCRF page 
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
93
Approved, Date: 23 August 2018
and note which arm in the source documents for future reference. The arm with the higher blood pressure 
should be used for all subsequent blood pressure measurements during the study to reduce any potential 
inter-arm variability.
If possible, if the blood pressure is measured manually, it should be taken by the same individual, using 
the same equipment, at each visit so as to reduce inter-observer variability (Pickering 2005). 
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
94
Approved, Date: 23 August 2018
10.7.
Appendix 7: Standardized Nonpharmacologic Weight Reduction Therapy
At randomization (ie, Day 1), trained counselors will utilize standard educational materials to deliver a 
counseling session. This session will assist the counselors in providing subjects with a variety of diet and 
physical activity tools to help subjects incorporate healthy practices into their daily lives. Subjects will be 
provided with user-friendly and interactive subject support materials. Subject support materials contain 
educational insight into the topic area, specific action steps to improve lifestyle habits, and interactive 
exercises that make it easy for each subject to think through and apply. 
General patient education materials will be supplied to support diet counseling. Study sites are 
encouraged to provide diet and physical activity information (eg, pamphlets or brochures or other such 
material) relevant to the local country or region.
a.
Weight Loss Diet
The energy level of the prescribed diet will be 600 kcal (2,083 kilo Joules [kJ]) less than the individual 
subject’s calculated total energy expenditure, and should have:

<10% of calories per day derived from added sugars

<10% of calories per day derived from saturated fat

<2.3 g of sodium per day
Basal metabolic rate (BMR) is estimated as kilocalories per day by means of the Harris-Benedict 
equation.

For men: 66.473 + (5.003 x height [cm]) + (13.752 x weight [kg]) – (6.755 x age)

For women: 655.096 + (1.850 x height [cm]) + (9.563 x weight [kg]) – (4.676 x age)

Total energy expenditure is estimated as: BMR*1.3 (correction factor for mild to 
moderate activity)
                                                

Harris JA, Benedict FG. A biometric study of basal metabolism in man. Washington, DC: Carnegie Institute of 
Washington; 1919:Publication 279.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
95
Approved, Date: 23 August 2018
10.8.
Appendix 8: Hypoglycemia: Definitions, Symptoms, and Treatment
Hypoglycemia is defined and classified as follows:
Documented symptomatic hypoglycemia is an event during which typical symptoms of hypoglycemia are 
accompanied by a measured plasma glucose (PG) concentration 70 mg/dL (3.9 mmol/L)
Asymptomatic hypoglycemia is defined as an event not accompanied by typical symptoms of 
hypoglycemia but with a measured PG concentration 70 mg/dL (3.9 mmol/L)
Probable symptomatic hypoglycemia is defined as an event during which symptoms of hypoglycemia are 
not accompanied by a PG determination.
Severe hypoglycemia is defined as an event requiring the assistance of another person to actively 
administer a carbohydrate, glucagon, or other resuscitative actions. A subject is considered to "require 
assistance" if he/she is unable to help himself/herself. An act of kindness to assist a subject when it is not 
necessary does not qualify as "requiring assistance". These episodes may be associated with sufficient 
neuroglycopenia to induce seizure or coma. Plasma glucose measurements may not be available during 
such an event, but neurologic recovery attributable to the restoration of PG to normal is considered 
sufficient evidence that the event was induced by a low PG concentration.
The classification of hypoglycemic episodes will determine how the event is captured in the eCRF. 
Symptoms
Subjects will receive counseling regarding the symptoms of and treatment for hypoglycemia. Signs and 
symptoms of hypoglycemia and other specific details will be captured in the blood sugar diary, which will 
be returned to the study site for review by study-site personnel at each visit. The following list of 
symptoms is not meant to be exhaustive but represents the more common symptoms associated with 
hypoglycemia:

Seizure

Loss of consciousness

Headache

Tremor

Hunger

Sweating

Nervousness

Palpitations

Light headedness

Blurred vision

Disorientation

Dizziness

Feeling faint
Treatment
The treatment of hypoglycemia requires the ingestion of glucose- or carbohydrate-containing foods. The 
acute glycemic response correlates better with the glucose content than with the carbohydrate content of 
the food. Therefore, glucose (15 to 20 g) is the preferred treatment for hypoglycemia. Although pure 
glucose may be the preferred treatment, any form of carbohydrate that contains glucose will raise blood 
glucose and may be used. Adding protein to a carbohydrate does not affect the glycemic response and 
does not prevent subsequent hypoglycemia. However, adding fat may retard and then prolong the acute 
hypoglycemic response. Treatment effects should be apparent within 15 minutes although the effects may 
only be temporary. Therefore, PG should be retested in approximately 15 minutes, as additional treatment 
may be necessary.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
96
Approved, Date: 23 August 2018
10.9.
Appendix 9: Clinical Laboratory Tests
The following tests will be performed according to the Schedule of Activities by the central laboratory:
Blood samples for serum chemistry and hematology, and urine samples for urinalysis will be collected 
at timepoints specified in the Schedule of Activities. The investigator must review the laboratory report,
document this review, and record any clinically relevant changes occurring during the study in the
Adverse Event section of the eCRF and take appropriate action (eg, repeating abnormal laboratory result
or further evaluation as considered clinically appropriate). The following tests will be performed by the 
central laboratory.

Hematology Panel
-hemoglobin
-platelet count
-hematocrit
-red blood cell (RBC) count
-white blood cell count with differential

Serum Chemistry Panel
-sodium
-alkaline phosphatase
-potassium
-creatine phosphokinase
-magnesium
-lactic acid dehydrogenase
-chloride
-pancreatic amylase
-bicarbonate
-lipase
-uric acid
-calcium
- blood urea nitrogen
-phosphate
-creatinine
-albumin
-aspartate aminotransferase
-total protein
-alanine aminotransferase
-gamma-glutamyltransferase
-total bilirubin

Serum ß-hydroxybutyrate

Serum calcitonin

Fasting insulin*

Fasting C-peptide*

Follicle-stimulating hormone only for women >45 years of age with amenorrhea for at least 
6 months and <18 months prior to screening

Fasting serum lipid profile (triglycerides, LDL-C, HDL-C, total cholesterol)*

HbA1c

Fasting plasma glucose*

Urinalysis
Dipstick done at central laboratory
-specific gravity
-pH
-protein
-blood
-ketones
-bilirubin
-urobilinogen
-nitrite
-leukocyte esterase
If dipstick result is abnormal, microscopic examination will be performed.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
97
Approved, Date: 23 August 2018

Serum (β-human chorionic gonadotropin [β-hCG] pregnancy testing will be conducted for all women 
of childbearing potential (ie, unless they are permanently sterilized or unless there is a documented 
history of their postmenopausal status) at the screening and Week 12/EOT visits along with a urine 
pregnancy test at Day 1. Additional serum or urine pregnancy tests may be performed throughout the 
study in sufficient number, as determined necessary by the investigator, or required by local 
regulation, to establish the absence of pregnancy during the study. 
* Subjects must be fasting for at least 8 hours before blood sample collections.
Estimated Glomerular Filtration Rate (eGFR)

The estimated glomerular filtration rate (eGFR) will be reported according to the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation** at study visits when serum 
creatinine is measured. The CKD-EPI equation based on serum creatinine, age, sex, and race for 
adults age 18 years expressed as a single equation is:
CKD-EPI Formula (for Scr expressed in mg/dL)
eGFR = 141 × min (Scr /, 1)× max(Scr /, 1)-1.209 × 0.993Age × 1.018 [if female] ×
1.159 [if black]
= 0.7 for females
= 0.9 for males
= -0.329 for females
= -0.411 for males
min = the minimum of Scr/or 1 max = the maximum of Scr/or 1
CKD-EPI Formula (for Scr expressed in mol/L)
eGFR = 141 × min (Scr /, 1)× max(Scr /, 1)-1.209 × 0.993Age × 1.018 [if female] ×
1.159 [if black]
= 61.9 for females
= 79.6 for males
= -0.329 for females
= -0.411 for males
min = the minimum of Scr/or 1 max = the maximum of Scr/or 1
**Levey AS, Stevens LA, Schmid CH, et.al. CKD-EPI (Chronic Kidney Disease Epidemiology 
Collaboration). Ann Intern Med. 2009;150(9):604-12.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
98
Approved, Date: 23 August 2018
10.10. Appendix 10: Algorithm for Monitoring Abnormal Liver Function Tests
If the investigator feels that the subject cannot safely continue administration of study drug regardless of the 
algorithm, the subject should discontinue study drug and continue to the EOT visit.
Key: ALT=alanine aminotransferase; EOT=End-of-Treatment; LFT=liver function test; Tbili=total bilirubin;
ULN=upper limit of normal
*  LFT (ie, alanine aminotransferase, aspartate aminotransferase, total bilirubin, alkaline phosphatase, GGT) within 
2 to 3 days of investigator receipt of report, with earlier testing (ie, within 1 day of receipt of laboratory report) 
for more substantial elevations in ALT (≥5 x ULN) or total bilirubin (≥2 x ULN) levels
** Focused medical history (including review of prior history of liver or biliary disorders, concurrent symptoms, 
review of all concomitant medications [eg, acetaminophen-containing medications, over-the-counter or herbal 
medications, nutritional supplements] including any changes in medications, detailed review of alcohol use; 
liver ultrasound and follow-up imaging as appropriate; hepatitis serology (anti-hepatitis A virus, HBsAg, anti-
HBs, anti-HB core, anti-hepatitis C virus (HCV), HCV RNA, EBV, and CMV screen) and autoantibodies 
(eg, ANA, anti-smooth muscle antibody) should be obtained as appropriate, with additional evaluation as 
clinically indicated. The extent of the evaluations should be made in consultation with the sponsor.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
99
Approved, Date: 23 August 2018
10.11. Appendix 11: Pancreatitis Monitoring and Withdrawal Criteria
All subjects will be carefully monitored for pancreatitis during the study. Investigators will urge subjects 
to make an appointment for an unscheduled visit if the subject experiences persistent nausea and/or 
vomiting for 3 days, with or without abdominal pain.
Blood samples for analysis of serum amylase and lipase by a central laboratory should be obtained at the 
visit, and other additional investigations should be performed in order to establish diagnosis, per 
investigator’s discretion.
Study drug should be interrupted immediately if any of the following circumstances occur at any time 
during treatment:

If pancreatitis is suspected, or

Serum amylase 2 x ULN, or

Serum lipase 2 x ULN.
The pancreatic enzyme tests should be repeated within 7 days after the first sample (with both samples 
analyzed by the central laboratory), and appropriate imaging tests should be performed to establish 
diagnosis. The results of these tests should be recorded in the source documents.
All subjects with elevated pancreatic enzymes should be followed-up with multiple serum amylase and 
lipase tests until resolution.
Study drug should be discontinued if acute pancreatitis is confirmed, based on at least 2 of the following 
3 signs or symptoms: 

characteristic abdominal pain, 

amylase and/or lipase >3 x ULN, or

characteristic findings on CT/MRI.
In any of the circumstances described above occur during the study, the investigator must complete the 
AE/SAE eCRF page and a Pancreatitis Adverse Event of Special Interest Form. If the event meets the 
SAE criteria, the information will be transmitted to the sponsor using the Serious Adverse Event Form
within 24 hours of the repeat laboratory test.
If a subject discontinues study drug according to the Pancreatitis Monitoring and Withdrawal Criteria 
then, the event should be recorded as an AE and the reason for withdrawal should be documented as an 
AE. The subject should be followed to a satisfactory conclusion (ie, until the adverse event resolves, the 
laboratory value returns to baseline, or the condition becomes stable).
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
100
Approved, Date: 23 August 2018
10.12. Appendix 12: Guidelines for Calcitonin Monitoring
Calcitonin 10 ng/L and <20 ng/L 
Confounders that can affect calcitonin measurements should be taken into consideration before aggressive 
diagnostic procedures are undertaken for subjects with calcitonin levels 10 to <20 ng/L at the screening 
visit. Specific history should be elicited to identify these confounders. Confounders (ie, drugs [H2 
blockers, proton pump inhibitors] other causes of hypergastrinemia [eg, pernicious anemia], smoking, 
autoimmune thyroiditis, presence of heterophilic antibodies) should be factored into the interpretation of 
the values on a case-by-case basis. If drugs can be discontinued safely, the screening calcitonin can be 
repeated after a wash-out period (eg, calcitonin levels return to the normal range by 10 days after 
stopping proton pump inhibitors).
Calcitonin 20 ng/L
All calcitonin values 20 ng/L will be flagged on the laboratory reports from the central laboratory and 
will be submitted to the sponsor and study site. Subjects will have to undergo a repeat measurement. The 
timing of the repeat measurement will depend on when the calcitonin value 20 ng/L was first observed. 
In particular:

calcitonin 20 ng/L on Day 1/Randomization visit: a repeat measurement of calcitonin should be 
performed preferably within 7 days.

calcitonin 20 ng/L at any time after Day 1/Randomization: a repeat measurement of calcitonin 
should be performed preferably within 2 weeks. 
If the repeat calcitonin is confirmed to be ≥20 ng/L, the event “elevated calcitonin” should be considered 
to be reported as an AE per investigator’s assessment if no previously documented elevation of calcitonin 
prior to study entry. 
Depending on the degree of the confirmed calcitonin elevation, additional clinical management or 
diagnostic procedures should be performed. In particular:
Calcitonin 20 ng/L and <50 ng/L
Subjects with calcitonin levels in this range at baseline Day 1 or subsequent visits should have the 
measurement repeated for confirmation per the suggested window period outlined above. This cohort will 
provide valuable insights into any potential effect that JNJ-64565111 may have on calcitonin levels in 
subjects with values above the normal range at baseline. If the repeat value or if any subsequent value 
measured during the trial is 50 ng/L then the subject moves into the evaluation category listed above for 
values 50 ng/L.
Calcitonin 50 ng/L and <100 ng/L
If subjects develop a calcitonin value within this specified range post-randomization, specific medical 
evaluation will be indicated including a thyroid ultrasound and a pentagastrin stimulation test if available 
and if not contraindicated (Note: pentagastrin is contraindicated in subjects with known coronary artery 
disease). Those subjects with positive pentagastrin stimulation tests will be considered to undergo 
surgery. In the US, where pentagastrin is not available, thyroid ultrasound and fine needle aspiration 
biopsy may add important clinical information informing the need for surgery.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
101
Approved, Date: 23 August 2018
Calcitonin 100 ng/L
For any value of 100 ng/L, the subject should be assumed to have significant C-cell disease and a high 
likelihood of having medullary carcinoma of the thyroid. Diagnostic evaluation should consist of thyroid 
ultrasound, fine needle aspiration of any nodules >1 cm and potentially surgery with neck dissection. 
Family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should be evoked 
and a rearranged during transfection (RET) proto-oncogene analysis should be undertaken.
NOTE: pg/mL is the conventional unit and ng/L is the SI unit. 
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
102
Approved, Date: 23 August 2018
10.13. Appendix 13: Instructions for the Completion of PRO Assessments
The following instructions are intended to assist investigators, study coordinators, and those with 
monitoring responsibilities with the accurate completion of all the PRO questionnaires. For some 
sites, PRO questionnaires will be completed during scheduled site visits while other PRO 
questionnaires will be completed at home by the subject. It is therefore important for sites to be 
familiar with the Time & Events schedule to ensure subjects complete the PROs at the correct 
setting and visit. Please refer to the PRO Completion Guide for further information.
Site Responsibilities (General)
For this study, we expect that it will take approximately 15 minutes for the subjects to be trained 
and complete the PROs that are intended to be completed during site visits. For those PROs that 
are intended to be completed at home, it will take subjects less than 5 minutes a day to complete. 
General:

Never copy PROs from other sources (eg, websites); use only the PRO provided. 
Site visit-based assessments, sites must:

Ensure subject completes the PROs before any clinical assessments are done or results are 
provided.

Please have the subject complete the PROs in the same order each time. 
Home-based assessments, sites must:

Ensure subject understands what is expected of them when they return home. 

Distribute the PRO home diary and have the subject review to see if they have questions.

Have the subject complete the PROs in the order that they appear in the diary.

Remind the subject to return the PRO home diary at their next scheduled visit. 
Preparing the Subject
General:

Instruct subjects to complete all PRO questionnaires using a blue or black ballpoint pen.  

Explain that all the information on the PROs is confidential, and that someone from the 
study staff will only check for completeness and not share the results with other clinical 
staff.

Explain to subjects the reasons why they are being asked to complete the PROs, ie, they are 
part of the overall medical assessment and are designed to find out more information about 
how having their disease has affected their life. 

Allow as much time as the subject needs to orient themselves and complete all PROs.

Instruct the subjects to: 

Read the instructions for each questionnaire carefully.

Note the recall period for each questionnaire.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
103
Approved, Date: 23 August 2018

Complete all PROs; Instruct the subject not to skip any questions/or questionnaires.

Subjects must interpret questions and complete the PROs without input from anyone. If 
asked for help interpreting or completing the PROs by the subject, please simply reply that 
there are no right or wrong answers and he/she should use his/her best judgment to complete 
each question (based on what the subject thinks the question is asking). 

Do not attempt to interpret or explain the instructions, questions, or response options.

If the subject has difficulty choosing between 2 response options, simply state “choose the 
answer that most closely matches your experience.”
Site visit-based assessments:

Provide a quiet, private or semi-private location for the subject to complete the PROs. 

Ensure subjects have access to study staff for questions.
Home-based assessments:

Instruct the subject to complete each daily assessment at the same time each day, in the same 
setting each day, for the following 7 consecutive days.

These questionnaires are administered at home because of the concepts being measured and 
the period of recall.   
Quality Control

Complete the subject number, visit date and time on every PRO questionnaire.
Site visit-based assessments:

Before the subject leaves:

Check for any questions that might have been skipped/left blank.

If an item has been skipped, point this out to the subject and ask them to complete.

If an item has more than one response, ask the subject to reconsider the question and try 
to choose the answer that most closely matches their experience.
Home-based assessments:

Before the subject leaves the appropriately scheduled site visit, distribute the PRO home 
diary, provide instructions for completion, and remind subject to return the booklet at the 
next scheduled site visit.

Questionnaires in the diary should be completed by the subject daily for the next 
7 consecutive days. 

Upon the subject’s return for their next scheduled site visit, collect the PRO home diary 
from the subject and check for completeness.
Special Issues

Subjects should be instructed to complete the PROs without input from anyone. However, if 
a subject cannot read the PROs or complete it/them independently (eg, due to visual 
impairment, limited literacy, or difficulty with pens), then a designated person can read the 
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
104
Approved, Date: 23 August 2018
items and response choices aloud and mark the appropriate response choices as verbally 
stated by the subject. 

The designated person should read each question in its entirety in a neutral voice, avoiding 
any cues, even if interrupted by the subject with an answer. The designated person should 
repeat each of the subject’s answers, eg, “A little bit.” The subject should not be prompted 
by the designated person in any other way. No help should be offered to the subject in 
interpreting the questionnaire.

If a person is designated to assist the subject with the PROs, this person should remain 
consistent across assessment questionnaires and across assessment periods.

If a designated person assists the subject with the PROs, this should be noted in the Footer 
section on the first page of each PRO assessment instrument.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
105
Approved, Date: 23 August 2018
10.14. Appendix 14: Protocol Amendment History
This is an original protocol.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
106
Approved, Date: 23 August 2018
11.
REFERENCES
1.
Adipex-P® [package insert] Horsham, PA. Teva Select Brands, 2014.
2.
American Red Cross. Blood Facts and Statistics. http://www.redcrossblood.org/learn-about-blood/blood-facts-
and-statistics Last accessed on 6 June 2016.
3.
Belviq® [package insert] Zofingen, Switzerland. Arena Pharmaceuticals GmbH, 2012.
4.
Bornkamp B, Pinheiro JC, and Bretz, F. MCPMod: An R package for the design and analysis of dose-finding 
studies. Journal of Statistical Software. 2009;29(7):1-23.
5.
Chandarana K, Batterham RL. Shedding pounds after going under the knife: metabolic insights from cutting 
the gut. Nat Med. 2012;18(5):668-669.
6.
Clinical Study Protocol 64565111EDI1002. A Double-Blind, Randomized, Placebo-Controlled, Multiple Dose 
Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in 
Men and Women with Type 2 Diabetes Mellitus. Janssen Research & Development (12 May 2017).
7.
Cohen MA, Ellis SM, Le Roux CW, et. al. Oxyntomodulin suppresses appetite and reduces food intake in 
humans. J Clin Endocrinol Metab. 2003;88(10):4696-4701.
8.
Contrave® [package insert]; Deerfield, IL; Takeda Pharmaceuticals America, Inc. 2014
9.
Coon CD, Cappeller, JC. Interpreting change in scores on patient-reported outcome instruments. Therapeutic 
innovation & regulatory Science. 2016;50(1):22-29. 
10.
Day, JW, Ottaway N, Patterson JT, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. 
Nat Chem Biol. 2009;5:749-757.
11.
Ettaro L, Songer TJ, Zhang P, Engelgau MM. Cost-of-illness studies in diabetes mellitus. Pharmacoeconomics 
2004;22:149-164.
12.
Field, BC, Wren AM, Peters V, et al. PYY3-36 and oxyntomodulin can be additive in their effect on food 
intake in overweight and obese humans. Diabetes. 2010;59:1635-1639.
13.
FDA. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to 
Support Labeling Claims. December 2009. Available at: 
https://www.fda.gov/downloads/drugs/guidances/ucm193282.pdf. Accessed 18 December 2017.
14.
Guidance for Industry Developing Products for Weight Management. U.S. Department of Health and Human 
Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). February 2007.
15.
Guideline on clinical investigation of medicinal products used in weight management. 
EMA/CHMP/311805/2014. 23 June 2016.
16.
Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of Obesity Among Adults and Youth: United States, 
2015-2016. https://www.cdc.gov/nchs/data/databriefs/db288.pdf. Accessed 06 Dec 2017.
17.
Hauber AB, Mohamed AF, Johnson FR, Oyelowo O, Curtis BH, Coon C. Estimating importance weights for 
the IWQOL-Lite using conjoint analysis. Qual Life Res. 2010;19(5):701-709.
18.
HealthMeasures website. Available at: http://www.healthmeasures.net/explore-measurement-systems/promis. 
Accessed: 26 January 2018.
19.
Investigator’s Brochure. JNJ-64565111, Edition 4. Janssen Research and Development (December 2017).
20.
Jonsson B. Code-2 Advisory Board. Revealing the cost of Type II diabetes in Europe. Diabetologia 
2002;45:S5-S12.
21.
Kolotkin RL, Crosby RD, Kosloski KD, Williams GR. Development of a brief measure to assess quality of life 
in obesity Obes Res. 2001;9(2):102-111.
22.
Kolotkin RL, Crosby RD. Psychometric evaluation of the impact of weight on quality of life-lite questionnaire 
(IWQOL-Lite) in a community sample. Quality of Life Research. 2002;11:157-171.
23.
Kyrgiou M, Kalliala I, Markozannes G, et al. Adiposity and cancer at major anatomical sites: umbrella review 
of the literature. BMJ. 2017;356:477.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
107
Approved, Date: 23 August 2018
24.
Laffel L. Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. 
Diabetes Metab Res Rev. 1999;6:412-426.
25.
le Roux CW Welbourn R, Werling M, et al. Gut hormones as mediators of appetite and weight loss after Roux-
en-Y gastric bypass. Ann Surg. 2007;246(5):780-785.
26.
Levey AS, Stevens LA, Schmid CH, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). 
Ann Intern Med. 2009;150(9):604-612.
27.
National Institutes of Health (NIH). The practical guide: identification, evaluation, and treatment of overweight 
and obesity in adults. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute, 
and North American Association for the Study of Obesity, 2000. NIH Publication Number 00-4084.
28.
Nichols GA, Horberg M, Koebnick C, et al. Cardiometabolic risk factors among 1.3 million adults with 
overweight or obesity, but not diabetes, in 10 geographically diverse regions of the United States, 2012-2013. 
Prev Chronic Dis. 2017;14:E22.
29.
Padwal R, Li SK, Lau, DC. Long-term pharmacotherapy for overweight and obesity: a systematic review and 
meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord. 2003;27:1437-1446.
30.
Pickering TG, Hall JE, Appel LJ. Recommendations for blood pressure measurement in humans and 
experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the 
Subcommittee of Professional and Public Education of the American Heart Association. Circulation. 
2005;111:697-716.
31.
Pinheiro J, Bornkamp B, Glimm E, Bretz, F. Model-based dose finding under model uncertainty using general 
parametric models. Stat Med. 2014;33(10):1646-1661.
32.
Qsymia® [package insert] Mountain View, CA; VIVUS, Inc. 2014.
33.
Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in 
the prediction of first atherothrombotic events. Circulation. 2004;109:Suppl 1:IV6-IV19.
34.
Saxenda® [package insert], Bagsvaerd, Denmark. Novo Nordisk A/S, 2017.
35.
WHO 2017. World Health Organization. World Health Factsheet, Fact sheet N°311 Updated October 2017: 
http://www.who.int/mediacentre/factsheets/fs311/en/. Accessed November 2017.
36.
Wolfe BM, Kvach E, Eckel RH. Treatment of Obesity: Weight Loss and Bariatric Surgery. Circ Res 
2017;118(11):1844-1855. 
37.
Wynne K, Park AJ, Small CJ, et al., Subcutaneous oxyntomodulin reduces body weight in overweight and 
obese subjects: a double-blind, randomized, controlled trial. Diabetes. 2005;54(8):2390-2395.
38.
Xenical [package insert] South San Francisco, CA. Genentech USA, Inc., 2015.
NCT03586830


JNJ-64565111
Clinical Protocol 64565111OBE2002 – Amendment 1
108
Approved, Date: 23 August 2018
INVESTIGATOR AGREEMENT
NCT03586830

SAP_001.pdf: 
1
Approved, Date: 19 April 2019
Janssen Research & Development 
Statistical Analysis Plan
A Randomized, Double-blind Placebo-controlled, Parallel-group, Multicenter, Dose-
ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese 
Subjects with Type 2 Diabetes Mellitus
Protocol 64565111OBE2002; Phase 2b
AMENDMENT 1
JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Status:
Approved
Date:
19 April 2019
Prepared by:
Janssen Research & Development, LLC
Document No.: EDMS-ERI-166155513, 2.0
Compliance: The study described in this report was performed according to the principles of Good Clinical Practice (GCP). 
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidential and 
may not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the 
information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed 
by them. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as 
privileged or confidential.
NCT03586830


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Statistical Analysis Plan 64565111OBE2002 – Amendment 1
2
Approved, Date: 19 April 2019
TABLE OF CONTENTS
TABLE OF CONTENTS ............................................................................................................................... 2
AMENDMENT HISTORY.............................................................................................................................. 4
ABBREVIATIONS ........................................................................................................................................ 6
1.
INTRODUCTION.................................................................................................................................. 7
1.1.
Trial Objectives ................................................................................................................................ 7
1.2.
Trial Design ...................................................................................................................................... 8
1.3.
Statistical Hypotheses for Trial Objectives....................................................................................... 9
1.4.
Sample Size Justification ............................................................................................................... 10
1.5.
Randomization and Blinding .......................................................................................................... 10
2.
GENERAL ANALYSIS DEFINITIONS .............................................................................................. 11
2.1.
Visit Windows................................................................................................................................. 11
2.2.
Analysis Sets.................................................................................................................................. 12
2.2.1.
All Randomized Analysis Set...................................................................................................... 12
2.2.2.
Efficacy Analysis Sets................................................................................................................. 12
2.2.3.
Safety Analysis Set..................................................................................................................... 12
2.2.4.
Pharmacokinetics Analysis Set .................................................................................................. 12
2.2.5.
Immunogenicity Analysis Set...................................................................................................... 12
2.3.
Definition of Subgroups.................................................................................................................. 13
2.4.
Study Day and Relative Day .......................................................................................................... 13
2.5.
Baseline ......................................................................................................................................... 13
3.
INTERIM ANALYSIS AND DATA MONITORING COMMITTEE REVIEW....................................... 13
4.
SUBJECT INFORMATION................................................................................................................ 14
4.1.
Demographics and Baseline Characteristics ................................................................................. 14
4.2.
Disposition Information................................................................................................................... 15
4.3.
Treatment Compliance................................................................................................................... 16
4.4.
Extent of Exposure......................................................................................................................... 16
4.5.
Protocol Deviations ........................................................................................................................ 16
4.6.
Prior and Concomitant Medications ............................................................................................... 16
5.
EFFICACY ......................................................................................................................................... 17
5.1.
Analysis Specifications................................................................................................................... 17
5.1.1.
Level of Significance................................................................................................................... 17
5.1.2.
Data Handling Rules................................................................................................................... 17
5.2.
Primary Efficacy Endpoint.............................................................................................................. 17
5.2.1.
Definition..................................................................................................................................... 17
5.2.2.
Estimand..................................................................................................................................... 18
5.2.3.
Analysis Methods........................................................................................................................ 18
5.3.
Major Secondary Endpoints........................................................................................................... 19
5.3.1.
Definition..................................................................................................................................... 19
5.3.2.
Analysis Methods........................................................................................................................ 19
5.4.
Exploratory Efficacy Variable(s)..................................................................................................... 19
5.4.1.
Definition..................................................................................................................................... 19
5.4.2.
Analysis Methods........................................................................................................................ 20
6.
SAFETY............................................................................................................................................. 21
6.1.
Adverse Events .............................................................................................................................. 21
6.2.
Clinical Laboratory Tests................................................................................................................ 23
6.3.
Vital Signs and Physical Examination Findings ............................................................................. 24
6.4.
Electrocardiogram.......................................................................................................................... 24
NCT03586830


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Statistical Analysis Plan 64565111OBE2002 – Amendment 1
3
Approved, Date: 19 April 2019
7.
PHARMACOKINETICS/IMMUNOGENICITY/PHARMACODYNAMICS .......................................... 24
7.1.
Pharmacokinetics........................................................................................................................... 24
7.2.
Immunogenicity.............................................................................................................................. 26
7.3.
Pharmacokinetic/Pharmacodynamic Relationships....................................................................... 27
REFERENCES............................................................................................................................................ 28
ATTACHMENTS......................................................................................................................................... 29
ATTACHMENT 1 CLINICAL LABORATORY TESTS ............................................................................... 29
ATTACHMENT 2 PRE-DEFINED LIMIT OF CHANGE (PDLC) CRITERIA FOR LABORATORY 
TESTS................................................................................................................................................ 31
ATTACHMENT 3 ADVERSE EVENTS OF SPECIAL INTEREST............................................................. 33
NCT03586830


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Statistical Analysis Plan 64565111OBE2002 – Amendment 1
4
Approved, Date: 19 April 2019
AMENDMENT HISTORY
SECTION(S)
CHANGE and RATIONALE
Global Change
“Pulse Pressure Product” and “Rate Pressure Product” were used interchangeably; the term 
“Rate Pressure Product” will be used going forward.
Abbreviations
Added abbreviation of ANCOVA, AHA and ATC. Remove abbreviations that are not in the 
body of the text. Minor corrections were made for AE(s), PRO, and PROMIS SF 10a.
1
Change the Clinical Protocol JNJ-64565111OBE2002 date to 5 April 2018.
2.1
Visit windows now include post-Week 12 to account for subjects brought back for visits to 
reduce Lost To Follow Ups.
2.2
Remove Section 2.2 Pooling Algorithm for Analysis Centers
2.2.2
Refined mITT Analysis Set definition to include subjects taking at least one dose of study 
medication.
2.2.2
Clarify that the Completers’ Analysis Set is defined by the Treatment Disposition eCRF status.
2.3
Remove Region because this study is conducted in the US only. Remove Ethnicity, Baseline 
fasting HOMA-B, and Baseline eGFR to reduce the number of subgroup analyses. A minor 
correction for the baseline HbA1c categories was made.
2.3, 4.1
Correct variable name for HOMA-B and HOMA-IR.
4.1
Demographics tables will be generated for 5 analysis sets: ITT, mITT, Safety, PK, and 
Completers. Added variables rate pressure product (bpm*mmHg), Beta-hydroxybutyrate 
(mmol/L). Removed ratios of LDL-C/LDL-C. Added unit (%) for HbA1c. A minor correction 
for baseline HbA1c categories was made.
4.2
Screen failures will not be summarized. Protocol deviations will be listed that may include 
deviations related to medication dispensed. Removed the bullet of “reasons for discontinuation 
from study” as it is redundant with the paragraph below.
4.3
Treatment compliance formula was refined to only account for period of time between first and 
last dose; non-compliance is not counted after the last dose.
4.2, 4.3
Changed “study agent” to “treatment” to keep the consistency through the SAP.
4.4
For the purpose of summarizing exposure, treatment duration does not take drug interruptions 
into account. Steps for imputing missing treatment end dates were refined. Removed “study 
agent” from the second paragraph of the section. Replaced “treatment duration prior to rescue 
medication” and “treatment duration” for “treatment duration” and “overall duration”, 
respectively.
4.5
Protocol deviations, as identified by the Study Team, will be listed but not summarized.
5.0, 5.2.3, 5.4.2
“Data collected after the last dose plus 7 days” changed to “Data collected after the last dose 
plus 14 days will be excluded from the mITT analysis.” This change is based on what is known 
about PK.
5.1.1
Clarify adjusted p-values will be presented comparing each JNJ-64565111 dose to placebo in 
the summary tables.
5.2.3, 5.4.2
For endpoints with only one post-baseline visit, an ANCOVA model will be used with treatment 
as a fixed factor and baseline as a covariate.
5.2.3
Change “Sensitivity Analysis” to “Supportive Analysis”.
5.2.3
Change the minimum number of subjects from 80 to 40 as the threshold to perform subgroup 
analyses. Clarified 2- and 3-way interaction terms with treatment will be included in the model.
5.2.3, 5.3.2
Allow for copy control method to be used if there are not enough retrieved drop-outs to impute 
missing data as originally intended.
1.3, 5.3.1, 5.4.1
Reworded the efficacy endpoints to reduced awkwardness of phrasing (e.g., “absolute change 
from baseline in body weight” from “absolute change in body weight from baseline”).
5.3.2, 5.4.2
The analysis of categorical endpoints will be performed using logistic regression given the 
challenges of running a longitudinal categorical analysis in which few subjects at the early time 
points are considered responders. 
5.4.2
Added lists of endpoints for MMRM and ANCOVA analyses. Added shift table for obesity 
class.
5
All efficacy analyses for non-glycemic endpoints will be performed regardless of rescue 
medication. Analyses of glycemic endpoints (i.e., HbA1c, FPG, fasting insulin, HOMA-B, 
HOMA-IR) will accordingly be based on a prior to rescue medication analysis.
NCT03586830


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Statistical Analysis Plan 64565111OBE2002 – Amendment 1
5
Approved, Date: 19 April 2019
SECTION(S)
CHANGE and RATIONALE
6
Reference to Section 2.3.4 should be 2.2.3.
6.1
Mild and Moderate AEs will not be pooled for the purpose of summarizing AEs by severity.
6.2, 6.3
References to Attachments 4 and 5 should be Attachments 1 and 2, respectively.
6.2
Shift tables for laboratory values will not be generated.
6.2
“Markedly abnormal” laboratory values are not defined.
7.1
The details under which measurements should be excluded from the PK analysis are provided.
References
Added references 4 and 5 for IWQOL-Lite.
ATCH 2
Added PDLCs for calcitonin, amylase and lipase.
ATCH 2
Beta-Hydroxybutyrate above 20.822 mg/dL will be flagged as PDLC.
ATCH 3
Refer to Excel files; reference in ERIS.
NCT03586830


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Statistical Analysis Plan 64565111OBE2002 – Amendment 1
6
Approved, Date: 19 April 2019
ABBREVIATIONS
-hCG
Serum -human chorionic gonadotropin
ADA
anti-drug antibody
AE(s)
Adverse event(s)
AHA
Antihyperglycemic agent
ANCOVA
Analysis of Covariance
ATC
Anatomical Therapeutic Chemical
BMI
Body mass index
bpm
Beats per minute
CI
Confidence interval
CKD-Epi
Chronic Kidney Disease Epidemiology Collaboration
DBP
Diastolic blood pressure
DMC
Data Monitoring Committee
eCRF(s)
Electronic case report form(s) 
eGFR
Estimated glomerular filtration rate
EOT
End-of-treatment
ERCQ 
Eating-related Concept Questionnaire
FPG
Fasting plasma glucose
GCP
Good Clinical Practice
GLP-1
Glucagon-like peptide-1
HbA1c
Hemoglobin A1c
HDL-C
High-density lipoprotein cholesterol
HOMA-B
HOMA-IR
Homeostasis Model Assessment for B cell function
Homeostasis Model Assessment of insulin resistance
IA
Interim analysis
ITT
Intent-to-treat
IWQOL-Lite
Impact of Weight on Quality of Life-Lite
IWRS
Interactive web response system
LDL-C
Low-density lipoprotein cholesterol
MACE
Major adverse cardiovascular events
MedDRA
Medical Dictionary for Regulatory Activities
mITT
Modified intent-to-treat
mmHg
Millimeters mercury
MMRM
Mixed model for repeated measures
PK
Pharmacokinetics
PRO
Patient-reported outcome (paper or electronic as appropriate for this study)
PROMIS SF 10a
PROMIS physical function Short Form 10a
SAE(s)
Serious adverse event(s)
SAP
Statistical analysis plan
SBP
Systolic blood pressure
SC
Subcutaneous, subcutaneously
SD
Standard deviation
SI
International System of Units
T2DM
Type 2 diabetes mellitus
TEAE(s)
Treatment-emergent adverse event(s)
ULN
Upper limit of normal
WHO
World Health Organization
NCT03586830


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Statistical Analysis Plan 64565111OBE2002 – Amendment 1
7
Approved, Date: 19 April 2019
1.
INTRODUCTION
This statistical analysis plan (SAP) contains the definitions of analysis sets, key derived 
variables, and statistical methods for the analyses of efficacy and safety data from study 
JNJ-64565111OBE2002. This SAP is based on the Clinical Protocol JNJ-64565111OBE2002
dated 5 April 2018. Titles, mock-ups and programming instructions for all statistical outputs 
(tables, figures and listings) will be provided in a separate document entitled Data Presentation 
Specifications (DPS). A separate Data Monitoring Committee (DMC) SAP will describe the data 
analysis for DMC reviews.  
1.1.
Trial Objectives
Primary Objectives
The primary objectives are to assess the effects of JNJ-64565111 compared with placebo in 
severely obese subjects with Type 2 Diabetes Mellitus (T2DM) after 12 weeks of treatment on:

the percentage change from baseline in body weight 

safety and tolerability
Secondary Objectives
The secondary objectives are to assess the effects of JNJ-64565111 compared with placebo in 
severely obese T2DM subjects after 12 weeks of treatment on:

the absolute change from baseline in body weight 

the proportion of subjects with 5% weight loss from baseline
Exploratory Objectives
The exploratory objectives are to assess the effects of JNJ-64565111 compared with placebo in 
severely obese T2DM subjects after 12 weeks of treatment on:

the proportion of subjects with 10% weight loss from baseline

the change from baseline in body mass index (BMI)

the change from baseline in waist circumference

the change from baseline in glycated hemoglobin (HbA1c)

the change from baseline in fasting plasma glucose (FPG)

the change from baseline in fasting insulin

the change from baseline in fasting C-peptide 

the changes from baseline in Homeostasis Model Assessment for B cell function 
(HOMA-B) and HOMA-insulin resistance (IR) 

the change from baseline in systolic blood pressure (SBP)

the change from baseline in diastolic blood pressure (DBP)
NCT03586830


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Statistical Analysis Plan 64565111OBE2002 – Amendment 1
8
Approved, Date: 19 April 2019

the change from baseline in pulse rate 

the change from baseline in rate pressure product 

the change from baseline in fasting lipids (total cholesterol, low-density lipoprotein 
cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C], and triglycerides) 

pharmacokinetic (PK) exposure

the change from baseline in scores on the Impact of Weight on Quality of Life – Lite 
(IWQOL-Lite) 

the change from baseline in scores on the Patient-Reported Outcomes (PRO) Measurement 
Information System (PROMIS®) Physical Function Short Form 10a (PROMIS SF 10a)

the change from baseline in scores on the Eating-related Concept Questionnaire (ERCQ)
1.2.
Trial Design
This is a randomized, double-blind, placebo-controlled, parallel-group, 4-arm, multicenter study 
in severely obese subjects with T2DM. Subjects who are 18 and 70 years of age and have a 
BMI ≥35 kg/m2 to ≤50 kg/m2 are eligible to participate if they have a HbA1c of 6.5% to ≤9.5% 
at the screening visit on diet and exercise alone or on a stable dose of single oral 
antihyperglycemic agent (AHA) or dual-combination oral AHAs for 12 weeks prior to 
screening. A target of 188 subjects will be randomly assigned in this study.
Subjects meeting all enrollment criteria will enter a 2-week run-in phase, which is to occur 
approximately 1 week after the screening visit and is designed to train the subject on SC self-
injection and to establish the subject’s ability to comply with the protocol-specified 
requirements. On Day 1 (date of first dose), subjects who continue to meet eligibility criteria, 
will be randomly assigned in a 1:1:1:1 ratio to blinded treatment with placebo or JNJ-64565111 
5.0 mg, 7.4 mg, or 10 mg and enter a 12-week treatment phase. Post-randomization visits will be 
conducted at Week 2, 6, 12/end-of-treatment [EOT] visit, and the SAE follow-up visit 5 weeks 
after the last dose of study drug. At Weeks 4 and 10, all subjects will be contacted preferably by 
telephone to reinforce the adherence to diet and exercise, study drug dosing reminder, 
assessment of subjects’ status, and compliance with the protocol procedures (eg, diary 
completion reminder).
Subjects who withdraw from the study will not be replaced.
During the 12-week treatment phase (Day 1 to Week 12), subjects meeting protocol-specified 
glycemic rescue criteria will have rescue therapy initiated, and will remain in the study, 
continuing double-blind study drug. Rescue therapy may include increasing the dose of a current 
AHA or the initiation of a new AHA. Investigators will manage rescue therapy, including the 
selection of the specific AHA, its clinically appropriate initial dose and titration regimen (if 
applicable), the need to switch from one AHA rescue medication to another (ie, poor glycemic 
response to prior rescue medication), and be consistent with the labeled use within the country of 
the study site. Metformin, sulphonylureas, thiazolidinediones (TZDs), sodium-glucose 
cotransporter 2 (SGLT-2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, and insulin (basal 
NCT03586830


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Statistical Analysis Plan 64565111OBE2002 – Amendment 1
9
Approved, Date: 19 April 2019
only) are allowed as rescue medication; GLP-1 agonists and short-acting or intermediate insulins 
are not allowed as rescue medication.
The overall study duration is approximately 19 weeks and comprises of 3 phases:

Pretreatment phase: 3 weeks comprised of:

Screening phase: 1 week

Run-in (injection-training) phase: 2 weeks

Treatment phase (double-blind)

Placebo-controlled treatment phase: 12 weeks

Post-treatment phase (SAE follow-up visit): 4 weeks
A diagram of the study design is provided in Figure 1.2.1.
Figure 1.2.1: Schematic Overview of the Study
1.3.
Statistical Hypotheses for Trial Objectives
In severely obese T2DM subjects, at least one dose JNJ-64565111 compared with placebo at 12 
weeks leads to a greater:
Primary: 

percentage reduction from baseline in body weight
NCT03586830


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Statistical Analysis Plan 64565111OBE2002 – Amendment 1
10
Approved, Date: 19 April 2019
Secondary: 

absolute reduction from baseline in body weight 

proportion of subjects with 5% weight loss from baseline
1.4.
Sample Size Justification
A total of 188 subjects will be randomly assigned in this study with 47 subjects per group 
allocated to each of the 4 treatment groups. Sample size was determined based on assessing the 
primary hypothesis that at least one dose of JNJ-64565111 leads to greater percentage reduction 
in body weight at 12 weeks compared with placebo. 
Assuming a common SD of 4% with respect to percent change in body weight at Week 12 and a 
2-sided type I family-wise error rate of 0.05, it is estimated that a sample size of 47 randomly 
assigned subjects per group will have approximately 90% power to detect a treatment difference 
of 2.7%.
1.5.
Randomization and Blinding
On Day 1, subjects will be randomly assigned to 1 of 4 treatment groups based on a computer-
generated randomization schedule prepared before the study by or under the supervision of the 
sponsor. The randomization will use randomly permuted blocks.
At baseline (Day 1), the treatment code, which is linked to the randomization schedule, will be 
assigned after logging on to the IWRS designated by the sponsor. The requestor must use his or 
her own user identification and personal identification number when contacting the IWRS, and 
will then give the relevant subject details to uniquely identify the subject. Based on this 
information, the IWRS will assign a unique treatment code, which will dictate the treatment 
assignment and matching study drug kit for the subject. As subjects are randomly assigned to 
treatment, the IWRS will assign a study drug kit to be dispensed at that visit. New study drug kits 
will be assigned each time the IWRS is accessed for dispensing additional study drug.
Blinding
The investigator will not be provided with randomization codes. The codes will be maintained 
within the IWRS, which has the functionality to allow the investigator to break the blind for an 
individual subject.
Data that may potentially unblind the study drug assignment (ie, study drug serum 
concentrations, anti-JNJ-64565111 antibodies, study drug preparation/accountability data, study 
drug allocation, FPG, HbA1c, serum β-hydroxybutyrate, and urine ketones) will be handled with 
special care to ensure that the integrity of the blind is maintained and the potential for bias is 
minimized. This can include making special provisions, such as segregating the data in question 
from view by the investigators, clinical team, or others as appropriate until the time of database 
lock and unblinding.
Under normal circumstances, the blind should not be broken until all subjects have completed 
the study and the database is locked. The investigator may in an emergency determine the 
NCT03586830


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Statistical Analysis Plan 64565111OBE2002 – Amendment 1
11
Approved, Date: 19 April 2019
identity of the study drug by contacting the IWRS. While the responsibility to break the study 
drug code in emergency situations resides solely with the investigator, it is recommended that the 
investigator contact the sponsor or its designee if possible to discuss the particular situation, 
before breaking the blind. In the event the blind is broken, the sponsor must be informed as soon 
as possible. The date and reason for the unblinding must be documented in the appropriate 
section of the eCRF and in the source document. The documentation received from the IWRS 
indicating the code break must be retained with the subject's source documents in a secure 
manner so as not to unblind the treatment assignment to the study site or sponsor personnel. The 
investigator is also advised not to reveal the study treatment assignment to the study site (except 
as necessary for the clinical management of the subject) or sponsor personnel.
In general, treatment codes will be disclosed fully only after the study is completed and the 
clinical database is closed.
2.
GENERAL ANALYSIS DEFINITIONS
2.1.
Visit Windows
As subjects do not always adhere to the protocol visit schedule, the following rules are applied to 
assign actual visits to analysis visits. Listed below are the visit windows and the target days for 
each visit. The reference day is Study Day 1 (date of first dose). If a subject has 2 or more actual 
visits in one visit window, the visit closest to the target day will be used as the protocol visit for 
that visit window. The other additional visit(s) will not be used in the summaries or analyses but 
they can be used for determination of clinically important endpoints. If 2 actual visits are 
equidistant from the target day within a visit window, the later visit is used.
All assignments will be made in chronological order. Once a visit date is assigned to a visit 
window, it will no longer be used for a later time point except for the endpoint. Listed below 
(Table 2.1.1) are the visit windows and the target days for each visit defined in the protocol. A 
Post-Week 12 window was created to account for subjects who returned at a timepoint after the 
Week 12 visit window.  
Table 2.1.1: Visit Windows
Parameter
Scheduled Visit 
Number
Time Interval
(label on output)
Time Interval
(Day)a
Target Time Point 
(Day)
All
2
Baseline
1b
1
3
Week 2
1c–28
15
4
Week 6
29-64
43
5
Week 12
65-105
85
6
Post-Week 12
≥106
a
Relative to the day of the first dose of double-blind study medication.
b
Up to the first dose of double-blind study medication.
NCT03586830


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Statistical Analysis Plan 64565111OBE2002 – Amendment 1
12
Approved, Date: 19 April 2019
2.2.
Analysis Sets
2.2.1.
All Randomized Analysis Set
The all randomized analysis set will include all subjects who are randomly assigned to a 
treatment group.
2.2.2.
Efficacy Analysis Sets

The intent-to-treat (ITT) analysis set will include all subjects who are randomly assigned to 
a treatment group and have a baseline body weight measurement. 

The modified intent-to-treat (mITT) analysis set includes all ITT subjects who have taken at 
least one dose of study medication and have at least 1 post-baseline body weight 
measurement.  

The completers’ analysis set will consist of all mITT subjects who have completed 12 weeks 
of treatment (i.e., documented in the Treatment Disposition eCRF by the investigators that 
the subject has completed treatment through the Week 12 visit window). 
The primary efficacy analysis, to demonstrate the superiority of JNJ-64565111 compared to 
placebo on percentage reduction in body weight from baseline to Week 12, as well as all 
secondary efficacy analyses, will be based on the mITT analysis set.
A secondary analysis of the primary and secondary efficacy endpoints will be based on the ITT 
population (including data after initiation of rescue medication and data after the on-treatment 
period). This analysis will include all measurements through the Week 12 visit window. 
Supportive analyses based on the completers’ analysis set will also be performed for the primary 
endpoint. 
2.2.3.
Safety Analysis Set
The safety analysis set will include all randomized subjects who have received at least one dose 
of study drug.
2.2.4.
Pharmacokinetics Analysis Set
The PK analysis set includes treated subjects (received at least one dose of JNJ-64565111) who 
have at least one post baseline PK sample for analysis.  
Pharmacokinetics analyses will be performed using the PK analysis set.  Analysis will be based 
on actual treatment received.
2.2.5.
Immunogenicity Analysis Set
The immunogenicity evaluable (IE) analysis set includes treated subjects (received at least one 
dose of JNJ-64565111) who have a sample at baseline and at least 1 post-baseline sample for 
analysis. Immunogenicity analyses will use this analysis set. Analysis will be based on the actual 
treatment received.
NCT03586830


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Statistical Analysis Plan 64565111OBE2002 – Amendment 1
13
Approved, Date: 19 April 2019
2.3.
Definition of Subgroups
Subgroup analyses may be performed as defined below when there are at least 40 subjects within 
each subgroup category.
Subgroup
Definition
Sex
female
male
Age
18-59 years
60-70 years
Race
White
Black or African American
Asian
Other
Baseline BMI
<40 kg/m2
≥40 kg/m2
Baseline HbA1c
<8%
8% to <9%
9% to <10%
≥10%
Baseline fasting HOMA-IR
≤the median
> the median
2.4.
Study Day and Relative Day
“Study Day 1” or “Day 1” refers to the day of the first study agent administration on or after the 
randomization date. All efficacy and safety assessments at all visits will be assigned a day 
relative to this date.
Study day or relative day for a visit is defined as:

Visit date - (date of Study Day 1) +1, if visit date is ≥date of Day 1

Visit date - Date of Day 1, if visit date < date of Day 1
There is no 'Day 0'.
2.5.
Baseline 
Baseline is defined as the last observation prior to first administration of the study agent on or 
after the randomization date.
3.
INTERIM ANALYSIS AND DATA MONITORING COMMITTEE REVIEW
A pre-planned interim analysis was performed in Study 64565111OBE2001; at the time of the 
interim analysis, available unblinded safety data from this study (64565111OBE2002) was 
reviewed by the DMC. These analyses were described in a separate DMC SAP. 
NCT03586830


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Statistical Analysis Plan 64565111OBE2002 – Amendment 1
14
Approved, Date: 19 April 2019
4.
SUBJECT INFORMATION
The number of subjects in each analysis set will be summarized and listed by treatment group,
combined JNJ-64565111 treatment group and overall. In addition, a frequency table of the 
number of subjects by site will be presented.
4.1.
Demographics and Baseline Characteristics
Table 4.1.1 presents a list of the demographic variables that will be summarized by treatment 
group, combined JNJ-64565111 treatment group, and overall for the ITT analysis set, mITT 
analysis set, safety analysis set, completers’ analysis set, and PK analysis set.
Table 4.1.1: Demographic Variables
Continuous Variables
Summary Type
Age (years)
Descriptive statistics 
(N, mean, standard 
deviation [SD], 
median and range 
[minimum and 
maximum]).
Weight (kg)
Height (cm)
Body Mass Index (BMI) (kg/m2)
Waist circumference (cm)
Pulse rate (bpm)
Systolic Blood Pressure (mmHg)
Diastolic Blood Pressure (mmHg)
Rate pressure product (bpm*mmHg)
eGFR (mL/min/1.73m2)
HbA1c (%)
FPG (mmol/L)
Fasting insulin (pmol/L)
Duration of diabetes (years)
Duration of oral antidiabetic treatment prior to study entry (years)
HOMA-B
HOMA-IR
Fasting C-peptide (nmol/L)
Fasting serum lipids: total cholesterol, triglycerides, high-density-lipoprotein cholesterol 
(HDL-C), low-density-lipoprotein cholesterol (LDL-C)
IWQOL-Lite physical function domain score
Beta-hydroxybutyrate (mmol/L)
Categorical Variables
Summary Type
Age (18-30 years, 31-50 years, 51-64 years, and 65 years)
Frequency 
distribution with the 
number and 
percentage of 
subjects in each 
category.
Age for analysis (18-59 years and ≥60 years)
Sex (male, female)
Racea (White, Black or African American, Asian, American Indian or Alaska Native, Native 
Hawaiian or other Pacific Islander, Multiple, Other)
Race for analysis (White, Black or African American, Asian, and Other)
Ethnicity (Hispanic or Latino, Not Hispanic or Latino, Unknown, Not reported)
Baseline BMI (<40, ≥40 kg/m2)
Baseline HbA1c (<8%, 8% to <9%, 9% to <10%, ≥10%)
Baseline fasting HOMA-B (≤ the median, > the median)
Baseline fasting HOMA-IR (≤ the median, > the median)
Baseline eGFR (<90, ≥90 mL/min/1.73m2)
Baseline SBP (<140 mmHg, ≥140 mmHg)
a
If multiple race categories are indicated, the Race is recorded as 'Multiple'
NCT03586830


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Statistical Analysis Plan 64565111OBE2002 – Amendment 1
15
Approved, Date: 19 April 2019
4.2.
Disposition Information
The number of subjects in the following disposition categories will be summarized by treatment 
group and overall:

Subjects randomized;

Subjects in the ITT analysis set;

Subjects in the mITT analysis set;

Subjects in the completers’ analysis set;

Subjects in the mITT analysis set who discontinue from treatment before the Week 12 visit 
(i.e. investigator indicates on the eCRF [treatment disposition page] that the subject 
discontinued from the treatment);

Subjects in the mITT analysis set who discontinue from study before the Week 12 visit 
(i.e., investigator indicates on the eCRF [trial disposition page] that the subject discontinued 
from study);

Subjects in the mITT analysis set who receive glycemic rescue therapy (documented in the 
eCRF by investigator) before the Week 12 visit;

Subjects in the safety analysis set
For subjects who discontinue from the study after randomization, the corresponding reasons for 
(1) discontinuation from the treatment and (2) discontinuation from the study during the 12-week 
treatment phase will be summarized.
The distribution of the time to study discontinuation for the 12-week treatment phase will be 
displayed with Kaplan-Meier curves. Subjects who terminate study participation prematurely at 
any time will be considered an ‘event’ and their date of study discontinuation will be used in the 
time to event calculation. Subjects who complete the study will be censored on their date of 
study completion. Descriptive analyses for the time to early discontinuation will be provided.
Listings of subjects will be provided for the following categories:

Subjects who discontinued from treatment 

Subjects who discontinued from the study prematurely

Subjects who were unblinded during the study period

Subjects who were randomized but did not receive treatment.
NCT03586830


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Statistical Analysis Plan 64565111OBE2002 – Amendment 1
16
Approved, Date: 19 April 2019
4.3.
Treatment Compliance
Treatment compliance will be derived based on the information from the study drug 
administration eCRF page.
Treatment compliance will be calculated as follows:
Treatment compliance (%) = 100 x [number of doses taken/total treatment duration in weeks 
rounded up to nearest integer]
4.4.
Extent of Exposure
Treatment duration will be calculated (in days) based on the dosing schedule as follows:
Date of last dose – date of first dose + 8 days
If the end date of the study medication intake is not known (e.g., subject is lost to follow-up), it 
will be imputed as the earlier of: (1) the date of death, (2) the disposition date (i.e., end of study 
date, end of treatment date), or (3) 28 days from the date that the last medication kit was 
dispensed.  
Descriptive statistics (N, mean, standard deviation, median, and range) will be presented by 
treatment group for treatment duration prior to rescue medication (excluding the duration after 
initiation of rescue medications), and the overall treatment duration (including after initiation of 
rescue medication) for the safety analysis set.
The number and percentage of subjects who receive treatment will also be summarized by 
treatment group with the duration in each of the following categories:

For the entire double-blind treatment phase, <2 weeks, 2 to <6 weeks, 6 to <10 weeks, and 
≥10 weeks
4.5.
Protocol Deviations
Subjects with major protocol deviations will be identified prior to database lock and provided in 
a listing.
4.6.
Prior and Concomitant Medications
Prior and Concomitant medications will be coded using the World Health Organization Drug 
Dictionary (WHO-DD). Prior medications are defined as any therapy used before the day of first 
dose (partial or complete) of study agent. Concomitant medications are defined as any therapy 
used on or after the same day as the first dose of study agent, including those that started before 
and continue on after the first dose of study agent.
Summaries of concomitant medications will be presented by Anatomical Therapeutic Chemical 
(ATC) term and treatment group. The proportion of subjects who receive each concomitant 
NCT03586830


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Statistical Analysis Plan 64565111OBE2002 – Amendment 1
17
Approved, Date: 19 April 2019
medication will be summarized as well as the proportion of subjects who receive at least one 
concomitant medication. In addition, concomitant medications of interest will be presented.  
Prior medications will be summarized by treatment group/dose level and ATC term.
5.
EFFICACY
The primary analysis of the primary, secondary and exploratory efficacy endpoints will be based 
on the modified intent-to-treat (mITT) analysis set. Only those measurements taken up to the last 
dose of study drug plus 14 days will be included in the analysis. A secondary analysis of the 
primary and secondary efficacy endpoints will be based on the intent-to-treat (ITT) analysis set. 
This analysis will include post-baseline measurements taken within the 12-week double-blind 
phase regardless of rescue medication initiation, and regardless of whether on or off-treatment. 
Sensitivity analyses based on the completers’ analysis set will also be performed for the primary 
endpoint. 
Efficacy data will be analyzed according to the initial randomization assignment, regardless of 
the actual treatment received.
5.1.
Analysis Specifications
5.1.1.
Level of Significance
The type I error rate will be strongly controlled at α=5% for each of the primary endpoint and 
secondary endpoints. The Hochberg approach will be used to adjust for the multiplicity of the 
comparisons of each of the JNJ-64565111 doses versus placebo for each of the primary and 
major secondary efficacy endpoints. Adjusted p-values will be provided.
Unless otherwise specified, all statistical tests will be interpreted at a 2-sided significance level 
of 5% and all confidence intervals at a 2-sided confidence level of 95%. Nominal p-values will 
be presented for endpoints other than those described above.
5.1.2.
Data Handling Rules
Unlike other assessments which are scheduled to be collected once at each visit, three 
consecutive readings of the SBP, DBP and pulse rate will be measured (at intervals of at least 
1 minute apart) and recorded. The average of the multiple measurements will be computed at 
each visit for all subjects and this averaged value will be used in all the analyses and summaries 
of blood pressure and pulse rate. Details regarding the handling of missing and partial dates, the 
derivation of Patient-Reported Outcomes (PRO) measures are described in the Data Presentation 
Specifications (DPS).  
5.2.
Primary Efficacy Endpoint
5.2.1.
Definition
The primary efficacy endpoint will be the percentage change in body weight from baseline to 
Week 12.
NCT03586830


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Statistical Analysis Plan 64565111OBE2002 – Amendment 1
18
Approved, Date: 19 April 2019
5.2.2.
Estimand
Population: diabetic, obese subjects in the mITT analysis set who are ≥18 and ≤70 years of age,
have a BMI ≥35 to ≤50 kg/m2, and have a HbA1c 6.5% to 9.5%.
Variable: percentage change in body weight from baseline to Week 12
Population-level summary: mean percentage change in body weight from baseline to Week 12.
5.2.3.
Analysis Methods
Primary Analysis
The primary efficacy endpoint will be analyzed based on the mITT analysis set using a mixed 
model for repeated measures (MMRM). The analysis will use the observed data through 
Week 12 while on treatment (up to the last dose of study drug plus 14 days). The analysis model 
will include the fixed, categorical effects of treatment, visit, and treatment-by-visit interaction, as 
well as the continuous covariates of baseline body weight and baseline-by-visit interaction. An 
unstructured covariance will be used to model the within-patient errors. The treatment 
comparisons will be made between each of the JNJ-64565111 treatment groups and placebo at 
Week 12 based on this model.
Secondary Analysis
A secondary analysis of the primary endpoint will be based on the ITT analysis set and will 
employ pattern mixture models using multiple imputation methods. This analysis will use all 
observed data, including the measurements off treatment. Responses for subjects who 
discontinued from the study earlier than Week 12 will be imputed based on subjects who 
discontinued treatment prematurely but subsequently provided off-treatment measurements. The 
imputation will be done within randomized treatment groups. Data will be analyzed using the 
same model as in the primary analysis. The treatment comparisons between each of the 
JNJ-64565111 treatment groups and placebo will be made at Week 12 and adjusted p-values will 
be provided. Copy control imputation may be used as an alternative to a retrieved dropout 
approach.
Supportive Analyses
Sensitivity analyses for the primary efficacy endpoint will be performed based on the 
completers’ analysis set using the same mixed model for repeated measures as in the primary 
analysis.
Subgroup Analyses
Additional analyses of the primary efficacy endpoint in the mITT analysis set will be performed 
to assess consistency of treatment effect on percent weight loss for the subgroups defined in 
Section 2.3 (if there are at least 40 subjects in the subgroup). The interaction of treatment with 
each of the subgroups will be analyzed based on the MMRM model for the primary efficacy 
analysis with the addition of the subgroup and the appropriate corresponding 2- and 3-way
interaction terms with treatment. If an interaction is observed (2-sided p-value <0.10), then 
NCT03586830


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Statistical Analysis Plan 64565111OBE2002 – Amendment 1
19
Approved, Date: 19 April 2019
further evaluations will be performed to assess and explain the nature of the interaction 
[quantitative or qualitative interaction]. The percentage change from baseline and the 95% CI for
differences between each dose of JNJ-64565111 compared to placebo will be presented for the 
subgroups.
Exploratory Analyses
Additional analysis using a MCP-Mod (Multiple Comparison Procedure – Modelling) 
approach1,2 will be performed to explore the dose response relationship.
5.3.
Major Secondary Endpoints
5.3.1.
Definition
Secondary efficacy analyses at Week 12 will include the absolute change from baseline in body 
weight, and the proportion of subjects with 5% weight loss.
5.3.2.
Analysis Methods
Primary Analysis
The absolute change in body weight from baseline at Week 12 will be analyzed with an MMRM 
model similar to the primary efficacy endpoint based on the mITT analysis set.
The proportion of subjects with 5% weight loss at Week 12 will be analyzed using the mITT 
analysis set. Only subjects with observed data at Week 12 while on treatment (up to the last dose 
of study drug plus 14 days) are eligible to be considered responders (5% weight loss). Subjects 
without an on treatment weight measurement at Week 12 will be considered non-responders. A
logistic regression model including treatment as a fixed effect, and baseline weight as a covariate
will be used for the analysis. The odds ratio and adjusted p-value for the treatment comparison 
between each of the JNJ-64565111 treatment groups versus placebo at Week 12 based on this 
model will be provided.
Secondary Analysis
A secondary analysis of the secondary endpoints will be based on the ITT analysis set and will 
employ pattern mixture models using multiple imputation methods based on information from 
retrieved dropouts as described above. For the proportion of subjects with 5% weight loss, 
response status will be determined from the imputed continuous response based on subjects who 
discontinued treatment prematurely but subsequently provided off-treatment measurements.
Copy control imputation may be used as an alternative to a retrieved dropout approach. 
5.4.
Exploratory Efficacy Variable(s)
5.4.1.
Definition
The following exploratory efficacy endpoints at Week 12 will also be analyzed:

the proportion of subjects with 10% weight loss from baseline
NCT03586830


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Statistical Analysis Plan 64565111OBE2002 – Amendment 1
20
Approved, Date: 19 April 2019

the change from baseline in BMI 

the change from baseline in waist circumference 

the change from baseline in glycated hemoglobin (HbA1c) 

the change from baseline in fasting plasma glucose (FPG) 

the change from baseline in fasting insulin 

the change from baseline in fasting C-peptide 

the changes from baseline in Homeostasis Model Assessment for B cell function 
(HOMA-B) and HOMA-insulin resistance (IR) 

the change from baseline in SBP 

the change from baseline in DBP 

the change from baseline in pulse rate 

the change from baseline in rate pressure product 

the change from baseline in fasting lipids (total cholesterol, LDL-C, HDL-C, and 
triglycerides) 

the change from baseline in scores on the Impact of Weight on Quality of Life – Lite 
(IWQOL-Lite)4,5

the change from baseline in scores on the Patient-Reported Outcomes Measurement 
Information System (PROMIS®) Physical Function Short Form 10a (PROMIS SF 10a) 

the change from baseline in scores on the Eating-related Concept Questionnaire (ERCQ)
5.4.2.
Analysis Methods
The analysis of exploratory endpoints will use the observed data through Week 12 while on 
treatment (up to the last dose of study drug plus 14 days). The analysis of glycemic parameters 
(e.g., HbA1c, FPG, fasting insulin, HOMA-B, HOMA-IR) will be based on the measurements 
prior to rescue medication. The continuous exploratory efficacy endpoints (i.e., change from 
baseline in BMI, HbA1c, FPG, HOMA-B, HOMA-IR, SBP, DBP, pulse rate, and rate pressure 
product) with more than one planned post-baseline timepoint will be analyzed using a MMRM 
model similar to the model used to analyze the primary efficacy endpoint based on the mITT 
analysis set. An analysis of covariance (ANCOVA) model with treatment as a fixed effect and 
baseline measurement as a covariate will be used for endpoints with only one planned post-
baseline timepoint (e.g., waist circumference, fasting insulin, fasting C-peptide, total cholesterol, 
LDL-C, and HDL-C). Shift tables will be used to summarize obesity class (Class I = 30 kg/m2 –
34.9 kg/m2; Class II = 35 kg/m2 – 39.9 kg/m2; Class III = ≥ 40 kg/m2) at baseline versus end of 
treatment.
The categorical exploratory efficacy endpoints will be analyzed using a logistic regression model 
similar to the model used to analyze the proportion of subjects with 5% weight loss.
NCT03586830


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Statistical Analysis Plan 64565111OBE2002 – Amendment 1
21
Approved, Date: 19 April 2019
An ANCOVA model with treatment as a fixed effect and baseline measurement as a covariate 
will be used to analyze the exploratory PRO endpoints. The additional PRO analyses will be 
described in a separate SAP.
6.
SAFETY
All safety analyses and summaries will be based on the safety analysis set (Section 2.2.3). Safety 
data will be analyzed according to the predominant treatment received, in the event that a subject 
received a treatment other than that to which they were randomly assigned to receive. The 
predominant treatment is defined as the treatment to which the subject was exposed for the 
greatest duration during the double-blind treatment phase.
The evaluation of safety will be based on the incidence of adverse events, hypoglycemia 
episodes, and changes in clinical laboratory test results and vital sign results (blood pressure and
pulse rate). The safety analyses will be based on the safety analysis set including all data, 
regardless of the initiation of glycemic rescue therapy (ie, including data after initiation of rescue 
therapy). Additional analysis of hypoglycemia will be performed based on the data prior the 
initiation of glycemic rescue therapy only. There will be no imputation of missing values for 
clinical laboratory test results and vital sign measurements in the safety analyses and there will 
be no hypothesis testing for results from safety analyses. Summaries of AEs, clinical laboratory 
test results, and vital sign results will be provided by treatment group and for the combined 
JNJ-64565111 treatment group.
6.1.
Adverse Events
The verbatim terms used in the CRF by investigators to identify adverse events will be coded 
using the Medical Dictionary for Regulatory Activities (MedDRA). A treatment-emergent AE 
(TEAE) is defined as an adverse event with an onset after the initiation study medication and 
before the last study medication date of the double-blind (12-week) treatment phase plus 
35 days. AEs with a start date prior to initiation of double-blind study medication which are 
subsequently reported to have either an increase in intensity or change in attribution in 
relationship to study medication (i.e., no attribution to possible, probably, very likely) after the 
initiation of double-blind study medication will also be considered as TEAEs. 
If the event occurs on the day of the initial administration of study agent, and either event time or 
time of administration are missing, then the event will be assumed to be treatment emergent. If 
the event date is recorded as partial or completely missing, then the event will be considered to 
be treatment emergent unless it is known to be prior to the first administration of study agent 
based on partial onset date or resolution date. All reported treatment-emergent adverse events 
will be included in the analysis. For each adverse event, the number and percentage of subjects 
who experience at least 1 occurrence of the given event will be provided by preferred term, 
grouped by system organ class (SOC), and presented by treatment group. In addition, 
comparisons between treatment groups may be provided as needed.
NCT03586830


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Statistical Analysis Plan 64565111OBE2002 – Amendment 1
22
Approved, Date: 19 April 2019
Summary tables will be provided for:

AEs

AEs leading to discontinuation 

Drug-related AEs

Drug-related AEs leading to discontinuation

Serious AEs (SAEs)

Serious AEs leading to discontinuation

Serious drug-related AEs leading to discontinuation and deaths

AEs by system organ class

AEs by severity

AEs by relationship to study agent: related (which includes possibly related, probably 
related and very likely related, as reported by the investigator) and not related (which 
includes not related and doubtfully related, as reported by the investigator)

AEs by the action taken regarding the study medication

AEs by outcome
In addition to the summary tables, listings will be provided for subjects who had:

SAEs

AEs leading to discontinuation
Incidence of other treatment-emergent adverse events of special interest will be summarized.
Deaths will be displayed by actual treatment received. Frequencies for the following parameters 
will be included in the summary table:

Number of subjects who died

Cause of death

Relationship to study agent (yes/no)
A listing of subjects who died will be provided.
As a screening tool, the 95% CIs for percentage difference between JNJ-64565111 and placebo 
will be provided for the AEs which are reported in at least four or more subjects in any treatment 
group during the treatment phase. Four (rule-of-4) is chosen based on the recommendation from 
the Safety, Planning, Evaluation, and Report (SPERT).3 No multiplicity adjustment will be 
applied. The exclusion of “0” in the 95% CI around the difference in incidence (JNJ-64565111
compared to placebo) for a particular AE does not necessarily imply that the higher incidence is 
related to drug. The intent of providing the 95% CIs is as a filter to identify AEs that require 
additional assessment.
NCT03586830


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Statistical Analysis Plan 64565111OBE2002 – Amendment 1
23
Approved, Date: 19 April 2019
Adverse events that are identified by the above screening procedure will be subject to further 
evaluation. The additional assessment may include some or all of the following, comparing 
JNJ-64565111 and placebo:
1.
Investigator assessed relationship of AE to study drug, investigator assessed intensity of AE
2.
Time to AE relative to start of double-blind study medication, duration of AE, action taken 
on study drug/occurrence of AEs leading to discontinuation
3.
Other relevant safety information such as observations in other trials.
Adverse Events of Interest
Protocol prespecified AEs of interest included MACE, hypotension-related AEs, pancreatic 
events, calcitonin elevation, and thyroid neoplasm. Prior to study unblinding, additional AEs of 
interest were identified including nausea, vomiting, diarrhea, and AEs of injection site reaction. 
Since investigators may have reported the same clinical condition using different AE terms, prior 
to study unblinding a list of reported terms that are suggestive of the AEs of nausea, vomiting, 
diarrhea, injection site reactions, and pancreatic-related AEs was generated. These preferred 
terms were used to generate a combined analysis for each of these specific AEs of interest.
6.2.
Clinical Laboratory Tests
All clinical laboratory tests will be displayed for the subjects included in the safety analysis set.
Laboratory data will be summarized for each type of laboratory test listed in Attachment 1.
Normal reference ranges for each test will also be provided.
Descriptive statistics will be presented for all chemistry, hematology, and urinalysis (pH and 
specific gravity) laboratory tests at scheduled time points. Descriptive statistics will be presented 
based on measurements on study medication, including up to a maximum of 14 days for 
JNJ-64565111 and placebo subjects, as well as all measurements regardless of the time of the 
last dose of double-blind study drug for subjects who discontinue from treatment before 
Week 12. Summaries based on both standard units (SI) and conventional units will be provided.
Change from baseline to scheduled time point as well as the 95% CI will be summarized for 
chemistry, hematology, and urinalysis (pH, and specific gravity) tests and displayed by visit and 
treatment group.
Number and percentage of subjects with postbaseline clinically important laboratory values will 
be presented and treatment group.
The percentage of subjects with specific treatment-emergent laboratory values meeting pre-
defined limit of change (PDLC) criteria will be summarized for these laboratory analytes. The 
95% CI for the percentage difference between the treatment groups will be provided for each 
treatment and combined JNJ-64565111 treatment group for the PDLC criterion which have at 
least 4 or more subjects in any treatment group; a corresponding listing will also be provided. 
The criteria for PDLC values are listed in Attachment 2.
NCT03586830


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Statistical Analysis Plan 64565111OBE2002 – Amendment 1
24
Approved, Date: 19 April 2019
6.3.
Vital Signs and Physical Examination Findings
Continuous vital sign parameters including pulse and blood pressure (systolic and diastolic) will 
be summarized at each assessment time point. Changes from baseline will be summarized for the
12-week treatment phase. Descriptive statistics (mean, standard deviation, median, interquartile 
range [IQR], minimum and maximum) will be presented at each scheduled time point, including 
the 95% CI for the change from baseline for the 12-week treatment phase. The descriptive 
statistics will be presented based on measurements on study medication, including up to a 
maximum of 14 days for JNJ-64565111 and placebo subjects, as well as all measurements 
regardless of the time of the last dose for subjects who discontinue from treatment before 
Week 12. The pulse and blood pressure measurements will be based on the average of the 
consecutive sitting pulse and blood pressure readings that were collected at each visit.  
The percentage of subjects with specific treatment-emergent vital sign values meeting PDLC 
criteria (Attachment 2) will be summarized for these vital sign parameters. The 95% CI for the 
percentage difference between the treatment groups will be provided for each treatment and 
combined JNJ-64565111 treatment group for the PDLC criterion which have at least 4 or more 
subjects in any treatment group; a corresponding listing will also be provided.  
Physical examination findings will not be summarized except when reported as an adverse event.
6.4.
Electrocardiogram
A 12-lead ECG will be performed during screening. No summary is planned. 
7.
PHARMACOKINETICS/IMMUNOGENICITY/PHARMACODYNAMICS
7.1.
Pharmacokinetics
Pharmacokinetics (PK) samples for measuring serum JNJ-64565111 concentrations will be 
collected from all subjects at the specified visits as shown in the schedule of events of the 
protocol. In all subjects randomly assigned to JNJ-64565111 or matching placebo, venous blood 
samples will be collected according to the Time and Events Schedule for determination of serum 
trough concentrations of JNJ-64565111 to assess attainment of steady state concentrations. In 
addition, a sample at the 4-week safety follow-up visit will also be collected in all subjects. On 
the days of the trough clinic visits at which PK samples are to be obtained, subjects are not to 
inject the study drug before arriving at the clinic. In addition to the trough samples and a post-
treatment sample in all subjects, all subjects will have 1 additional visit (Day 4 ± 1 day sampling 
window) to collect a non-trough PK sample. All PK evaluations will be based on the PK analysis 
set. No imputation for missing concentration data will be performed. 
The data analysis of trough and non-trough serum JNJ-64565111 concentrations includes the 
following:

Tabular summary of serum JNJ-64565111 concentrations at each PK visit by treatment 
group.
NCT03586830


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Statistical Analysis Plan 64565111OBE2002 – Amendment 1
25
Approved, Date: 19 April 2019

Tabular summary of serum JNJ-64565111 concentrations at each visit by treatment group 
and body weight tertiles at baseline.

Proportion of subjects without detectable serum JNJ-64565111 concentration at each visit by 
treatment group.

Median trough, non-trough, and week 16 temporal serum JNJ-64565111 concentrations 
plotted over time by treatment group.

Median trough serum JNJ-64565111 concentrations plotted over time by treatment group to 
assess attainment of steady-state.
In addition, the relationship between serum JNJ-64565111 concentrations, and antibody to 
JNJ-64565111 status, safety and efficacy may be explored using graphical displays. 5% and 
10% weight loss response rates and % weight loss at Week 12 will be presented in a bar graph 
by the corresponding serum JNJ-64565111 concentration quartiles at Week 12 for subjects 
treated with JNJ-64565111.
For summary statistics of serum JNJ-64565111 concentrations, concentration values below the 
lower limit of quantification will be treated as zero. Once a subject meets one of the following 
dosing deviation criteria, the subject’s data will be excluded from the by-visit data analyses from 
that point onwards.
Dosing deviation criteria:

Discontinued SC study agent administrations.

Skipped a SC administration.

Received an incomplete/ incorrect SC dose.

Received an incorrect SC study agent.

Received an additional SC dose.
In addition, if a subject has an administration more than 4 days earlier or later than the scheduled 
dosing date, the concentration data collected between such a dosing visit and the subsequent 
dosing visit will be excluded from the by-visit data analyses. For the Week 12 visit, if the PK 
sampling time deviates more than 4 days earlier or later than the scheduled date, the PK 
concentration at this visit will be excluded from the by-visit data analyses.  
The conditions under which to exclude measurements from PK analysis:

If date/time of Baseline sample is after date/time of first dose, then exclude the Baseline 
sample

If Day 4 sample is >8 days after 1st dose, then exclude the Day 4 sample

If date of Week 2 sample – date of previous dose before date of Week 2 sample is < 3 days 
or > 11 days, then exclude Week 2 sample

If date of Week 6 sample – date of previous dose before date of Week 6 sample is < 3 days 
or > 11 days, then exclude Week 6 sample
NCT03586830


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Statistical Analysis Plan 64565111OBE2002 – Amendment 1
26
Approved, Date: 19 April 2019

If relative Study Day of Week 12 sample is < Day 80 or >Day 88 then exclude Week 12 
sample

If relative Study Day of Week 16 sample is < Day 108 or >Day 116 then exclude Week 16 
sample

If subject discontinues treatment early, then exclude the “Week 16” or “4 Week Follow-up” 
PK sample.  
Population PK analyses will be performed to characterize the population PK parameters based on 
the available JNJ-64565111 concentration data obtained through the Week 16 visit. Sparse PK 
data from the current study may be pooled with previous Phase 1 data with rich PK profiles to 
allow estimation of structural PK parameters. The population pharmacokinetic approach will also 
be used to identify and quantify any significant covariates such as demographic characteristics 
(including but not limited to body weight, ethnic origin, sex, and age) and concomitant 
medications that have substantial impact on the population pharmacokinetics of JNJ-64565111 in 
subjects with severe obesity. A detailed analysis plan for population PK analysis will be 
developed separately, and a stand-alone technical report will be written to summarize the results 
of the population PK analysis.
7.2.
Immunogenicity
Blood samples will be collected to examine the formation of antibodies to JNJ-64565111 at the 
specified visits (Day 1, Weeks 2, 6, 12, and 16) as shown in the schedule of events of the 
protocol. For subjects who discontinue SC study agent administrations, samples will be collected 
at their 4-week safety follow-up visit.
The data analysis of antibodies to JNJ-64565111 will be summarized if sufficient numbers of 
subjects are positive for antibodies and will include the following:

The antibody status (positive, negative) of subjects will be summarized by JNJ-64565111 
treatment groups. For subjects who discontinue SC study agent administrations and 
complete 4-week safety follow-up, a listing of their antibody status will be presented.

The relationship between antibody to JNJ-64565111 status and efficacy and safety may be 
assessed at Week 12. 

5% and 10% weight loss response rates and % weight loss at Week 12 by antibody to 
JNJ-64565111 status and treatment group

Injection site reaction by antibody to JNJ-64565111 status and treatment group.

The relationship between antibody to JNJ-64565111 status at Week 6 and antibody to 
JNJ-64565111 status at Week 12 will be explored.

The onset and duration of antibody to JNJ-64565111

Figure of median serum JNJ-64565111 concentrations by antibody to JNJ-64565111 status.
Other analyses may be performed to verify the stability of antibodies to JNJ-64565111 and/or 
further characterize the immunogenicity of JNJ-64565111.
NCT03586830


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Statistical Analysis Plan 64565111OBE2002 – Amendment 1
27
Approved, Date: 19 April 2019
7.3.
Pharmacokinetic/Pharmacodynamic Relationships
The relationship between serum JNJ-64565111 concentrations and % weight loss may be 
explored and results will be reported in an independent technical report.
NCT03586830


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Statistical Analysis Plan 64565111OBE2002 – Amendment 1
28
Approved, Date: 19 April 2019
REFERENCES
1.
Bornkamp B, Pinheiro JC, and Bretz, F. MCPMod: An R package for the design and analysis of dose-finding 
studies. Journal of Statistical Software. 2009;29(7):1-23.
2.
Pinheiro J, Bornkamp B, Glimm E, Bretz, F. Model-based dose finding under model uncertainty using general 
parametric models. Stat Med. 2014;33(10):1646-1661.
3.
Crowe BJ et al., 2009, Recommendations for safety planning, data collection, evaluation and reporting during 
drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team. Clin 
Trials 6, 430-40. 
4.
Kolotkin RL, Crosby RD, Kosloski KD, Williams GR. Development of a brief measure to assess quality of life 
in obesity Obes Res. 2001;9(2):102-111.
5.
Kolotkin RL, Crosby RD. Psychometric evaluation of the impact of weight on quality of life-lite questionnaire 
(IWQOL-Lite) in a community sample. Quality of Life Research. 2002;11:157-171.
NCT03586830


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Statistical Analysis Plan 64565111OBE2002 – Amendment 1
29
Approved, Date: 19 April 2019
ATTACHMENTS
ATTACHMENT 1 CLINICAL LABORATORY TESTS
Blood samples for serum chemistry and hematology, and urine samples for urinalysis will be collected 
at timepoints specified in the Time and Events Schedule. The investigator must review the laboratory
report, document this review, and record any clinically relevant changes occurring during the study in the
Adverse Event section of the eCRF and take appropriate action (eg, repeating abnormal laboratory result
or further evaluation as considered clinically appropriate). The following tests will be performed by the 
central laboratory.

Hematology Panel
-hemoglobin
-platelet count
-hematocrit
-red blood cell (RBC) count
-white blood cell count with differential

Serum Chemistry Panel
-sodium
-alkaline phosphatase
-potassium
-creatine phosphokinase
-magnesium
-lactic acid dehydrogenase
-chloride
-amylase
-bicarbonate
-lipase
-uric acid
-calcium
- blood urea nitrogen
-phosphate
-creatinine
-albumin
-aspartate aminotransferase
-total protein
-alanine aminotransferase
-gamma-glutamyltransferase
-total bilirubin

Serum ß-hydroxybutyrate

Serum calcitonin

Fasting insulin*

Follicle-stimulating hormone only for women >45 years of age with amenorrhea for at least 
6 months and <18 months prior to screening

Fasting serum lipid profile (triglycerides, LDL-C, HDL-C, total cholesterol) *

HbA1c

Fasting plasma glucose*

Urinalysis
Dipstick done at central laboratory
-specific gravity
-pH
-protein
-blood
-ketones
-bilirubin
-urobilinogen
-nitrite
-leukocyte esterase
If dipstick result is abnormal, microscopic examination will be performed.

Serum (β-human chorionic gonadotropin [β-hCG] pregnancy testing will be conducted for all 
women of childbearing potential (ie, unless they are permanently sterilized or unless there is a 
documented history of their postmenopausal status) at the screening and Week 12/EOT visits. 
NCT03586830


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Statistical Analysis Plan 64565111OBE2002 – Amendment 1
30
Approved, Date: 19 April 2019
Additional serum or urine pregnancy tests may be performed throughout the study in sufficient 
number, as determined necessary by the investigator, or required by local regulation, to 
establish the absence of pregnancy during the study. 
*
Subjects must be fasting for at least 8 hours before blood sample collections.
Estimated Glomerular Filtration Rate (eGFR)

The estimated glomerular filtration rate (eGFR) will be reported according to the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation** at study visits when serum 
creatinine is measured. The CKD-EPI equation based on serum creatinine, age, sex, and race for 
adults age 18 years expressed as a single equation is:
CKD-EPI Formula (for Scr expressed in mg/dL)
eGFR = 141 × min (Scr /, 1)× max(Scr /, 1)-1.209 × 0.993Age × 1.018 [if female] ×
1.159 [if black]
= 0.7 for females
= 0.9 for males
= -0.329 for females
= -0.411 for males
min = the minimum of Scr/or 1 max = the maximum of Scr/or 1
CKD-EPI Formula (for Scr expressed in mol/L)
eGFR = 141 × min (Scr /, 1)× max(Scr /, 1)-1.209 × 0.993Age × 1.018 [if female] ×
1.159 [if black]
= 61.9 for females
= 79.6 for males
= -0.329 for females
= -0.411 for males
min = the minimum of Scr/or 1 max = the maximum of Scr/or 1
**Levey AS, Stevens LA, Schmid CH, et.al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). 
Ann Intern Med. 2009;150(9):604-12.
NCT03586830


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Statistical Analysis Plan 64565111OBE2002 – Amendment 1
31
Approved, Date: 19 April 2019
ATTACHMENT 2 PRE-DEFINED LIMIT OF CHANGE (PDLC) CRITERIA FOR 
LABORATORY TESTS
Laboratory Test
Parameter for ANY value and LAST value
CHEMISTRY
Albumin
Composite: <LLN and >25% decrease from BL
ALT
Absolute Value: >3X ULN
Absolute Value: >5X ULN
Absolute Value: >8X ULN
AST
Absolute Value: >3X ULN
Absolute Value: >5X ULN
Absolute Value: >8X ULN
ALT >3X ULN and Tbili >2X ULN
Composite: ALT >3X ULN and Tbili >2X ULN [with the Tbili elevation >2 X ULN 
within 30 days of the ALT elevation >3x ULN]
AST >3X ULN and Tbili >2X ULN
Composite:  AST >3X ULN and Tbili >2X ULN [with the Tbili elevation >2 X ULN 
within 30 days of the AST elevation >3x ULN]
Amylase
Absolute Value: >2X ULN
Absolute Value: >3X ULN
Absolute Value: >5X ULN
Beta-Hydroxybutyrate
Absolute value > 20.822 mg/dL (>2.0 mmol/L)
Bilirubin
Composite:  >ULN and > 25% increase from BL
Absolute Value: >2XULN
Bicarbonate
Absolute Value: <16 mEq/L
Calcitonin
Absolute Value: >20 ng/L (>5.85 pmol/L)
Absolute Value: >50 ng/L (>14.63 pmol/L)
Absolute Value: >100 ng/L (>29.26 pmol/L)
Calcium
Composite: >ULN and >10 % increase from BL
Creatinine Kinase
Absolute Value: >1000 U/L
eGFR
Composite: < 80 and decrease>30% from BL
Change:  decrease>50% from BL
Lipase
Absolute Value: >2X ULN
Absolute Value: >3X ULN
Absolute Value: >5X ULN
Magnesium
Composite: <LLN and >25% decrease from BL
Composite: >ULN and >25% increase from BL
Phosphorus
Composite: <LLN and >25% decrease from BL
Composite: >ULN and >25% increase from BL
Potassium
Composite: <LLN and >15% decrease from BL
Composite: >ULN and >15% increase from BL
Sodium
Composite: <LLN and decrease >5 mEq/L or more from BL
Composite: >ULN and increase >5 mEq/L or more from BL
Absolute Value: <125 mEq/L
Uric Acid
Composite: <LLN and >25% decrease from BL
HEMATOLOGY
Hemoglobin
Change: ≥2 g/dl decrease from BL
Change: ≥2 g/dL increase from BL
Platelets
Composite: >ULN and increase >25% from BL
White Blood Count
Composite: < LLN and >25% decrease from BL
Composite: > ULN and >50 % increase from BL
VITAL SIGNS
Pulse Rate
Absolute Value: ≤50 beats per minute
Absolute Value: ≥90, ≥100 beats per minute
Changes from baseline >30 bpm, >50 bpm
Absolute value ≥120 bpm and >30 bpm increase from baseline
Absolute value ≤50 bpm and >20 bpm decrease from baseline
Decreases from baseline >5, >10, >15, >20 bpm at consecutive visits
Increases from baseline >5, >10, >15, >20 bpm at consecutive visits
Systolic Blood Pressure
Composite: ≥20 mm Hg decrease from BL and ≤90 mm Hg
Composite: ≥20 mm Hg increase from BL and ≥160 mm Hg
Composite: ≥30 mm Hg decrease from BL and ≤90 mm Hg
Composite: ≥30 mm Hg increase from BL and ≥160 mm Hg
NCT03586830


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Statistical Analysis Plan 64565111OBE2002 – Amendment 1
32
Approved, Date: 19 April 2019
Laboratory Test
Parameter for ANY value and LAST value
Decreases from baseline >5, >10, >15, >20, >25, >30 mmHg at consecutive visits
Increases from baseline >5, >10, >15, >20, >25, >30 mmHg at consecutive visits
Diastolic Blood Pressure
Composite: ≥15 mm Hg decrease from BL and ≤50 mm HG
Composite: ≥15 mm Hg increase from BL and ≥100 mm Hg
Composite: ≥20 mm Hg decrease from BL and ≤50 mm HG
Composite: ≥20 mm Hg increase from BL and ≥100 mm Hg
Decreases from baseline >5, >10, >15, >20, >25, >30 mmHg at consecutive visits
Increases from baseline >5, >10, >15, >20, >25, >30 mmHg at consecutive visits
NCT03586830


JNJ-64565111  (LAPS-GLP1/Glucagon dual receptor agonist)
Statistical Analysis Plan 64565111OBE2002 – Amendment 1
33
Approved, Date: 19 April 2019
ATTACHMENT 3 ADVERSE EVENTS OF SPECIAL INTEREST
In order to support the additional assessment of particular categories of adverse events of interest, a list of 
selected preferred or high-level terms have been created. A blinded review prior to database lock was to 
be performed to assure that no reported term suggestive of the AE of interest was omitted. AEs of interest 
include:
•
Vomiting 
•
Diarrhea
•
Nausea
•
Pancreatic events
•
Injection site reactions
The list of preferred and high-level terms for the pre-specified adverse events is provided in EDMS-ERI-
181673715.   
NCT03586830